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General Introduction 
Aim and Outline of 
this Thesis 
 
Elucidation of the cellular and genetic molecular mechanisms involved in cancer onset has 
provided several targets for the development of genetic and chemotherapeutic drugs. After surgical 
removal and/or radiation of the primary tumor, the remaining cancer cells can be treated with a 
variety of chemotoxic or genetic drugs. Despite the identification and development of several new 
drugs, cancer therapy encounters several barriers to become really effective. Due to the 
abnormalities and deficiencies in tumor vasculature and interstitial transport, current 
chemotherapeutic treatments are hampered by the non-uniform and insufficient delivery of anti-
cancer agents to tumor cells. Due to the non-selective nature of several chemotherapeutics, resulting 
in neutropenia, therapies are often delayed and drug doses limited. This can result in the 
development of multi-drug resistance in a variety of tumors, responsible for treatment failure and 
non-responsive recurrence in several patients.  
Treatment of cancers by gene therapy requires the development of intelligent delivery systems 
that are able to selectively stimulate gene uptake in cancer cells. To be effective, genetic drugs must 
conquer several barriers before reaching their intracellular target site. Although, viral gene carriers 
are by far the most efficient gene delivery carriers, their clinical use is hampered by the risk of 
insertional mutagenesis and severe immune responses. As a consequence, several non-viral gene 
carriers are currently under development, although their transfection efficiencies remain rather low. 
Intravenous administration of microbubbles combined with ultrasound radiation of the tumor has 
been recently proposed as a strategy to help non-viral gene carriers to (a) overcome biological 
barriers in drug delivery and (b) selectively enhance drug uptake in cancer cells. As current cancer 
treatments are hampered by the lack of an efficient and targeted delivery of drugs or genes to cancer 
cells, the general aim of this thesis was to design drug carrying microbubbles that are able to 
selectively deliver their content to cancer cells upon ultrasound radiation.  
Chapter 1 gives a short overview of treatment strategies currently developed or employed in 
cancer therapy. Also, the basic concepts regarding the interaction between ultrasound energy and 
microbubbles as well as the clinical applications of microbubbles are summarized. As drug loaded 
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mirobubbles show potential for ultrasound guided drug delivery we aimed at developing cationic 
charged albumin-shelled microbubbles to enable electrostatic loading of plasmid DNA (chapter 2). 
Although the microbubbles could be efficiently loaded with plasmid DNA, and though the loaded 
DNA seemed well protected against degradation by nucleases, transfection efficiencies obtained 
after ultrasound exposure of this microbubbles remained rather low (chapter 3). We showed that 
this is due to the formation of large aggregates consisting of microbubble shell fragments and 
plasmid DNA, which seemed to be too large to enter the cells. To tackle this problem we aimed at 
developing a new concept in chapter 4, in which pre-defined plasmid DNA-liposome complexes 
(lipoplexes) were attached onto the surface of a lipid shelled polymer. In chapter 5 of this thesis we 
demonstrate that ultrasound exposure of such lipoplex loaded microbubbles results in the release of 
intact lipoplexes, which are immediately deposited inside the cytoplasm of the target cells, making 
an endocytic uptake and release redundant. The same microbubbles were loaded with short 
interfering RNA and evaluated for gene silencing purposes (chapter 6). Finally, in chapter 7 we tried 
to answer the question whether this type of microbubbles is also promising for the ultrasound 
triggered delivery of doxorubicin to cancer cells. 
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ABSTRACT 
 
Cancer is a major cause of death in the world. Nearly 13% of all deaths in 2007 were caused by 
cancer according to the World Health Organization. The recent advances in understanding the basic 
molecular mechanisms involved in the onset of cancer provide a framework for the pharmacological 
and genetic treatment of cancer. Several anti-neoplastic agents, acting at several stages in tumor 
development, have been developed. The identification of some important genes involved in the 
genetic onset of several cancers, like the p53 tumor suppressor gene and the ras oncogene, has led 
to a growing interest in cancer gene therapy. 
Ultrasound has recently gained attention in the drug delivery field. Its non-invasive nature, 
local applicability and cheapness make ultrasound attractive for specific drug delivery purposes. 
Microbubbles are gas-filled micron-sized structures which were originally implemented to obtain a 
better contrast in ultrasound imaging techniques. Some of them have been FDA approved and are 
clinically used in ultrasound imaging. They recently became of interest to the drug delivery 
community as they may enhance the efficiency of ultrasound guided drug delivery by lowering the 
threshold for acoustic cavitation. Furthermore, microbubbles can be loaded with drugs which can be 
locally delivered upon ultrasound application. 
In this chapter we give a short introduction on the onset of cancer and summarize some of the 
most important chemotherapeutics and genetic drugs that are currently used or under development 
to treat cancer. The most important viral and non-viral gene carriers are briefly discussed. Also the 
basic physics of ultrasound waves, their biological implications and therapeutic applications are 
described. Finally, we introduce the concept of microbubble-based ultrasound guided drug delivery 
and review some of the recent attempts made in the design of drug loaded microbubbles.  
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Chapter 1 
Introduction 
CANCER 
 
Cancer is the transformation of normal cells into malignant cells as a result of mutations in the 
genome. A majority of these mutations are not inherited but arise spontaneously as a consequence 
of chemical damage to the DNA, resulting in an altered function of crucial genes1. The continuous 
renewal of cells in the human body is controlled by a network of molecular mechanisms which 
govern cell proliferation and apoptosis. Mutations in the genes that control cell proliferation and 
apoptosis are responsible for the onset of cancer. These genes can be broadly divided into two 
classes: pro-oncogenes are responsible for the upregulation of their encoding proteins after 
mutation and oncogene formation, while the proteins encoded by tumor suppressor genes are 
inactivated or suppressed after mutation. Oncogenes are involved in signaling pathways which 
stimulate cell proliferation, while most human suppressor genes code for proteins controlling cell 
proliferation or cell death. In general five different pathways must be activated or inactivated in the 
genesis of a cancer cell1: 
 
 The cell must become independent of growth stimulatory signals. 
 The cell must develop a refractory state to growth inhibitory signals. 
 The cell must become resistant to apoptosis. 
 The cell must overcome cell senescence i.e. require infinite proliferation properties. 
 The cell must develop the capacity to form new blood vessels for nutrient supply. 
 
Several genes are identified to play a crucial role in the development of cancers. An example of 
a crucial oncogene is ras, which is the most widely activated oncogene in human cancers. This gene 
codes for signal transduction molecules and mutations can result in a growth factor independent cell 
proliferation2. The p53 gene has been identified as an important tumor suppressor gene in many 
cancers. This gene manages cell cycle and apoptosis. As a result, mutations can prevent cell apoptosis 
as a response to cell stress. The same gene also plays a role in regulating cell senescence3.  
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CANCER THERAPEUTICS 
 
CHEMOTHERAPEUTICS 
 
The majority of chemotherapeutic drugs can be divided into alkylating agents, antimetabolites, 
antibiotics and topoisomerase inhibitors. All of these drugs affect cell division or DNA synthesis and 
function in some way. Some newer agents do not directly interfere with DNA. These include 
monoclonal antibodies and the tyrosine kinase inhibitors which directly target a molecular 
abnormality in certain types of cancer. A very short overview of the most common anticancer drugs 
is given below. 
 
Alkylating agents. This group of anticancer agents includes the nitrogen mustard derivates and 
platinum anticancer agents. Alkylating agents are highly reactive drugs, alkylating several cellular 
components like proteins, RNA and DNA. Their main mechanism of action is their interaction with 
DNA, thereby blocking vital aspects of DNA metabolism4. This results in a transcriptional arrest and 
the activation of DNA damage pathways resulting in apoptosis4. Because of their cell cycle phase 
independence, alkylating agents are effective against a wide variety of cancers, although they are 
mainly used to treat slowly dividing tumors. Cisplatin and carboplatin have been widely used for 
many years to treat several forms of cancer. Cisplatin can form covalent crosslinks between the 
guanine bases of two DNA strands5. However, their activity remains limited due to side effects and 
the inherent and acquired resistance to these drugs. For this reason, several new platinum derivates 
are currently investigated6.  
 
Antimetabolites. The structure of antimetabolites is similar to certain compounds such as 
vitamins, amino acids, and precursors of DNA or RNA, found naturally in the human body. 
Antimetabolites interfere with cancer cell division and hinder the growth of tumor cells as they get 
incorporated in DNA, RNA or prevent the formation of new nucleotides. The toxicities associated 
with these drugs are seen in cells that are growing and dividing quickly. Examples of antimetabolites 
include purine antagonists, pyrimidine antagonists, and folate antagonists7-9. 
 
Antitumor antibiotics. These antibiotics interfere with DNA and can prevent transcription, 
which makes them cell cycle nonspecific10-12. The most well known antibiotic is doxorubicin. Three 
different working mechanisms have been identified, including DNA intercalation, lipid peroxidation 
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and inhibition of topoisomerase II13. Other antitumor antibiotics are daunorubicin, epirubicin and 
bleomycin. 
 
Topoisomerase inhibitors. Topoisomerases are essential enzymes that maintain the topology 
of DNA. Inhibition of type I or II isomerases interferes with both DNA transcription and replication by 
preventing DNA supercoiling. Examples of topoisomerase inhibitors are doxorubicin, genistein and 
topotecan14.  
 
Microtubule-targeted anticancer drugs (anti-mitotic dugs). Microtubules are key components 
of the cytoskeleton that are responsible for the transport of vesicles through the cell and play an 
important role in cell signalling and cell division. Microtubule-targeted drugs, including taxanes 
(paclitaxel, docetaxel) and Vinca alkaloids (vinblastine, vincristine), can suppress microtubule 
dynamics leading to mitotic block and apoptosis15. 
 
Monoclonal antibodies. Monoclonal antibodies work by attaching to certain parts of the 
tumor-specific antigens and make them easily recognizable by the host’s immune system. They 
also prevent growth of cancer cells by blocking the cell receptors to which chemicals called 
‘growth factors’ attach promoting cell growth. Several antibodies have been approved for cancer 
treatment and most of these agents are combined with conventional chemotherapeutics or 
radiotherapy16. 
 
CANCER GENE THERAPY 
 
The discovery that the transformation of normal cells into malignant ones is associated with 
multi-mutational alterations on the genetic level of these cells, makes cancer cells an important 
target for gene therapy. The first approach in gene therapy is the introduction of a therapeutic gene, 
either transient or by inserting it into a non-specific place in the genome. This results in the 
expression of a therapeutic protein that was previously absent or malfunctioning. Another approach 
is to regulate the expression of a disease causing protein by degrading its mRNA. This can be 
accomplished by using antisense oligonucleotides, ribozymes or small interfering RNA17-19. 
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DNA-based therapeutics 
 
Plasmid DNA. Plasmids are high molecular weight, double-stranded DNA constructs containing 
transgenes, which encode specific proteins. Gene therapy involves the use of plasmid DNA to 
introduce transgenes into cells that inherently lack the ability to produce a certain protein, encoded 
by the transgene20. After cellular entry, the plasmid DNA should be able to enter the cell nucleus, to 
become transcribed by the cellular transcription machinery. Both the cellular entry and especially the 
nuclear entry are difficult processes and a good plasmid DNA carrier is essential for intracellular 
delivery of plasmid DNA. The mRNA, obtained after transcription, is subsequently transported to the 
cytoplasm of the cell, where it is translated into a functional protein (Figure 1)20. 
 
 
Figure 1 Mechanism of plasmid DNA transfection resulting in the expression of a therapeutic protein. 
 
Antisense Oligonucleotides (ONS). ONs are short single stranded DNA molecules that 
selectively bind to their target mRNA in the cytoplasm. The duplex formation between ONs and 
mRNA blocks the translation process. Several mechanisms have been proposed to explain their 
antisense action. One theory suggests that binding of the ONs to the mRNA prevents interaction with 
the cellular machinery required for protein synthesis. Alternatively, ONs can function by activation of 
RNase H, an enzyme that degrades the targeted mRNA20,21. Because of their rapid degradation by 
circulating nucleases in the body, ONs with several backbone modifications have been designed to 
withstand this degradation22. 
 
Introduction – Chapter 1 
 
27 
Ribozymes and DNAzymes. A problem with the use of ONs is that their ability to impede DNA 
translation is concentration dependent and therefore tumour cells often continue to express low 
levels of the oncoprotein. This has led to the development of ribozymes. Ribozymes are RNA 
molecules that bind and cleave mRNA molecules with a specific sequence. After binding to the target 
mRNA, the formed duplex is easily hydrolyzed20,23. An important disadvantage of ribozymes is their 
low in vivo stability, as they are quickly destroyed by circulating RNases. For this reason, DNAzymes 
have been developed, which are analogs of ribozyms with greater biological stability. The RNA 
backbone is replaced by a DNA backbone, thereby improving biological stability20,24. They are also 
easier to modify synthetically, thereby generating even more stable second-generation analogs25. 
 
Short Interfering RNA (siRNA). RNA interference (RNAi) is a naturally occurring gene silencing 
mechanism initiated by double stranded RNA (dsRNA). When long dsRNA is introduced into a cell, it 
is processed by a dsRNA-specific enzyme, Dicer. This enzymatic cleavage degrades the RNA into a 19-
23 basepare duplex, also called short interfering RNA (siRNA). The siRNA then binds to the RNA-
induced gene silencing complex (RISC), which retains only the antisense strand of the siRNA. 
Subsequently, this activated RISC binds to the mRNA molecule of interest and stimulates mRNA 
degradation by the enzyme Slicer, leading to specific gene silencing (Figure 2)26-30. Because long 
dsRNA molecules can induce severe interferon responses in mammalian cells31, inducing RNAi is 
mostly accomplished by the addition of chemically synthesized 21mer siRNAs, mimicking Dicer 
cleavage products, or by the intracellular production of siRNAs from short hairpin RNA (shRNA) 
precursors that can be continuously expressed from RNA polymerase III driven expression 
cassettes32. Important advantages of siRNAs are their higher resistance to degradation and their 
higher specifity compared to ONs or ribozymes20. 
 
Figure 2 Mechanism of antisense therapy with siRNA molecules. 
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Strategies in cancer gene therapy 
 
Cancer gene therapy can be used to compensate the genetic malfunctions by replacing the 
defective genes with their wild-type counterpart or to silence oncogenes. A second strategy is to 
make the cancer cells more visible for the immune system and employ the host’s physiological 
immune response to selectively kill the cancer cells33. A schematic overview of the different 
strategies is shown in Figure 3. 
 
 
Figure 3 Schematic overview of different strategies in cancer gene therapy. 
 
Oncogene inactivation. Mutations in proto-oncogens can lead to the formation of oncogens. 
The enhanced transcription of these genes makes unlimited division of the cancer cells possible.  One 
form of cancer gene therapy is the silencing of these oncogenes. Antisense oligonucleotides, 
ribozymes and siRNAs can be used to degrade the mRNA, thereby preventing the translation of the 
oncogene mRNA into oncoproteins34,35. 
 
 Tumor suppressor gene replacement. Tumor suppressor genes like p5336, are responsible for 
repair or elimination of cells with DNA damage. By inhibiting the expression of tumor suppressor 
genes, cancer cells can continue to proliferate and avoid apoptosis. One strategy in cancer gene 
therapy is to replace the damaged tumor suppressor gene by plasmid DNA transfection. A successful 
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transfection of the cancer cell with the tumor suppressor gene will result in the production of 
proteins arranging growth arrest and apoptosis37. 
 
Immunologic therapies. Immunopotentiation is the enhancement of the immune system’s 
ability to destroy cancer cells. Passive immunopotentiation involves boosting of the natural immune 
response to make it more effective38. One of the frequently encountered genetic immunotherapy 
strategies involves the ex vivo transfection of immunologic blood cells (macrophages, dendritic cells, 
cytotoxic T-cells) with a transgene encoding cytokines and growth factors39-41. Another possibility is 
the in vitro manipulation of antigen presenting cells to enable them of active tumor antigen 
presentation. Transfection of these antigen presenting cells with a plasmid DNA containing the 
genetic code of a tumor antigen results in antigen presentation, triggering the immune system42.  
Active immunopotentiation is used to initiate an immune response against an unrecognized or 
poorly antigenic tumor38. Tumor cells can be genetically modified to express a variety of factors 
including tumor antigens, cytokines or antigen presenting molecules43. The transfected tumor cells 
are then irradiated both to minimize malignant potential and to improve immunogenicity before 
being introduced by vaccination into the patient38. Another possibility is to inject the plasmid DNA, 
containing the antigen-encoding genes, subcutaneously or intramuscularly resulting in a genetic 
vaccination against the tumor cells44.  
 
Suicide gene therapy. This is the transfection of cancer cells with genes encoding enzymes 
able to activate non-toxic pro-drugs in situ to form cytotoxic drugs. After insertion of the suicide gene 
constructs into cancer cells, treatment with high dose of a relatively non-toxic pro-drug results in a 
local conversion of these prodrugs into cytotoxic drugs, leading to cancer cell death45,46. An important 
advantage of suicide gene therapy is that only a fraction of the cancer cells has to be transfected to 
initiate tumor regression, as the cytotoxic drugs diffuse out of the transfected cells and are also 
capable of killing neighboring cells (bystander effect)38. 
 
Drug resistance genes. One major obstacle to a successful treatment with chemotherapy is the 
multidrug resistance of several tumor cells. Expression of the P-glycoprotein in cancer cells leads to 
the detection and the efflux of several drugs, resulting in a decreased sensitivity of the tumor cells 
for these drugs47-49. Gene silencing therapies like siRNA and ONs are implemented to prevent the 
expression of these drug transporters thereby lowering the chemotherapeutic drug doses 
(chemosensitization)50-53. Alternatively, hematopoetic stem and progenitor cells can be transfected 
with plasmid DNA encoding drug resistance genes. This is an important strategy to protect normal 
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cells from the toxic side-effect of therapeutic agents, thereby preventing myelosuppression 
(chemoprotection)54. 
 
Inhibition of angiogenesis, tumor invasion and metastasis. Recently, remarkable progress has 
been made in understanding the molecular mechanisms of angiogenesis, tumor invasion and 
metastasis. Several genes involved in these mechanisms are either deficient or overexpressed in 
tumor cells54. Molecules such as vascular growth factor (VEGF) are known to enhance angiogenesis55 
and can be targeted by ONs, ribozymes and siRNA56,57. Alternatively, tumor cells can also be 
transfected with plasmids encoding proteins involved in controlling tumor metastasis and invasion 
like TIMP-1 and others58. 
 
Viral Gene Delivery systems 
 
Over several years, viruses have evolved to very infectious agents that are able to efficiently 
transfer their DNA to target cells. Despite their high transfection efficiency, there are several 
concerns over the use of viruses as gene delivery systems in humans. The chief concern is the toxicity 
and the potential of generating a strong immune response. Ad random genomic integration of the 
viral genome, can generate insertional mutagenesis, that may inhibit expression of normal cellular 
genes or activate oncogenes. A more practical limitation of viral gene carriers is their limitation on 
the size of the incorporated expression plasmid20.  
     
Retroviruses. Retroviruses are single-stranded RNA viruses surrounded by a protein capsid and 
a lipid bilayer20. The virus attaches to cell-surface receptors via an envelope surface protein, followed 
by receptor-mediated endocytosis. After removal of the envelop, the viral genome undergoes 
reverse transcription to form a double-stranded DNA intermediate. The newly synthesized DNA 
enters the cell nucleus and integrates randomly in the host genome, at which point the retroviral 
vector is referred to as a provirus59. The stably integrated viral genome can be transmitted to 
daughter cells, making stable and long-term gene expression possible. Important drawbacks of 
retroviral gene therapy are the requirement of cell division for the provirus integration, which limits 
their use to dividing cells and the limitation of the incorporated DNA to 8kb54. 
 
Adenoviruses. Adenoviruses are DNA containing, non-enveloped viruses. Adenoviruses enter 
the cell by receptor mediated endocytosis. Once the virus genome is released into the nucleus, the 
viral early genes are transcribed, leading to DNA replication, late transcription, synthesis of viral 
structural proteins and virus assembly. Because of their large packaging capacity (up to 35kb) 
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adenoviruses can be used to transfer larger genes54. Adenoviruses produce high levels of gene 
expression in a large variety of dividing and non-dividing cells. However, the use of adenoviruses as 
vectors is limited by the fact that they do not integrate into the host chromosomes and the severe 
immune responses they can cause44.   
 
Adeno-associated viruses (AAV). Adeno-associated viruses are small, single-stranded DNA 
viruses, which need a helper-virus like adeno- or herpesvirus for productive virus replication. Similar 
to adenoviruses, AAV vectors can infect both dividing and non-dividing cells. However they integrate 
their DNA into the host cell genome specifically. In chromosome 19 of the human genome. Such 
specificity reduces the risk of insertional mutagenesis encountered in retroviral gene therapy44,54. 
Disadvantages are the need for helper viruses during AAV production, which can result in 
contaminated AAV vectors during production and  their limited DNA capacity (less then 5kb)44. 
 
Herpes simplex viruses (HSV). Herpes simplex viruses are large enveloped viruses with double 
stranded DNA. Features of HSV vectors are the possibility to incorporate very large genes (up to 
150kb) and their ability to transfect dividing and non-dividing cells60. Problems associated with the 
use of HSV vectors are the vector induced cytotoxicity and the transient nature of gene 
expression38,54,59. 
 
Non-viral Gene Delivery Systems 
 
As explained above, viral gene delivery systems can cause some severe side-effects, such as 
cytotoxicity, immunogenicity and insertional mutagenesis. Therefore, several non-viral vectors have 
been developed. An ideal vector should be able to (1) protect the genetic material from degradation, 
(2) bring it into the cell cytoplasm (ONs, ribozymes, siRNA) or in the nucleus of the target cells and (3) 
limit cytotoxic side-effects. In general, non viral gene delivery systems are classified into chemical 
delivery systems, including polymers and lipids, and physical delivery systems, comprising 
electroporation, hydrodynamic gene delivery, laser beam transduction, magnetofection and 
ultrasound-based delivery systems. 
 
Liposomes. Liposomes are vesicles that arise spontaneously when phospholipids are dispersed 
in an aqueous medium. Due to their polar head group and hydrophobic hydrocarbon tail, bilayered 
structures are formed with the tails pointing to each other and the polar head groups protruding in 
the aqueous environment61. Liposomes are used as versatile drug carriers, as both hydrophilic and 
hydrophobic drugs can be incorporated. For gene delivery purposes, they mostly contain a positive 
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charged lipid and a helper lipid61. Mixing of the cationic liposomes and nucleic acids results in the 
formation of lipoplexes, in which nucleic acids are sandwiched between lipid bilayers. Due to their 
net positive charge, they are easily taken up by endocytosis after electrostatic interaction with the 
cell membrane. The helper lipid, like DOPE (1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine), is 
believed to increase membrane fluidity and facilitate lipid exchange and membrane fusion between 
lipoplexes and the endosomal membrane, resulting in a good endosomal escape62. To prevent any 
unwanted interactions with serum proteins or reduce complement activation, a third PEGylated lipid 
has to be incorporated in the liposomes. The resulting PEG corona around the lipoplexes shields their 
positive charge, providing longer circulation times63. However, an important drawback is the reduced 
transfection efficiency after PEGylation, resulting from a limited endosomal uptake and endosomal 
release64,65. Several research groups are investigating the possibility of using acid-cleavable PEGylated 
lipids66. These lipids lose their PEG-chain after endosomal uptake, promoting endosomal escape. 
Figure 4 shows the general structure of a PEGylated lipoplex together with the chemical structure of 
three commonly used lipids: the cationic lipid DOTAP (N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-
trimethylammoniumchloride), the helper-lipid DOPE and the PEGylated lipid DSPE-PEG (1,2-
distearoyl-sn-glycero-phosphoethanolamine-N-[(polyethyleneglycol)-2000]. 
 
 
Figure 4 Chemical structure of the helper lipid DOPE (A), cationic lipid DOTAP (B) and PEGylated lipid DSPE-PEG-
biotin (C). Figure D shows a PEGylated lipoplex. 
 
Polymers. Several natural or synthetic cationic polymers have been evaluated as DNA carriers, 
including poly-(L-lysine) (pLL), Poly(ethylenimine) (pEI), chitosan, cationic proteins and cationic 
peptides. Most of these polymers condense the DNA into small particles (polyplexes) and facilitate 
intracellular uptake via endocytosis through electrostatic interactions with anionic sites on cell 
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surfaces67. Large differences exist in the transfection efficiency and cytotoxicity among the different 
polymers62. Several synthetic biodegradable polymers are synthesized to reduce the cytotoxic side-
effects and enhance transfection68.  
 
Electroporation. This technique comprises the direct application of electric pulses on tissues or 
cells. The electric field causes a transient permeabilization of the cell membrane and allows the 
entrance of nucleic acids69. When the applied external field exceeds the capacity of the cell 
membrane, hydrophilic pores are formed through which water enters the cell. The degree of pore 
formation can be controlled by changing the intensity of the electric field, pulse duration and pulse 
number70. Advantages of this technique are the simplicity, efficiency and safety. However, 
applications are limited to tissues where the electrodes can be inserted. Electroporation has been 
used in cancer gene therapy for genetic vaccination against melanoma antigens. In 2004 several 
clinical trials have been performed for the IL-12 transfection of melanoma cells finding encouraging 
results71,72.  
 
Hydrodynamic Delivery. Hydrodynamic gene delivery is a simple method that introduces 
naked plasmid DNA in highly perfused organs73. Hydrodynamic gene delivery has been mainly applied 
for hepatic gene delivery. Tail vein injection of mice with an extremely large DNA containing volume, 
causes a transient overflow at the vena cava that exceeds the cardiac output. As a result, the 
injection induces a flow of DNA solution in retrograde into the liver and causes a rapid rise of 
intrahepatic pressure, resulting in liver expansion and reversible disruption of the liver fenestrae62,74. 
 
Gene Gun. In this delivery method, the DNA is deposited on the surface of gold particles, 
which are then accelerated by pressurized gas and expelled onto tissue. In this way, the particles are 
able to penetrate a few millimeters deep into the tissue and release the DNA. The major application 
of this technology is genetic immunization, although it has also been used for cancer pro-drug 
therapy75. 
 
Magnetofection. In this method, the nucleic acid is reversible attached to magnetic particles, 
which are then focused to the target site via a high-energy magnetic field72. This technique allows 
delivery of the genetic particles into the target cells and can even cause extravasation75. The genetic 
material dissociates from the magnetic particles after cellular entry. Magnetofaction has shown in 
vitro to promote rapid and high gene expression levels and has also been applied to achieve genetic 
vaccination72.  
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ULTRASOUND AND MICROBUBBLES 
 
ULTRASOUND 
 
What is ultrasound?  
 
Sound is a longitudinal compressional wave as depicted in Figure 5. When the frequency of the 
sound wave is above the typical human audible range (> 20 kHz), it is called ultrasound76. Ultrasonic 
waves are generated by transducers which are piezoelectric elements producing elastic vibrations77. 
The ultrasound wave consists of high pressure and low pressure areas. As the ultrasound wave is 
passing through a medium, the radiated material vibrates. Figure 5 shows the displacement of the 
different particles in a certain medium as the ultrasound wave is passing through. In the high 
pressure areas (compression), the particles are squeezed together, whereas at the low pressure areas 
(rarefaction) they are spread apart.  
 
 
 
Figure 5 Schematic representation of a single-frequency ultrasonic wave (a). The ultrasound wave consists of 
low pressure (rarefaction) and high pressure (compression) phases. Part (b) shows the displacement of 
particles in a material as the ultrasonic wave is passing through. Part (c) displays the acoustic pressure of the 
ultrasound beam as a function of distance, and shows the amplitude (A) and wavelength (λ) of the wave. 
Adapted from reference
76
. 
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The ultrasound wave is characterized by a specific frequency (f). While the frequency is 
unaltered when the ultrasound travels through different media, this is not the case for the 
wavelength (λ). The relation between the velocity (v), wavelength (λ) and frequency (f) is given by the 
following equation. 
 
As the ultrasound is travelling through a more denser medium, its velocity and wavelength will 
increase. The intensity of the ultrasound is given by the amplitude (A) of the wave and is expressed 
as pressure (Pa). A summary can be found in Table 1. 
 
Frequency (f) f Number of times a particle experiences a complete 
compression/rarefaction cycle in 1 second. ( (Hz) 
Wavelength λ The distance between two equivalent points on the waveform in a 
particular medium. (nm) 
Period T Duration of 1 cycle ( ). (s)  
Amplitude A Peak pressure. (Pa) 
Table 1   Different parameters characterizing an ultrasonic wave, passing through a particular medium.  
 
Besides continuous ultrasound, ultrasound can also be repeatedly turned on and off. This is 
called pulsed wave ultrasound (PW). This generation mode is accomplished by exciting or shocking 
the ultrasonic transducer with very short electrical signals, waiting for some time and then repeating 
the electrical shocking. Figure 6 represents a pulsed ultrasonic wave, and indicates the pulse duration 
(τ) and Pulse Repition Period (PRP). The different parameters characterizing a pulsed ultrasound 
wave are explained in Table 2. 
 
 
Figure 6 Schematic representation of a pulsed ultrasound wave with indication of the wavelength (λ), 
amplitude (A), pulse duration (τ) and Pulse Repetition Period (PRP). 
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Pulse duration τ Duration of one ultrasound pulse. (s) 
 
Pulse repetition period PRP Time between the beginning of an ultrasound pulse and 
the beginning of a second one. (s) 
Duty Factor DF Fraction of the time the ultrasound is “on” ( .  
Pulse Repetition frequency PRF Number of pulses occurring during 1 second ( . ( ) (Hz) 
Table 2 Different parameters characterizing a pulsed ultrasound wave. 
  
The velocity of an ultrasound wave is independent of the frequency, but depends on the 
material and is listed for several media in Table 376. The mass and spacing of the molecules of the 
material and the attracting force between the particles of the material all have an effect on the 
speed of the ultrasound as it passes through. Ultrasound travels faster in dense materials and slower 
in compressible materials. For medical applications the propagation speed in tissue is typically 
assumed to be constant at 1540 m/s. 
 
Medium Propagation Speed (m/s) 
Air 330 
Water 1520 
Soft tissue 1540 
Bone 3800 
Table 3  Speed of sound in different media. Adapted from reference
77
. 
 
When ultrasound waves pass through tissue, their intensity decreases as a result of reflection, 
refraction and absorption of the ultrasound76. The decrease in ultrasound intensity is called 
attenuation and depends on the type of tissue through which the ultrasound is passing. At the 
boundaries between tissues with different acoustic properties, the ultrasound wave will be partially 
reflected. This reflection becomes larger as the difference in acoustic properties of the tissues 
increases. So, for example, the reflection will be very high at the boundary of bone and soft tissue. As 
explained further in this introduction, this principle forms the basis of acoustic imaging. Another 
phenomenon that takes place is absorption of the ultrasound energy by the material. Because of the 
movement of the different particles in a tissue (Figure 5), part of the acoustic energy is converted 
Introduction – Chapter 1 
 
37 
into heat. This absorption increases with rising frequency and can be used to ablate tumor tissue, as 
will be explained later on.  
 
Biophysical effects of ultrasound 
 
 A tissue subjected to ultrasound can experience several biological effects. Generally these 
effects can be classified into primary physical effects and secondary effects. The most important 
primary physical effect of ultrasound is the direct deposition of acoustic energy as heat in the tissue. 
This phenomenon is used in High Intensity Focused Ultrasound (HIFU) to ablate tumor tissue. 
Ultrasound might also interact with pre-existing gas bubbles in tissue, resulting in cavitation of these 
“microbubbles”. However, little evidence is available that cavitation indeed develops in vivo, without 
previously injecting microbubbles78. To enhance acoustic cavitation, microbubbles are injected into 
the bloodstream. The cellular effects associated with acoustic cavitation will be described in the 
microbubble section.  
Other non-thermal, secondary effects are directly related to the non linear propagation of an 
ultrasonic wave79. When the intensity of the ultrasound wave is high enough, the ultrasound starts to 
propagate non-linearly in the tissue. When a fluid or tissue is compressed in the high pressure phase, 
its stiffness and density increases. As a result, the high pressure peaks will travel faster than the low 
pressure phases76 (Figure 7a). This non linear propagation leads to the distortion of the initially 
sinusoidal waves and can ultimately result in the generation of a shock wave (Figure 7b). As a 
consequence of the distortion of the wave in time, additional frequencies are generated, also called 
“harmonics” of the initial frequency80. Pressure gradients coming directly from the ultrasonic wave 
normally have a rather long wavelength, which means that a broad distance exists between a high 
and low pressure phase (Figure 7a: D). However, when non linear propagation occurs, this distance is 
drastically shortened (Figure 7b: D’). Due to the sudden changes in pressure occurring at short 
distance, biological tissues are subjected to very high shear forces, which can damage the tissue81.  
Other secondary physical effects are the formation of radiation pressure when the ultrasonic 
wave is reflected at a boundary. Due to the partial reflection of the ultrasound wave, the intensity is 
lowered and a difference in mean pressure on the boundary and behind arises. As a result particles in 
the medium can experience an acoustic radiation force, which can result in the displacement of 
particles. A second effect, called acoustic streaming, arises directly from the attenuation of the 
ultrasonic wave. During its passage through the tissue, the intensity of the ultrasonic wave decreases 
as energy is absorbed from the beam. A pressure gradient is formed and when this acts upon a liquid, 
a fluid stream develops that is directed away from the ultrasonic transducer76,76,80.  
 
Chapter 1 – Introduction 
 
38 
 
 
Figure 7 Schematic representation of shock wave formation (b) due to non linear propagation of the ultrasound 
(a). D and D’ show the distance between the area of maximal compression and maximal decompression in a 
normal ultrasound wave and shock wave respectively.  Adapted from reference
76
. 
  
Medical applications 
 
The biophysical effects of ultrasonic radiation can provoke several biological responses. 
Whereas diagnostic ultrasound preferably should be free of medically significant bio-effects, the 
objective of therapeutic ultrasound is to provoke a specific biological response82,83. Which biophysical 
effect will dominate mainly depends on the frequency and intensity of the applied ultrasound. High 
frequency ultrasound is more readily absorbed by tissue and is therefore extremely suited for HIFU 
applications. On the other hand, when cavitation should occur, low frequency ultrasound is more 
appropriate and pulsed ultrasound can be used to decrease heat formation78,83 (figure 8). Ultrasound 
therapy can be broadly divided into two subcategories: “high” power and “low” power therapies. 
High power acoustic therapies include HIFU and lithotripsy, whereas low power therapies comprises 
sonophoresis and physiotherapy.  
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Figure 8 Overview of different ultrasound frequencies used for medical applications. 
 
Ultrasound imaging. As mentioned above, part of the ultrasound becomes reflected at tissue 
interfaces. Image formation depends entirely on the returning echoes, which are converted into an 
electric signal by the transducer. The intensity or amplitude of the reflected wave, as well as the time 
between emission and receiving the signal are registered. An image is then constructed based on this 
information. Early imaging modalities displayed the amplitude of the signal as a function of time (A-
mode: Amplitude)84. Current imaging modalities build up a grayscale image, in which higher 
intensities can be seen as brighter areas and lower intensities as darker areas (B-mode: Brightness). 
As explained above, a shift to higher frequencies is observed as a result of the non linear propagation 
of the ultrasound wave. This principle is used in harmonic imaging80,84. In this case, only harmonics of 
the initial frequency are registered to improve the signal-to-noise ratio and enhance the contrast. 
 Also Doppler imaging is widely used to image blood flow patterns. This imaging technique is 
based on the Doppler principle. Imaging of the moving blood flow results in a change in frequency of 
the reflected ultrasound. Higher frequencies are received from blood cells moving towards the 
transducer, while lower frequencies are received when blood cell move away. From the shift in 
frequency the direction and rate of the blood flow can be deducted77. Compared to other imaging 
modalities, ultrasound has several advantages. Only minor side effects exist due to its non-invasive 
character and the fact that no ionizing radiation is used. Furthermore, ultrasound is a non-expensive 
and portable technique that is therefore widely used in pregnancy follow-up and diagnosis. However, 
it cannot be used to image air-containing media like lungs or bowl and imaging of deeper lying 
structures is sometimes impossible.  
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High Intensity Focused Ultrasound (HIFU). HIFU is more and more established as a full-fledged 
tumor ablation technique. In contrast to surgery it is a non-invasive technique and toxicity can be 
seriously reduced85. Unlike other ablation techniques like radiotherapy or cryotherapy, areas located 
deeper in the body can be reached and HIFU lesions are well defined with no surrounding cellular 
damage. This makes HIFU extremely suited for ablation of tumors close to sensitive tissues that must 
be spared like prostate or oesophagus. When the ultrasound beam is passing through a tissue, a 
certain amount of the acoustic energy is absorbed by this tissue and converted into heat86. If the 
ultrasound beam is brought into focus, the energy within the focal volume can cause a local rise in 
temperature that is high enough to induce tissue necrosis. In HIFU treatment, the temperature of an 
isolated tumor volume is raised above 55°C for longer than 1 second. This leads to necrosis and 
immediate cell death85-87.   
Another phenomenon that enhances tissue necrosis is the appearance of cavitation88,89. 
Cavitation can damage cells directly, but the strong scattering of the microbubbles also leads to the 
entrapment of the acoustic energy in the cavitating region. This increases the heat deposition in the 
immediate surroundings of the cavitating microbubble. Lesion dimensions depend on frequency and 
device geometry, but are in the mm range. If larger tumor volumes are treated, the transducer is 
moved in discrete steps until the whole tumor volume is ablated or the active transducer can be 
moved in a pre-determined track. Ultrasound frequencies used in HIFU treatment largely depend on 
the target region. As attenuation increases with higher ultrasound frequencies, frequencies up to 
8MHz are used to treat shallow tumors, while lower frequencies (0.5 or 1MHz) at higher intensities 
are used to reach tumors more deeply within the body90. Despite the above mentioned advantages, 
some limitations exist for HIFU treatment. Ultrasound is not able to propagate through air-filled 
organs like lungs or bowl and also other structures like bone can absorb or reflect the ultrasound 
beam91.  
Several clinical trials have been established using HIFU for the treatment of breast92,93, 
prostate94 and liver cancer95. The results look very promising and further clinical research is required 
to verify whether HIFU can become an alternative to surgery in these different applications. 
 
Lithotripsy. Low frequency ultrasound can be applied extracorporally to induce fragmentation 
of bile and urine stones. After fragmentation, the small remainders can pass spontaneously through 
the urinary tract96,96,97,97. Short pulses with high intensity are focused on the stones. As the 
ultrasound wave propagates non linear, a shock wave is focused in the stone. Due to the high 
pressure gradients in the stone, shear stress and finally tensile stress and strain are created resulting 
in the erosion of the surface98.  If the waves are less sharply focused, the ultrasound beam becomes 
reflected at the water-stone interface, which leads to the splitting of stone material. 
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Sonophoresis. Ultrasound can be used to locally enhance the transport of low and high 
molecular weight drugs through the skin99-104. The stratum corneum is the main barrier for drug 
delivery through the skin105. Corneocytes are embedded in a continuous matrix of lipid bilayers, 
which effectively prevent the diffusion of drug molecules. Recent publications have shown that the 
stratum corneum becomes disrupted after ultrasound treatment and that localized regions of high 
permeability appear because of the creation of aqueous channels106-113. Cavitation is thought to be 
the main mechanism of this enhanced drug transport114. Inertial cavitation (see microbubble chapter) 
of the gas bubbles present in the coupling medium between transducer and skin layer can cause the 
formation of shock waves and microjets that are able to disrupt the stratum corneum. Both high 
frequency and low frequency ultrasound have been used, although low frequency ultrasound has 
proven to be more effective, due to the higher level of cavitation. The passage of several low and 
high molecular weight drugs like insulin, NSAID, oligonucleotides and local anesthetics115-120 has been 
demonstrated and the recent development of easy-to-use devices could lead to the application of 
sonophoresis in clinical medicine105. 
 
Physiotherapy. Therapeutic ultrasound has been addressed to treat soft tissue injuries, 
accelerate wound healing, reduce pain and soften scar tissue83,121-124. The mechanisms involved are 
very complex and include thermal aspects, as well as non-thermal aspects125-127. Ultrasound has been 
shown to promote inflammation and stimulate tissue healing and wound repair, mainly in vitro128. 
However, most in vivo trials have not succeeded in finding a beneficial effect of therapeutic 
ultrasound in physiotherapy128.   
 
Bone healing. The use of low frequency ultrasound for the stimulation of bone growth, has 
been approved by several in vitro and in vivo studies129-132. Bone formation is a very complex process 
involving inflammation, proliferation (angiogenesis, callus formation and hardening) and remodeling 
of the bone tissue127. Ultrasound exposure of the fracture promotes inflammation and angiogenesis. 
Also, the proliferation of stem cells and ossification of the matrix have been reported129,133. In 2000 a 
commercial available ultrasound device became available, especially for fracture healing (EXOGENTM, 
Smith and Nephew).  
 
Sonodynamic therapy. The term “sonodynamic therapy” was originally introduced to describe 
the phenomenon of sonochemical activation of photosensitive materials for cancer therapy. 
Ultrasound exposure of certain prodrugs like porphyrines causes the creation of reactive oxygen 
species which are able to destruct cancer tissue134-137. The prodrug itself has a very low cytotoxicity 
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and can be locally activated, so that only the tumor tissue will be affected138. The same term is 
sometimes used to describe more generally the use of ultrasound to enhance drug delivery. These 
applications are described in the next paragraph. 
 
Drug delivery.  Ultrasound can be used to disrupt micelles and encourage drug release in the 
desired region. The physical entrapment of several anticancer drugs like doxorubicin and paclitaxel 
has been achieved and ultrasound has shown to promote their release from the micelles139. Besides 
increasing the local concentration of anticancer drugs, a synergistic effect between ultrasound and 
chemotherapeutics has been described138,140-144. After ultrasonic treatment, tissues can become more 
sensitive to lower chemotherapeutic drug concentrations. 
 
MICROBUBBLES 
 
Microbubble composition 
  
Microbubbles are gas-filled structures consisting of a gaseous core surrounded by a stabilizing 
shell (Figure 9).  
 
 
Figure 9 Transmission image of lipid coated microbubbles (A). Schematic and 3D representation of a 
microbubble with indication of the gas core and microbubble shell (B).  
 
Core. First generation contrast agents were filled with air. Due to the relative high water 
solubility of air, these microbubbles quickly dissolve in the bloodstream145. For this reason, second 
generation microbubbles are prepared with perfluorocarbon gases (CnFn+2) or sulfur hexafluoride 
(SF6)
146. These gases are hydrophobic and prevent premature gas loss from the microbubble145,147-149. 
Perfluorocarbons are extremely stable, biologically inert molecules that are not metabolized in the 
body, but exhaled within a few minutes145. 
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Shell. The shell of a microbubble is essential to prevent or lower gas diffusion from the 
microbubble and hence, prevent microbubble dissolution. A disadvantage of this coating is the 
reduction of the microbubble oscillations in the ultrasonic field. Microbubbles can be divided into 
soft-shelled and hard-shelled contrast agents150. First generation microbubbles were prepared with 
cross-linked albumin, which forms a stiff shell. A disadvantage of this shell type is the fact that the 
high stiffness reduces the extent of cavitation. Recently, also polymer-shelled microbubbles have 
been introduced. Polymer microbubbles have a thicker and even stiffer shell than albumin 
microbubbles151. This leads to a reduced scattering efficiency, which makes these microbubbles less 
suited for diagnostic applications. However, they have an improved stability and above a certain 
threshold the polymer shell fractures151making these microbubble types very appropriate for drug 
delivery applications. 
Lipid microbubble shells are more flexible and constrain the microbubble oscillations to a 
lesser extent147. These shells are also more resistant to rupture, due to their higher flexibility152. The 
lipids are able to reseal and this leads to a longer lifetime, before and during cavitation153. Another 
advantage of lipid shelled microbubbles is the easy modification of the shell by including different 
lipids. By increasing the chain length of the lipids more robust microbubbles are formed154.  Also, the 
inclusion of PEGylated lipids prevents any unwanted immune responses in vivo.
Table 4 Commercially available microbubble agents.  
Microbubbles normally have a size distribution between 0.5 and 10 µm. As microbubbles become 
larger, they become more echogenic. However, a compromise must be made between this 
echogenicity and the maximum size of bubbles for intravascular use, as the passage through the 
pulmonary capillary bed is restricted to particles with a size of 10µm.  
 
Name Manufacturer Stabilizing Coat Gas Core Availability 
Sonovue Bracco Diagnostics Phospholipid SF6 EU, China, South America 
Definity Lantheus Medical Imaging Phospholipid C3F8 USA, Canada 
Optison GE Healthcare Albumin C3F8 EU, USA 
Sonazoid Amersham Health Lipids C4F10 Japan 
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Safety and clearance of microbubbles 
 
The safety of approved microbubble contrast agents has been reviewed in 2005155. Guidelines 
for their clinical use in humans were published by the European Federation of Societies for 
Ultrasound in Medicine and Biology156. In general, ultrasound contrast agents are extremely safe and 
well tolerated. In humans, the incidence of side effects is low, predominantly minor in nature 
(headache, nausea) and self-limiting. Hypersensitivity or allergic events occur rarely. There is no 
evidence of nephrotoxicity, cardiotoxicity, cerebral or liver toxicity157.  
After intravenous injection microbubble-based contrast agents present a pure intravascular 
distribution in the peripheral circle and are defined blood pool agents. Some agents like Levovist, 
Sonavist and Sonazoid present a late hepatosplenic-specific phase158-160. This has been explained by 
the adherence and selective pooling of the micobubbles in the hepatic sinusoids or by the selective 
uptake from the circulation by phagocytic cells of the reticuloendothelial system in the liver and 
spleen158,159,161. Removal of the microbubbles by the reticuloendothelial systems largely depends on 
the materials present on the microbubble shell162. Microbubbles that are not quickly taken by 
phagocytic cells, gradually dissolve in the blood stream145,162. The gas content of the microbubbles is 
eliminated through the lungs. Perfluorocarbons and sulphur hexafluoride are inert gases which do 
not undergo metabolism in the human body but are exhaled via the lungs after a few minutes145. The 
microbubble shell components are filtered by the kidney, eliminated by the liver or enter normal 
metabolism157.  
 
Response of microbubbles to ultrasound 
  
Microbubbles are highly compressible, gas-filled structures surrounded by a stabilizing 
shell. The behaviour of microbubbles in an ultrasonic field mainly depends on the frequency, and 
intensity of the applied ultrasound. 
At very low acoustic pressures (< 100kPa for 1MHz), the microbubbles oscillate in a 
symmetrical, linear way. This means that their expansion and compression is inversely 
proportional to the pressure phases in the ultrasound field151,163. As a result, the microbubbles 
produce a backscatter with the same frequency of the transmitted ultrasound (linear 
backscatter). The intensity of this backscatter depends on the microbubble size, as the response 
of the microbubbles is higher when the frequency is closer to their natural resonant frequency. 
The higher the microbubble radius, the lower the resonant frequency163. 
At higher ultrasound intensities (0.1-1 MPa; 1MHz), the microbubbles behave non-linearly. 
Then the expansion phase of the microbubbles lengthens, as the microbubbles are more 
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resistant to compression than to expansion150,154. This phenomenon is also known as stable 
cavitation or non-inertial cavitation151. During cavitation of the microbubble, there is gas influx 
(during rarefaction) and gas efflux (during compression). In the case of symmetrical oscillations, 
the netto gas influx over one expansion/compression cycle is zero. However, when the expansion 
phase prolongates, there is a netto gas influx into the microbubble. For this reason, the 
microbubble grows until it reaches its resonant size, whereupon it demonstrates stable, low 
amplitude oscillation (Figure 10b). Such stable oscillations create a strong liquid flow around the 
microbubbles, the so-called microstreams. Microstreams can apply a shear stress on cell 
membranes which may result in a transient opening of the membranes154,164-166.  
At even higher ultrasound intensities (> 1MPa; 1MHz), the oscillation amplitude of the 
microbubbles grows rapidly during the rarefaction phase, until the microbubble collapses due to 
the inertia of the inrushing fluid. This results in the fragmentation of the microbubbles into many 
smaller microbubbles. This type of cavitation is called inertial cavitation (Figure 10). During the 
collapse of the microbubbles, shock waves are generated in the fluid near the microbubble. 
Finally, also jet formation can occur when a collapsing microbubble is located close to a surface 
like a cell wall. In this case an asymetrical collapse takes place, which results in the formation of 
a liquid jet towards the surface. The shock waves and microjets create very high forces that can 
perforate cell membranes and even permeabilize blood vessels. 
 
 
Figure 10 Schematic representation of microbubbles undergoing stable (b) or inertial cavitation (c) under the 
influence of an ultrasonic field (a). Adapted from reference
76
. 
Bio-effects of cavitating and imploding microbubbles  
 
The gentle (microstreaming) or strong (shock waves and microjets) forces that develop in the 
neighbourhood of cavitating microbubbles can affect biological tissues167. 
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Microstreams around a cavitating microbubble are much more powerful than acoustic streaming, 
arising from ultrasound treatment of tissue without microbubbles78. The intensity of the 
microstreams quickly drops with increasing distance from the microbubble. As a result, cells or 
surfaces closely located to cavitating microbubbles are subjected to high shear stresses. This can 
temporarily permeabilize cell membranes and stimulate drug transport in the cell168.  
In the case of an imploding microbubble, even more powerful forces develop. Several in vitro 
and in vivo studies have reported capillary rupture, microvascular leakages and hemolysis169-173. This 
offers great potential for drug delivery applications as several pharmaceutical carriers are not able to 
cross the endothelial cell barrier. A schematic overview of different bio-effects is represented in 
Figure 11. 
In addition, several papers have describe the formation of reactive oxygen species during 
cavitation. These can put a chemical stress on cell membranes and in turn permeabilize cell 
membranes174-176. Most likely, a combination of mechanical and chemical phenomenons is 
responsible for the creation of cell membrane pores and vascular defects. Depending on the 
frequency and intensity of the applied ultrasound, different bio-effects may become more important.  
 
 
Figure 11 Bio-effects caused by a stably cavitating microbubble (left side) or imploding microbubble (right side). 
Adapted from reference
177
. 
   
Medical applications of microbubbles 
 
Microbubbles were originally implemented in ultrasound imaging, as they increase the 
ultrasound reflection and are therefore also called “ultrasound contrast agents”. Several of these 
agents are now FDA approved and are already in use in daily clinic. Besides their diagnostic value,  
microbubbles are investigated as versatile therapeutic tools.  
 
Enhanced ultrasound imaging. Because of their high compressibility, microbubbles can 
increase the reflection of the transmitted ultrasound wave and are therefore used to obtain a better 
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resolution in conventional imaging techniques178. As microbubbles are not able to leave the blood 
stream, their use remains restricted to the imaging of myocardium and vasculature of different 
organs154. While conventional ultrasound transmits and receives the same ultrasound frequency, 
harmonic imaging is based on the detection of harmonics of the transmitted frequency. Because of 
the non-linear behaviour of the microbubbles, subharmonics of the original frequency are returned 
to the transducer. This significantly improves the signal-to-noise ratio and refines the image. 
Microbubbles are particulary useful in myocardial imaging to diagnose infarction and identify 
coronary artery stenosis179. Microbubbles also have an important role in imaging blood-flow and 
neovascularization180. Another application is the diagnosis of breast tumors. Determination of the 
tumor vasculature can be extremely important in differentiating between benign and malign 
tumors142. Also, some specific liver contrast agents exist like Levovist, Sonavist and Sonazoid. These 
agents are easily taken up by the reticulo endothelial system (RES) of the liver161,181,182. This can be 
employed to improve the detection of liver malignancies and to study the condition of patients 
undergoing metastasis resection183.  
Ultrasound imaging aims to detect diseases or any abnormalities without causing bio-effects. 
Therefore, the ultrasound intensity is often low. In this case, inertial cavitation of the microbubbles is 
prevented, which contributes to a longer enhanced contrast of the image. 
 
Sonothrombolysis. Ultrasound is used in the treatment of acute myocardial infarctions and 
ischemic stroke184-188. Both diseases originate from the presence of a thrombus in the coronary 
arteries or brain vasculature respectively, which blocks the blood circulation and leads to tissue 
necrosis. Dissolution of the clot within three hours after appearance of the first symptoms can 
drastically reduce mortality and reduce disability. Ultrasonic radiation of the thrombus results in the 
dissolution of the thrombus and reperfusion of the tissue. Low frequency ultrasound with a high 
intensity is delivered via a catheter, to minimize tissue damage, and can mechanically disrupt the 
clot189. This has the advantage that also old thrombi and calcified clots can be destroyed. Another 
option is to treat the clot with high frequency ultrasound after the intravenous injection of 
thrombolytic agents like tissue Plasminogen Activator (tPA)190,191. Several papers have reported an 
enhanced thrombolytic effect of tPA after ultrasound application. The acoustic streaming increases 
the permeability of the clot and rearranges the fibrin strands, which makes them more accessible for 
enzymatic degradation192. Another promising approach is the injection of ultrasound contrast agents 
in combination with low or high frequency ultrasound189,193-195. The microstreamings, shock waves 
and microjets developed during inertial cavitation of the microbubbles, mechanically disrupt the 
clot189,190,190. Several clinical trials already reported the beneficial effect of sonothrombolysis, and 
further randomized controlled clinical trials are currently going on to confirm these results190.  
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Disruption of the brain-blood barrier. A new and very exciting application of microbubbles 
and ultrasound is their use as blood-brain barrier (BBB) disrupters196. Drug transport to the brain is 
restricted by the impermeable BBB197. The endothelial cells of the central nerve system are tightly 
attached to each other by intercellular attachments known as adherens junctions and tight junctions, 
the latter preventing intermixing of apical and basolateral surface components198. Low frequency, as 
well as high frequency ultrasound with low intensity can be used to temporarily open the BBB. 
Although disruption with ultrasound alone has been demonstrated, BBB opening after the 
intravenous injection of microbubbles is the only method to produce reversible BBB disruption 
without brain tissue damage199. Again, cavitation of the microbubbles with the corresponding 
microstreams, shock waves and microjets are responsible for this reversible opening200. Three 
different mechanisms have been identified that allow drug transport across the BBB after exposure 
to microbubbles and ultrasound. First, micro-disruptions of the brain capillaries were observed 
together with the extravasation of red blood cells201. This effect is probably the result of powerful 
microjets that perforate vessel walls. Due to the risk of brain hemorrhages, extravasation should be 
limited, which can be done by restricting the ultrasound intensity202. Second, dye leakage was 
observed through intact endothelium, in which the tight junctions were widened201,203. Enhanced 
drug transport maintained for 1 or 2 hours after ultrasound exposure, and tight junctions completely 
recovered within 4 hours199. Third, vacuoles were detected transporting marker molecules through 
the endothelial cells203. These effects have been observed in vitro201,204, as well as in vivo205,206 and 
further research is required to optimize ultrasound settings, necessary to obtain a suitable 
ultrasound intensity through the skull199,203. 
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DRUG AND GENE DELIVERY WITH MICROBUBBLES AND ULTRASOUND 
 
WORKING PRINCIPLE 
 
As explained earlier, microbubbles can undergo stable or inertial cavitation when exposed to 
ultrasound. While stable cavitation results in the formation of rather “gentle” microstreams, 
imploding microbubbles can induce very high forces like shock waves. Also, when an imploding 
microbubble is located close to a boundary like a cell layer, a microjet is formed directed towards the 
cell surface. These phenomenoms can result in the formation of transient pores in the cell 
membranes. The size and duration of the cell membrane pores depends on the ultrasound 
conditions, microbubbles and cell types used (Figure 11). In some studies 30 to 100 nm pores were 
reported207-209, while in other studies cell membrane perforations of a few micrometers in size were 
observed210-212. Most cells are able to reseal these cell membrane wounds after several seconds to 
minutes208,209,212. Recent publications have demonstrated that this recovery process is energy 
dependent212. Cell membrane wounds are resealed by the exocytosis of intracellular vesicles212. 
Lysosomes fuse with each other and are then transported to the cell membrane where they fuse 
with the cell membrane lipids213, a process which is also seen when cells are subjected to other 
physical stress, like cell scraping212. Macromolecular drugs are able to reach the cytoplasm of the cell 
through these cell membrane pores. The intracellular uptake of several drugs like proteins, plasmid 
DNa, siRNA has been demonstrated after exposure to microbubbles and ultrasound. The microjets 
and shock waves may also permeabilize blood vessels which can promote the extravasation of high 
molecular weight drugs and drug containing nanoparticles.  
Ultrasonic drug delivery offers many advantages. Ultrasound exposure of microbubbles can 
locally release drugs, assist in intracellular drug delivery and induce extravasation of drugs. Other 
advantages of ultrasound are related to the fact that it is a cheap, portable technique which is 
applicable to a major part of the body. As it is a non-invasive method, ultrasound could be 
particularly interesting for these applications where repeated treatment is required.  
 
MICROBUBBLE DESIGN  
 
Why designing a drug loaded microbubble? 
 
Early drug delivery studies involved the systemic co-injection of a drug (being in solution or 
incorporated in a particle) and microbubbles followed by the local application of ultrasound. 
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Although these studies were often successful in enhancing drug delivery, it would be even more 
advantageous to bind the drug molecules to the microbubbles. There are different reasons why drug 
loaded microbubbles are so interesting. First, a drug carrying microbubble can locally release its 
content and simultaneously increase the drug uptake in the ultrasound treated area. In this way, 
drug release and uptake in untreated (and unwanted) body parts can be drastically reduced. This is 
particulary useful in cases where the cytotoxicity of the drug is an issue.  
Second, the concurrent drug release during the implosion of the drug carrying microbubbles 
will result in a very high drug concentration close to the cell or blood vessel perforations. This is very 
important as drug transport through the sonoporated pores may significantly improve when the drug 
concentration near these pores is high.  
Third, a closer contact between microbubbles and drug will increase the chance that the drugs 
are taken by the microstreams and shock waves that develop around a cavitating microbubble. As 
these fluid streams are causing cell membrane perforations, drugs that are taken by these streams 
might be more easily pushed through the cell membrane disruptions. Also, many biological drugs 
under development, like nucleic acids and proteins, rapidly degrade in blood after systemic injection. 
Binding of such labile biologicals to microbubbles may protect them from degradation, which is 
another interesting feature. Especially as it may lower the required dose and thus the therapy costs.  
 
 
Figure 12 Schematic overview showing the advantages of targeted drug delivery with drug loaded 
microbubbles and ultrasound. 
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Finally, binding drug molecules to microbubbles will allow to „visualize‟ drug delivery. In this 
case, a low acoustic pressure can be applied to image the target site followed by a higher acoustic 
pressure to rupture the microbubbles and deliver the therapeutic agents in the target region. Clearly, 
drug loaded microbubbles show potential to reduce the required dose of a drug and hence toxic side 
effects, which is particulary useful for drugs with a low therapeutic index.  
 
Drug loaded microbubbles  
 
Generally speaking, as illustrated in Figure 13, drugs can be either (a) incorporated in the 
gaseous core, (b) incorporated in the microbubble shell or (c), (d) attached to the surface of the 
microbubbles. 
 
 
Figure 13 Schematic representation of possible drug cargo spaces in microbubbles. Drugs can be encapsulated 
within the perfluorocarbon core (a) or incorporated in the shell of the microbubble (b). Drug loading outside 
the microbubble shell can be accomplished through electrostatic interaction (c) or avidin-biotin linkage (d). 
Instead of a lipid microbubble shell, albumin or polymer shells can be used. 
 
Drugs incorporated in the gaseous core of the microbubble.  Incorporating drugs in the 
interior of the microbubbles has the advantage that it assures complete protection of the drug and 
that it lowers the chance of premature release i.e. drug release before applying ultrasound.  
Acoustically Active Liposomes (AALS) are microbubbles encapsulating an oil layer between the 
gaseous core and lipid shell in which hydrophobic drugs can be dissolved (Figure 14A). High drug 
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loading capacities have been reported with paclitaxel loaded AALS214. However, very high ultrasound 
intensities are required to obtain sufficient drug release, as the oil layer inside retards wall velocity 
associated with cavitation214,215. Recently also polymer-shelled, oil-filled microbubbles were reported 
encapsulating sudan black as model drug216.  
Echogenic Liposomes (ELIP) are another microbubble type, enabling the incorporation of 
hydrophilic drugs inside the microbubble217-219(Figure 14B). Drug loading and gas encapsulation is 
obtained after different freeze and thaw cycles in the presence of mannitol. This results in the 
rupture of the lipid bilayer which increases gas inclusion and makes drug loading possible153,219-221. 
Drug release from ELIPs is expected to occur relatively easy. Drugs are able to leak out when the 
expansion of the microbubble exceeds the elastic limit of the lipid shell. Furthermore, successive 
expansion cycles can be used to increase drug release, as the microbubble shell is able to reseal due 
to the flexibility of the lipid monolayer221.  
 
 
Figure 14 Schematic presentation of an acoustically active liposphere (AALS) encapsulating hydrophobic drugs 
and hydrophobic gas (A). Two possible presentations of an echogenic liposome encapsulating hydrophilic drugs 
and hydrophobic gas (B). 
 
An alternative strategy to enclose hydrophilic compounds is the formation of pLGA (poly-(D,L-
lactide-coglycolide)) microparticles222. This echogenic microcapsule has been loaded with pDNA and 
pDNA-polymer complexes. However, important drawbacks are the large size (3-7µm), the low 
loading efficiency and the fact that drugs are able to leak out before ultrasound exposure, due to the 
high porosity of this capsule.  
 
Drugs incorporated in the shell of a microbubble. Drug loading inside the microbubble shell 
has been demonstrated with pDNA loaded albumin microbubbles. In this case, the genetic material is 
Introduction – Chapter 1 
 
53 
added during microbubble preparation223,224. Experiments revealed that the DNA was still intact after 
sonication of the albumin solution. After intravenous injection of the microbubbles there might be a 
risk of premature release due to interaction of the micobubble shell with several blood components.  
Also, shell-loaded ELIP containing hirudin, a small (7kDa) thrombin inhibiting peptide, were 
prepared225. Therefore, the hirudin was added to the ELIPs after successive freeze-drying steps of the 
liposome mixture. Important remarks are the fact that drug loading is rather limited and will depend 
mainly on the polarity of the drug, as lipid microbubbles are surrounded by a mono-layer of 
phospholipids226. One can assume that only the hydrophobic parts of the peptide are present in the 
lipid shell, while the hydrophilic parts protrude in the aqueous phase. This saves place in the 
microbubble shell and might be a possible explanation for the high loading efficiency reported (30-
50%).  
Adenoviral (Ad) loaded microbubbles were prepared by reconstitution of commercially 
available Imagent™ microbubbles in the presence of Ad227. Exposure of the Ad containing 
microbubbles to human complement desactivated uncomplexed Ad. Exposure of the viral 
microbubble to ultrasound resulted in an ultrasound targeted viral gene expression. 
Another very interesting approach is the preparation of liquid perfluorocarbon (C5F12) 
nanoparticles encapsulating doxorubicin (DOX) in their shell228,229. After intravenous injection in mice, 
the nanodroplets accumulated in the tumor tissue as the high permeability of the tumor 
endothelium enabled the nanoparticles to extravasate from the tumor vasculature. The most 
innovative part of this work was that nanodroplets converted into microbubbles at body 
temperature. Microbubbles appeared in the tumor and remarkably enhanced echo contrast. 
Furthermore, DOX was released from the microbubbles and selectively taken up by the tumor cells 
after application of ultrasound with a higher intensity. 
 
Drugs electrostatically attached to the microbubble shell. The loading of drugs onto the 
surface of microbubbles through electrostatic interactions has especially been evaluated for the 
ultrasound mediated delivery of nucleic acids. Electrostatic loading of pDNA onto microbubbles was 
first demonstrated onto cationically charged lipid microbubbes230,231. pDNA loading can be achieved 
by simply mixing cationic microbubbles and pDNA, which avoids sonication in the presence of pDNA. 
Consequently, the risk of pDNA degradation is substantially lower. The reported loading efficiencies 
are rather low (6700 plasmids/microbubble), which might be due to the relatively low amount of 
cationic lipids in the microbubble shell. Although the loading of the microbubbles can be improved by 
increasing the amount of positive charges, too many charged lipids in the microbubble shell can 
disrupt lipid packing, resulting in a higher surface tension and subsequent lower microbubble 
stability154.  
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Also envelop-deficient (lacking envelop proteins), retroviruses were electrostatically coupled 
onto cationic lipid microbubbles232. After exposure to ultrasound, the viral particles were able to 
reach the cytoplasm of the target cells, where they could unpack and proceed to the nucleus for viral 
transcription. A very interesting feature of these microbubbles, is the fact that they will only be able 
to transfect ultrasound treated regions, thereby achieving a localized viral gene transfer. Viral 
particles that dissociate from the microbubbles outside the ultrasound will not be able to enter 
target cells. Also cationically charged AAV particles were loaded onto anionic lipid microbubbles233. 
However, in this case, transduction was also achieved in organs outside the ultrasound beam, as the 
AAVs were not made deficient.  
 
Drug loaded nanoparticles linked to the microbubble shell. A more advanced drug carrying 
microbubble was obtained by attaching nanoparticles to lipid microbubbles via avidin-biotin 
interactions. This concept was first demonstrated using avidinylated polystyrene beads234. 
Biotinylated lipid microbubbles are prepared by the inclusion of a biotinylated lipid in the 
microbubble shell. Also, biotinylated liposomes were attached after avidinylation of these 
microbubbles235. Liposomes are versatile drug delivery systems, able to encapsulate hydrophilic and 
hydrophobic drugs, their attachement onto the microbubble shell can drastically increase the drug 
loading capacity of the microbubbles.  
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ABSTRACT 
 
Ultrasound in combination with microbubbles has recently been considered by gene delivery 
scientists to be an interesting approach to enhance gene transfer into cells. Its low toxicity and 
simplicity to apply in vivo without major complications make this technology (sonoporation) 
especially attractive. Sonoporation of DNA has been evaluated in vivo by the injection of free plasmid 
DNA (pDNA) together with microbubbles (as used in diagnostic imaging) in the bloodstream. 
However, the in vivo gene-transfer efficiency in these experiments remained rather low. Both the 
enzymatic degradation of the injected pDNA as well as the low pDNA concentration in the 
neighborhood of sonoporated cell membranes may explain this low efficiency. Therefore, we 
developed polymer-coated microbubbles that can bind and protect the pDNA. Coating albumin-
shelled microbubbles with poly(allylamine hydrochloride) (PAH) makes the surface charge of the 
microbubbles positive without drastically affecting the size distribution of the microbubbles, thereby 
not affecting the ultrasound responsiveness and injectability. The cationic coating allowed both to 
bind up to 0.1 pg of DNA per microbubble as well as to protect the bound DNA against nucleases. 
Finally, the PAH coating significantly increased the lifetime of the microbubbles (half-life ± 7 h), 
making them more convenient for in vivo applications because more microbubbles are expected to 
reach the target organ. Binding and nuclease protection of DNA by polymer-coated diagnostic 
microbubbles has, to our knowledge, never been demonstrated. We conclude that these LbL-coated 
microbubbles might be significant in the further development of ultrasound-mediated gene delivery. 
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Polymer-coated albumin microbubbles 
that bind and protect plasmid DNA 
 
INTRODUCTION 
 
Gene therapy was put forward in the late 1980s as the most promising therapy for genetic 
diseases. However, gene therapy is currently caught in a bottleneck because of the lack of efficient 
and safe gene carriers. DNA molecules are large, negatively charged molecules and have major 
difficulties in entering the cell or cell nucleus. On top, DNA becomes rapidly degraded by extra- and 
intracellular nucleases1. Therefore, suitable DNA delivery systems are under development. The first 
system makes use of replication-deficient viruses that accommodate the therapeutic DNA in their 
genome1. These viral gene carriers transfect very efficiently because they have an ingenious system 
for the nuclear delivery of exogenous DNA. However, viral gene carriers have some important 
disadvantages: they often provoke an immune response and severe inflammation reactions2. 
Additionally, the risk for insertional mutagenesis and the size limitation of the DNA that they can 
accommodate are other drawbacks of viral gene carriers1. Therefore, nonviral transfection systems 
based on cationic lipids or cationic polymers have gained more and more attention.1 Although non-
viral carriers may be safer and cheaper, they have, especially in vivo, a much lower transfection 
efficiency than viral gene carriers.  
As outlined above, the in vivo application of viral and non-viral DNA delivery systems is 
currently hampered by safety concerns and low efficiency, respectively. To overcome the limitations 
of nonviral gene therapy, ultrasound energy, alone or in combination with gas-filled microbubbles, 
has recently been proposed to enhance the intracellular delivery of DNA, siRNA, and proteins3-11. 
Because ultrasound energy in combination with gas-filled microbubbles has been used for several 
years in medical imaging, it can be considered to be very safe12. The mechanism by which ultrasound 
mediates intracellular drug delivery has been ascribed as cavitation, which is the alternate growing 
and shrinking of gas-filled microbubbles as a result of the high- and low-pressure waves generated by 
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ultrasound energy. Finally, these “cavitating” (oscillating) microbubbles implode. The cavitation and 
especially the implosion of the microbubbles generate local shock waves and microjets that can 
temporarily perforate the cell membrane, allowing macromolecules to enter the cells8,13-16. This 
ultrasound-assisted delivery of macromolecules, often called sonoporation, has been proved to be 
effective both in vitro and in vivo3-11,17. However, a major limitation of the currently available 
microbubbles is that they have a short lifetime and neither bind nor protect the therapeutic DNA 
against nucleases. Binding of the DNA on the microbubbles will ensure that the DNA is present at the 
site of cell membrane poration, enhancing the chance that the DNA is dragged inside the cell or even 
inside the nucleus by the generated microjets.  
The aim of this work is to develop ultrasound-responsive microbubbles that (a) can bind the 
DNA, (b) protect the DNA against nucleases, and (c) remain stable for several hours. Therefore, we 
coated, to our knowledge for the first time, perfluorcarbon gas-filled microbubbles with a cationic 
polymer via the layer-by-layer (LbL) technique18. We characterized the physical properties, 
ultrasound responsiveness, DNA binding, and DNA protection toward nucleases of this new type of 
microbubble. 
 
MATERIALS & METHODS 
 
Preparation of microbubbles and PAH-coated microbubbles 
 
Microbubbles were prepared following the procedure developed by Porter et al.19 Briefly, 
one part of a 5% bovine serum albumin (Sigma Aldrich, St Louis, MO) solution in HEPES buffer (20 
mM, pH 7.4) was mixed with two parts of a 5 % dextrose (Sigma Aldrich, St Louis, MO) solution in 
HEPES buffer. Subsequently, the mixture was drawn into a 30 mL syringe and blended with 10 mL of 
perfluorobutane (MW 238 g/mol, F2 chemicals, Preston, Lancashire, U.K.) through a three-way valve. 
After mixing by hand, the solution was sonicated with a 20 kHz probe (Branson 250 sonifier, Branson 
Ultrasonics Corp., Danbury, CT). Following sonication, the microbubbles were centrifuged at 118g for 
1 min. The subnatants were discarded, and the microbubbles were washed three times with sterile 
HEPES buffer. Finally, the microbubbles were suspended in 5 mL of sterile HEPES buffer.  
The PAH-coated microbubbles were prepared by the layer-by layer (LbL) coating of the 
microbubbles obtained above. Five milliliters of a microbubble dispersion was incubated with 5 mL of 
a  poly(allylamine hydrochloride) (PAH, MW 70 000 g/mol, Sigma- Aldrich) solution (2 mg/mL, HEPES 
buffer). Subsequently, the PAH was removed by washing (three times) the microbubbles with sterile 
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HEPES buffer. Therefore, after each wash step the microbubbles were centrifuged at 118g for 1 min. 
Finally, the LbL-coated microbubbles were suspended in 5 mL of sterile HEPES buffer. 
 
Characterization of the microbubbles 
 
The concentration of the microbubble dispersions was determined immediately after their 
preparation with the aid of a Burker chamber and a light microscope. The concentrations of the 
uncoated and coated microbubble dispersions were 9.57 ± 0.65 x 108 and 1.99 ± 0.10 x 108 
microbubbles/mL, respectively. To visualize the microbubbles, they were brought into a µ-slide VI 
flow chamber (Ibidi Integrated BioDagnostics, Munchen, Germany) and studied via light (Nikon 
TS100-F, Melville, NY) or confocal laser scanning microscopy (CLSM) using a 40x lens. The size 
distribution of the microbubbles was determined within 10 min after preparation by laser diffraction 
(Mastersizer S, Malvern, Worcestershire, U.K.). The zeta potential of the microbubbles was measured 
by particle electrophoresis (Zetasizer 2000, Malvern, Worcestershire, U.K.). All the experiments were 
performed on microbubbles dispersed in HEPES buffer (20 mM, pH 7.4). 
 
Plasmid DNA preparation 
 
The plasmid DNA (pDNA; pGL3, Promega, Leiden, The Netherlands) used in this study 
contained as a reporter gene  luciferase from Photinus pyralis under the control of a simian virus 40 
promotor. After amplification of the pDNA in Escherichia coli, the pDNA was extracted and purified 
from the bacterial cells using the Qiagen giga kit (Valencia, CA). The pDNA concentration was set at 
1.0 mg/mL HEPES buffer assuming that the absorption at 260 nm of a 50 µg/mL DNA solution equals 
1. The pDNA showed a high purity because the ratio of the absorptions at 260 and 280 nm was 
between 1.8 and 2.0. 
 
Fluorescent labeling of albumin, PAH and pDNA 
 
Bovine serum albumin (BSA, Sigma-Aldrich) was labeled with fluoresceine isothiocyanate 
(FITC; Sigma-Aldrich) by vigorous mixing of 60 mL of FITC solution (0.2 mg/mL 0.1 M borate buffer at 
pH 8.5) with 60 mL of BSA (5 mg/mL 0.1 M borate buffer at pH 8.5). The labeling of PAH with 
rhodamine isothiocyanate (RITC) occurred in a similar way. Twelve milligrams of RITC and 300 mg of 
PAH were separately dissolved in 60 mL of borate buffer (0.1 M, pH 8.5) and subsequently mixed 
under vigorous stirring. After overnight incubation, the reaction mixtures were dialyzed (MW cutoff 
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of the membrane was 25 kDa) against pure water for several days. Finally, the dialyzed FITC-BSA and 
RITC-PAH were freeze dried, and the resulting fluffy solids were stored at 4 °C.  
Intercalating dyes YOYO-1 and TOTO-3 were used to label the pDNA. Therefore, 111 µg of 
pDNA was mixed with 57 µL of a 1/100 diluted YOYO-1 or TOTO-3 solution (Molecular Probes, 
Eugene, OR) and diluted in TE buffer (10 mM tris-HCl; 1 mM EDTA; pH 7.4) until a final pDNA 
concentration of 1 mg/mL was obtained. The dye/base pair ratio was 1:30 for both the YOYO-1 and 
TOTO-3 labeled pDNA. For the FCS measurements, the pDNA was labeled with cy-5, using the Mirus 
labeling kit (Mirus Bio Corporation, Madison, WI). The dye/base pair ratio was 1:2. 
 
Confocal laser scanning microscopy 
 
The microbubbles, put in µ-slide VI-flow chambers, were visualized by a confocal laser 
scanning microscope (CLSM, BioRad MRC1024, Hemel Hempstadt, U.K.) equipped with a krypton-
argon laser and a dichroic mirror that reflects the laser light in a 40x objective. The 488 nm line of 
this laser was used to excite YOYO-1 and FITC, and the 568 nm line was used to excite RITC. To 
ensure a proper spectral separation, appropriate emission filters were used before the green and red 
detector. 
 
Electron microscopy  
 
Five microliters of a coated microbubble dispersion was applied on a silicon wafer and air 
dried. The remains of the microbubbles were then examined with a scanning electron microscope 
(Quanta 200 FEG, FEI Company, Hillsboro, Oregon). 
 
Picogreen assay and fluorescence fluctuation spectroscopy 
 
To determine the maximal pDNA loading capacity of the microbubbles, we mixed 150 µL of 
the uncoated or coated microbubble dispersions with increasing amounts of pDNA. After 10 min of 
incubation, the microbubbles (with pDNA) were centrifuged at 118g, and the concentration of 
unbound pDNA in the subnatants was determined using PicoGreen (Invitrogen, Merelbeke, Belgium) 
and fluorescence correlation spectroscopy (FCS).  
For the PicoGreen assay, 50 µL of the subnatants was incubated with 1 mL of diluted (200-
fold in TE buffer) PicoGreen reagent for 5 min, and subsequently the fluorescence was determined 
(excitation= 480 nm and emission = 520 nm).  
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We also determined the maximal pDNA loading capacity in another way, making use of 
fluorescence fluctuation spectroscopy (FFS) to measure the fluorescence of the unbound pDNA in the 
subnatants. FFS monitors the fluorescence fluctuations in the excitation volume of the microscope. 
The fluorescence signal is fluctuating because of the diffusion of fluorescent molecules in and out of 
the excitation volume. From the fluorescence fluctuations, an autocorrelation curve can be derived 
that allows one to calculate both the diffusion coefficient of the fluorescent molecules as well as the 
number of fluorescent molecules in the excitation volume20. Details of the FFS setup used are 
explained in our earlier reports21. For these experiments, Cy5-labeled pDNA was used, and samples 
were excited with 6% laser intensity (647 nm). First, a diluted solution of Cy5-pDNA was measured. 
Afterwards, 50 µL of a coated bubble suspension was incubated with 2 µg of pDNA. After 5 min of 
incubation, the sample was diluted to the same Cy5-pDNA concentration, and the amount of free 
pDNA was determined via FCS.  
 
Ultrasound responsiveness of the microbubbles 
 
The ultrasound responsiveness of pDNA-loaded, PAH-coated microbubbles was determined 
by comparing their (number) concentration before and after exposure to ultrasound. pDNA-loaded 
microbubbles were prepared by mixing 100 µL of a PAH-coated microbubble dispersion with 2 µg of 
pDNA. After 10 min of incubation, the concentration of the pDNA-loaded microbubbles was 
determined in a Burker chamber. Subsequently, the pDNA loaded microbubbles were sonicated (1 
MHz, 1 W/cm2; 50% duty cycle) for 30 s using a Sonitron 2000 (RichMar, Inola, Oklahoma) and again 
counted in a Burker chamber. 
 
Gel electrophoresis to evaluate the stability of microbubble- bound pDNA to rhDNase I  
 
To determine whether the microbubbles were able to protect the pDNA against rhDNase I 
(Pulmozyme, Roche, Belgium), gel electrophoresis experiments were performed. Two micrograms of 
pDNA were mixed with 50 µL of a PAH-coated microbubble dispersion. After 5 min of incubation, the 
pDNA/microbubble mixtures were diluted in HEPES buffer supplied with 110 mM potassium acetate 
and 2 mM magnesium acetate (pH 7.4), which is necessary to activate the rhDNase I. Subsequently, 
rhDNase I was incubated with the pDNA/microbubbles mixtures for 15 min at room temperature. 
The rhDNase I activity in the microbubble dispersions was 200 U/L. Microbubble dispersions 
“incubated with inhibited rhDNase I” received 8 µL of Na2EDTA (50 mM) before the addition of the 
rhDNase I to the pDNA/ microbubble mixtures. Na2EDTA inhibits rhDNase I by complexing the 
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divalent cations, which are required for activating rhDNase I. Other samples were supplemented with 
Na2EDTA after incubation with rhDNase I.  
After the incubation period with rhDNase I, the pDNA was released from the microbubbles to 
investigate whether it survived the exposure to rhDNase I. Therefore, NaCl was added to the 
pDNA/microbubbles dispersions at a final concentration of 5M. Subsequently, the pDNA/ 
microbubbles dispersions were centrifuged for 1 min at 118g. Fifty microliters of the subnatants was 
mixed with 10 µL of a 30% glycerol solution and loaded onto a 1.5% agarose gel prepared in TBE 
(10.8 g/L tris base, 5.5 g/L boric acid, and 0.58 g/L EDTA). The samples were subjected to 
electrophoresis at 100 V for 60-90 min, and the pDNA was visualized by ethidium bromide (0.5 
µg/mL) staining prior to UV photography. 
 
RESULTS & DISCUSSION 
 
Preparation and characterization of uncoated and PAH-coated microbubbles 
 
After the preparation of perfluorocarbon microbubbles stabilized with (FITC-labeled) 
albumin, CLSM experiments revealed the existence of micrometer-sized spherical structures covered 
with green-labeled albumin (Figure 1) that floated atop the liquid. Because the size of the 
microbubbles determines their ability to serve as cavitation nuclei, we subsequently studied the size 
distribution of freshly made microbubbles by laser diffraction22. Most of the albumin-stabilized 
microbubbles (about 90%) were between 1 and 5 µm diameter (Figure 2), which is a size known to 
favor cavitation upon exposure to clinically used ultrasound frequencies (such as 1 MHz)22. 
 
 
 
Figure 1 Confocal fluorescence microscopy image of perfluorocarbon microbubbles stabilized with FITC-labeled 
albumin. Depending on the position of the confocal plane in the microbubbles, we observed fluorescent rings 
(confocal plane in the middle of the microbubbles) or filled circles (confocal plane at the top or bottom of the 
microbubbles). 
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Figure 2 Size distribution of uncoated and PAH-coated albumin/ perfluorocarbon microbubbles as measured by 
laser diffraction. The y axis shows to what extent a certain class of microbubbles is present, normalized to the 
most abundant fraction of microbubbles (y = 1) (number fraction). Data are the means of three independent 
measurements. 
 
The albumin chains, which cover the gaseous cores, stabilize the microbubbles because they 
reduce the diffusion of the perfluorocarbon gas out of the microbubbles in the surrounding water. 
The shell-forming properties of albumin most likely originate from its amphiphilic nature. The 
presence of negative charges at the surface of the albumin-stabilized microbubbles was indeed 
confirmed from zeta potential () measurements: the average  equalled -45 mV (Figure 3).  
 
 
Figure 3 Zeta potential of uncoated microbubbles (A), uncoated microbubbles (50 µL) incubated with 1 µg of 
pDNA (B), PAH coated microbubbles (C), and PAH-coated bubbles (50 µL) incubated with 1 µg of pDNA (D). The 
data are the means of three independent measurements. 
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One can expect that the negative charges at the microbubbles’ surface would enable them to 
be coated with cationic polymers. Therefore, we tried to apply a positively charged layer around the 
albumin shell using PAH, a polycation that is widely used in the LbL coating of planar substrates and 
colloidal templates23-25. Figure 4 shows CLSM images of microbubbles prepared with (non 
fluorescently labeled) albumin and coated with RITC-labeled PAH. Clearly, the PAH chains cover the 
outer surface of the microbubbles and are not incorporated into the perfluorocarbon gas core. Also, 
after the PAH coating, the zeta potential of the microbubbles became positive (15 mV; Figure 3), 
which further confirms the presence of PAH at the surface of the microbubbles. Apart from a slightly 
elevated fraction in the 5-20 µm range, which is probably due to the aggregation of smaller 
microbubbles after coating, the PAH coating changed the size distribution of the microbubbles only 
moderately (Figure 2). In the remainder of this article, we use the terms “uncoated: and “PAH-
coated” microbubbles to refer to albumin/perfluorocarbon microbubbles without and with a PAH 
coating, respectively. 
 
 
 
Figure 4 Confocal fluorescence microscopy image (A) and transmission image (B) of PAH-coated microbubbles 
made with unlabeled albumin and RITC-labeled PAH. 
 
 
Stability of uncoated and PAH-coated microbubbles 
 
It is well known that the lifetime of air-filled albumin-stabilized microbubbles is very short 
because the air diffuses rapidly out of the microbubbles26. The use of perfluorocarbon gas, which has 
a lower water solubility than air, effectively delays gas diffusion27. Nevertheless, their lifetime 
remains very short. Coating microbubbles with PAH should offer a solution to this problem because 
polyelectrolyte multilayers have been reported to prevent or drastically decrease gas diffusion28. 
Therefore, we evaluated the stability of the microbubbles at room temperature by following the 
concentration of the microbubbles as a function of time. Figure 5A shows the percentage of 
remaining uncoated and PAH-coated microbubbles as a function of time. Uncoated microbubbles 
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seem to destabilize very rapidly: after 75 min, 50% of the uncoated microbubbles have already 
disappeared. In contrast, PAH-coated microbubbles clearly existed for much longer times: half of the 
PAH-coated microbubbles had disappeared after 6 h. 
 
 
 
Figure 5 (A) Stability of uncoated and PAH-coated microbubbles. The concentration of the microbubbles was 
measured as a function of time and normalized to the concentration just after preparation. The dispersions 
were placed at room temperature under continuous stirring at 750 rpm, and the concentration of 
microbubbles was determined microscopically using a Burker chamber. (B) Light microscopy images of a 
destabilizing PAH-coated microbubble. The inset is a SEM image of the remaining polymer coating. Gradual 
shrinking was also observed on uncoated microbubbles, although it occurred faster. 
 
 
DNA binding properties of the microbubbles 
 
The pDNA binding properties of the microbubbles were first evaluated by CSLM. To enable 
the visualization of the binding of pDNA to the microbubbles, YOYO-1-labeled pDNA (green) and RITC 
labeled PAH (red) were used. Uncoated and PAH-coated albumin microbubbles were incubated with 
pDNA for 2 min, transferred to a µ-slide VI flow chamber, and studied via CLSM. Figure 6 shows the 
results. Clearly, the green-labeled pDNA does not bind to the uncoated albumin microbubbles but 
remains in solution (Figure 6A). However, the green-labeled pDNA does bind to the RITC-PAH-coated 
microbubbles (Figure 6B) because yellow rings are present around the microbubbles, indicating the  
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Figure 6 (A) Confocal fluorescence images of uncoated microbubbles (50 µL) incubated with 1 µg of YOYO-1-
labeled DNA, (B) RITC-labeled PAH-coated microbubbles (50 µL) incubated with 2.6 µg of YOYO-1-labeled 
pDNA, and (C) unlabeled AH-coated microbubbles (50 µL) incubated with 1 µg of YOYO-1-labeled pDNA. (D) 
Transmission image corresponding to image C. 
 
 
co-localization of pDNA and PAH. Between the microbubbles in Figure 6B, some green fluorescence 
(i.e., unbound pDNA) is still detected. This could be expected because the maximal pDNA loading 
capacity of the microbubbles was exceeded (see below). When the microbubbles (in this experiment, 
unlabeled) were incubated with lower amounts of YOYO-1-labeled pDNA, green fluorescence 
between the microbubbles was no longer observed (Figure 6C). Successful loading of the PAH-coated 
microbubbles with pDNA could also be observed from zeta potential measurements because the 
addition of pDNA turned the zeta potential of the PAH-coated microbubbles negative (Figure 3). This 
most likely indicates that pDNA is bound to the surface of the PAH-coated microbubbles. In contrast, 
the addition of pDNA to the uncoated albumin microbubbles did not drastically alter the zeta 
potential of the uncoated microbubbles (Figure 3), which is in line with the observations above. 
Previously, Porter et al. reported that oligonucleotides do bind to albumin microbubbles19. However, 
these authors used phosphorothioate-modified oligonucleotides, which are known to interact 
nonspecifically with proteins29. To estimate the maximal pDNA binding capacity of the PAH-coated 
microbubbles, they were incubated (for 5 min) with increasing amounts of pDNA, and the amount of 
unbound (i.e., free) pDNA in the subnatants (obtained after centrifugation) was determined via both 
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the PicoGreen assay and FCS. Both tests revealed that 50 µL of the PAH-coated microbubble 
dispersion could maximally bind 1 µg of pDNA (data not shown). Taking into account that 50 µL of 
microbubble dispersion contains about 9.95 x 106 microbubbles, one can estimate that the PAH 
coating of the microbubbles enables them to carry 0.1 pg of pDNA or about 20 000 pDNA molecules 
per microbubble. These experiments prove that coating the microbubbles with PAH enables a very 
efficient loading of albumin microbubbles with plasmid DNA. As mentioned above, pDNA-loaded 
microbubbles have also been developed by other groups. Christiansen et al. and Vannan et al. 
prepared cationic microbubbles using lipids as a shell-forming material11,13. Compared to PAH-coated 
microbubbles, these microbubbles have a 2.5-fold lower pDNA loading capacity. However, we should 
take into account that in their studies the average microbubble size was smaller, which automatically 
implies a lower DNA loading. Also, cationic lipid based microbubbles are probably more expensive. 
Frenkel et al. showed that the sonication of a solution of dextrose, albumin, and pDNA with 
perfluoropropane gas leads to microbubbles that contain albumin and pDNA in their shell11,30. 
However, a major drawback of this technique is that only a small fraction of the pDNA seems to 
become incorporated into the shell. 
 
Ultrasound responsiveness and DNase protection 
 
Microbubbles enhance the efficiency of ultrasound-assisted gene delivery as they generate microjets 
that, upon implosion, temporarily perforate the cell membranes8,13-16.  Given the importance of 
cavitation, the ultrasound responsiveness of the uncoated and pDNA-loaded PAH-coated 
microbubbles was studied by exposing them for 30 s to ultrasound energy (1 MHz, 1 W/cm2, 50% 
duty cycle). After ultrasound radiation, 99% and 95% of the uncoated and PAH-coated microbubbles, 
respectively, were destroyed, which is in agreement with previous reports19,31. Despite their higher 
stability (Figure 5), PAH-coated microbubbles are thus clearly ultrasound-responsive. Subsequently, 
the ability of the microbubbles to protect pDNA against nucleases was tested using gel 
electrophoresis. As described in the Materials and Methods section, the microbubble dispersions 
were exposed to 200 U/L rhDNase-I, which is about 20-fold higher than the DNase activity found in 
human blood32. Figure 7 shows the gel electrophoresis results on pDNA released from pDNA-loaded 
microbubbles (by NaCl) that were exposed to DNase-I. As shown in Figure 7A, DNase-I degrades both 
free pDNA (lane 3) and pDNA in the presence of uncoated microbubbles (lane 6). In contrast, the 
pDNA on PAH-coated microbubbles remains mainly protected (Figure 7B) because only a very small 
part of degraded pDNA seems to be present (arrow in lane 6). The latter can be explained by the fact 
that in this experiment a small amount of the pDNA remained in the solution as the maximal loading 
capacity of the microbubbles was exceeded. Clearly, in Figure 7B (lanes 5-7) a part of the pDNA 
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remained in the slots of the agarose gel. Most presumably, this is attributed to the fact that, besides 
free pDNA, (high molecular weight) pDNA-PAH complexes were also liberated from the microbubbles 
upon adding NaCl. This implies that the electrostatic binding between DNA and PAH is stronger than 
the interaction between the albumin and PAH. Thus, a second advantage of the PAH-coated 
microbubbles compared to the microbubbles of Frenkel’s group is that they also protect DNA against 
DNase-I degradation. From Figure 7B (lanes 2 and 5), we can also conclude that no conformational 
change of the pDNA occurred upon binding to the microbubbles. Indeed, the released DNA (lane 5) is 
visible at the same height on the gel as the free pDNA (lane 2). 
 
 
 
 
Figure 7 Gel electrophoresis of pDNA present in an uncoated and PAH-coated microbubble dispersion with or 
without DNase-I, respectively. The data obtained with uncoated microbubbles are shown by gel A, and those 
with PAH-coated microbubbles, by gel B. Each lane contains 1 µg of pDNA. Lane 1, DNA molecular weight 
marker; lane 2, free pDNA; lane 3, free pDNA incubated with DNase-I; lane 4, free pDNA incubated with 
inhibited DNase- I; lane 5, microbubbles and pDNA; lane 6, microbubbles and pDNA incubated with DNase-I; 
lane 7, microbubbles and pDNA incubated with inhibited DNase-I. Smiling appeared because of the high salt 
concentrations used (5 M NaCl). 
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Conclusions 
 
A major issue in ultrasound-assisted gene transfer is the development of microbubbles that 
both bind and protect pDNA against circulating DNases in the bloodstream. It is well known that 
binding pDNA with cationic polymers or lipids protects the pDNA against degradation by DNase I.1 
Therefore, we evaluated the possibility of coating the medically used albumin/perfluorocarbon 
contrast agents with a cationic polymer. A successful coating of the albumin-shelled perfluorocarbon 
microbubbles with PAH was evidenced from CLSM and zeta potential measurements. The positive 
charges on the surface of the PAH coated microbubbles allowed the binding of up to 0.1 pg of pDNA 
on the wall of a single microbubble. The pDNA bound on PAH-coated microbubbles was clearly 
protected against nucleases. The presence of pDNA on the microbubble may also enhance the 
number of pDNA molecules that can enter a cell during sonoporation. Indeed, small pores (up to 100 
nm large) created by imploding microbubbles have a very short lifetime (millisecond range).16 To 
increase the number of pDNA molecules that pass through these quickly closing pores, it seems clear 
that it is important to co-localize DNA and pore-forming microbubbles. Furthermore, PAH coating of 
the microbubbles improved their stability, thereby increasing their (average) lifetime from 75 min to 
6 h while they remained ultrasound-responsive. Their longer lifetime makes them more convenient 
for in vivo therapy because more microbubbles are expected to reach the target organ. In this study, 
we used PAH as a cationic polymer to coat the microbubbles. This polymer is not suitable for in vivo 
applications because, as a result of its high molecular weight and nonbiodegradability, it will not be 
efficiently cleared from the human body. However, it is obvious that other cationic polymers that are 
more biocompatible and biodegradable may also be used as coating material. Also, coating 
microbubbles with cationic polymers may be an attractive strategy to promote the targeting of 
microbubbles because it is rather straightforward to attach targeting ligands to the polymer coating. 
This could further enhance the site-specific delivery of pDNA and could provide an even higher pDNA 
concentration close to cell membrane perforations33. However, to obtain good gene transfer it is also 
important that the pDNA dissociates from the microbubble upon ultrasound exposure. In our future 
work, we will tackle this issue and perform transfection experiments with our microbubbles. 
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ABSTRACT 
 
Microbubbles in combination with ultrasound are currently considered as a very promising 
new gene delivery method. The use of a pDNA loaded microbubbles offers several advantages as the 
pDNA is protected against degradation and is only locally released in the ultrasound treated areas. 
This can reduce the required pDNA dose and prevent the uptake of pDNA in unwanted areas. 
Albumin microbubbles can be coated with a cationic polymer, enabling electrostatic pDNA loading 
onto the microbubble shell. In this study, we evaluated the transfection efficiency of uncoated and 
polymer-coated albumin microbubbles on primary Vascular Smooth Muscle Cells (VSMC) and 
melanoma cells. We showed that it is imported to pre-incubate uncoated albumin microbubbles with 
pDNA to obtain a good transfection efficiency. Despite their high pDNA loading, the polymer-coated 
microbubles failed to transfect primary VSCM and melanoma cells. Confocal images showed that this 
is most likely due to the presence of large aggregates consisting of microbubble shell fragments and 
pDNA, which arise upon ultrasound induced implosion of the microbubbles. Additionally, gel 
electrophoresis experiments indeed showed that the pDNA remained attached to microbubble shell 
fragments after ultrasound exposure. It was also shown that the unprotected pDNA became 
subjective to mechanical degradation in the presence of albumin microbubbles and exposure to 
ultrasound intensities of 2W/cm2.  
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Chapter 3 
Transfection properties of uncoated and 
polymer-coated albumin microbubbles 
 
INTRODUCTION 
 
Due to fact that ultrasound is a cheap, non-invasive and local applicable technique, it is a very 
attractive drug delivery strategy1-3. Ultrasonic drug delivery often requires the presence of 
microbubbles, also called echo contrast agents4. These microbubbles are intravenously injected and 
subsequently start to cavitate and implode when they enter an ultrasound field. This can result in the 
formation of cell membrane pores, which leads to drug uptake in the insonated areas5. Additionally, 
extravasation can occur, thereby reaching areas further away from the blood vessels. Because only 
the targeted region will be treated with ultrasound, it is possible to obtain an ultrasound controlled 
local drug delivery. The preparation of a gene loaded microbubble is advantageous for several 
reasons. First, the enclosed gene will be protected against enzymatic degradation during circulation 
in the bloodstream. Second, the gene will only be released in ultrasound treated regions upon 
microbubble implosion. This can prevent the gene transfection of undesired tissues and will limit 
therapy costs, as the genetic drug dose can be significantly lowered. Moreover, a local release of the 
pDNA can assure that more pDNA is locally available for uptake through the created cell membrane 
pores.  
We previously succeeded in preparing polymer-coated albumin microbubbles6. Therefore 
albumin microbubbles were incubated with the cationic polymer poly-(allylamine hydrochloride) 
(PAH) and washed several times to remove the unbound polymer. Subsequently, the cationic 
microbubbles were mixed with plasmid DNA (pDNA), that electrostatically bound to the microbubble 
shell. This novel microbubble has the advantage that more pDNA can be bound to the surface of the 
microbubbles and the increased microbubble stability. In a next step we wanted to compare the 
transfection efficiencies of uncoated albumin microbubbles and polymer coated microbubbles.  Here, 
we evaluate their transfection efficiency on primary Vascular Smooth Muscle Cells (VSMC) and 
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melanoma cells. Additionally, the ultrasound induced release of pDNA from polymer-coated 
microbubbles was evaluated and visualized with confocal microscopy. We also studied the influence 
of different ultrasound parameters on the stability of naked pDNA in the presence of uncoated 
microbubbles. 
 
MATERIALS & METHODS 
 
Preparation of microbubbles and PAH-coated microbubbles 
 
Microbubbles were prepared following the procedure developed by Porter et al.7 Briefly, one 
part of a 5% bovine serum albumin (Sigma Aldrich, St Louis, MO) solution in HEPES buffer (20 mM, pH 
7.4) was mixed with two parts of a 5 % dextrose (Sigma Aldrich, St Louis, MO) solution in HEPES 
buffer. Subsequently, the mixture was drawn into a 30 mL syringe and blended with 10 mL of 
perfluorobutane (MW 238 g/mol, F2 chemicals, Preston, Lancashire, U.K.) through a three-way valve. 
After mixing by hand, the solution was sonicated with a 20 kHz probe (Branson 250 sonifier, Branson 
Ultrasonics Corp., Danbury, CT). Following sonication, the microbubbles were centrifuged at 118g for 
1 min. The subnatants were discarded, and the microbubbles were washed three times with sterile 
HEPES buffer. Finally, the microbubbles were suspended in 5 mL of sterile HEPES buffer.  
The PAH-coated microbubbles were prepared by layer-by-layer (LbL) coating of the 
abovementioned microbubbles. Five milliliters of a microbubble dispersion was incubated with 5 mL 
of a poly(allylamine hydrochloride) (PAH, MW 70 000 g/mol, Sigma- Aldrich) solution (2 mg/mL, 
HEPES buffer). Subsequently, the PAH was removed by washing (three times) the microbubbles with 
sterile HEPES buffer. Therefore, after each wash step the microbubbles were centrifuged at 118g for 
1 min. Finally, the LbL-coated microbubbles were suspended in 5 mL of sterile HEPES buffer. 
 
Plasmid DNA preparation 
 
The plasmid DNA (pDNA; pGL3, Promega, Leiden, The Netherlands) used in this study 
contained as a reporter gene luciferase from Photinus pyralis under the control of a simian virus 40 
promotor. After amplification of the pDNA in Escherichia coli, the pDNA was extracted and purified 
from the bacterial cells using the Qiagen giga kit (Valencia, CA). The pDNA concentration was set at 
1.0 mg/mL HEPES buffer assuming that the absorption at 260 nm of a 50 µg/mL DNA solution equals 
1. The pDNA showed a high purity because the ratio of the absorptions at 260 and 280 nm was 
between 1.8 and 2.0. 
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Cell culture and transfection experiments 
The experiments performed on primary cells were done in the lab of Prof. Newman  
(Cardiovascular Division, Northern General Hospital, Sheffield University). Vascular smooth muscle 
cells (VSMCs) from the thoracic aorta of Yorkshire White cross pigs aged <6 months were cultured in 
DMEM containing 10% porcine serum. The transfections were performed for 3 hours at 37°C in 24-
well plates with cells at 60% to 70% confluence and were stopped by dilution with 1 mL of fresh 
culture medium. Transfection was performed with 300 µL transfection medium per well. This 
contained 10% microbubbles (either the Bracco microbubbles, albumin microbubbles or polymer 
coated microbubbles) and 0.75 µg of pGL-3 diluted in Optimem (Gibco, Merelbeke, Belgium). 
Microbubbles and plasmid DNA were mixed according to the different protocols (Figure 1) and 
subsequently diluted in optimem. Secreted alkaline phosphatase (SEAP) expression plasmid (pMet7 
hβ SEAP) was used to presaturate the albumin microbubbles with DNA (5µg). Lipofection was done 
with Lipofectin. The transfection medium was prepared in a similar way for transfection experiments 
with naked pDNA, except that the microbubble solution was replaced by an equal volume of HEPES. 
Immediately after addition of the microbubbles to the well plates, ultrasound exposure (USE) was 
performed for 60 seconds with a custom-built, 10mm diameter, 1-MHz piezoelectric ceramic 
transducer within the transfection medium 2 mm above the cell monolayer and the 24-well plates 
suspended in a polystyrene water bath at 37°C to minimize acoustic reflections (<5%) and standing 
wave formation. The transducer was calibrated to produce continuous-wave 1-MHz ultrasound at a 
spatial average temporal average intensity of 0.4 W/cm2. USE caused only minor acute damage to the 
cell monolayer.  
BLM cells (melanoma cells)8 were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
with the growth factor F12 and phenol red containing 2 mM glutamine, 10% heat-deactivated fetal 
bovine serum (FBS), 1% penicillin–streptomycin (Gibco, Merelbeke, Belgium), and HEPES buffer (100 
mM, pH7.4). The cells were grown to 90% confluency in Opticell units (Biocrystal, Westerville, OH, 
USA) inside a humidified incubator at 37 °C under 5% CO2. Subsequently, the cells were washed with 
10 mL of phosphate buffered saline (PBS, Gibco) and the transfection medium was added. The 
transfection was peformed in the same way as described above. The pDNA concentration was the 
same as in the experiments described above. The microbubbles were mixed with the pDNA according 
to the different protocols (Figure 1) and diluted in optimem. For the ultrasound treatment, the 
Opticells were placed in a water bath at 37 °C with an absorbing rubber substrate at the bottom and 
immediately subjected to ultrasound radiation. The ultrasound radiation was performed for 10 s with 
a Sonitron 2000 instrument (RichMar, Inola, OK, USA) equipped with a 22 mm probe. In all these 
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ultrasound-assisted experiments, the following ultrasound settings were used: 1 MHz, 10% duty 
cycle, and an ultrasound intensity of 2 W/cm2. The areas treated with ultrasound were marked and 
after radiation the Opticells were incubated for an additional 2h at 37 °C. At the end of this 
incubation period, the transfection medium was removed and the cells were washed two times with 
PBS, before adding fresh culture medium. Each transfection experiment was performed three times.  
Assays for Luciferase Activity, Adherent Cell Number, and Viability 
Analysis of the VSMC 
For each condition, four wells were used. Three wells were analysed for luciferase expression 
and one well was used to measure the cell concentration. Luciferase activity in cell lysates 48 hours 
after transfection was measured with the GenGlow kit (Labtech International) and 1253 Luminometer 
(BioOrbit) and expressed as relative light units (RLU) per 104 cells. Background luminescence was zero 
in untransfected cell lysates. Cell counts were assayed by a Beckman Coulter Counter. 
Analysis of the BLM cells 
Luciferase expression by the cells was analyzed 24 h after transfection. The culture medium 
was removed and the cells were washed with PBS. The areas exposed to ultrasound (20 mm 
diameter) were cut from the Opticell membrane and placed in a 24 well plate. A 80 µL solution of cell 
culture lyse reagent (CCLR, Promega, Leiden, The Netherlands) buffer was added to each well and 
incubated at room temperature for at least 20 min to allow cell lysis. 20 µL of the cell lysate was 
transferred to a 96 well plate and the luciferase activity was measured using a Glomax 96 Microplate 
Luminometer (Promega), as described previously in the literature9. An aliquot (20 µL) of each cell 
lysate was also analyzed for protein concentration using the bichinconinic acid (BCA) protein assay 
(Pierce, Rockford, IL, USA). The transfection results are expressed as relative light units (RLU) per 
milligram of protein. 
 
Gel electrophoresis 
 
Two micrograms of pDNA were mixed with 50 µL of an uncoated or PAH-coated microbubble 
dispersion. After 5 min of incubation, the pDNA/microbubble mixtures were exposed to different 
ultrasound parameters. Ten microliters of the subnatants was mixed with 10 µL of a 30% glycerol 
solution and loaded onto a 1.5% agarose gel prepared in TBE (10.8 g/L tris base, 5.5 g/L boric acid, 
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and 0.58 g/L EDTA). The samples were subjected to electrophoresis at 100 V for 60-90 min, and the 
pDNA was visualized by ethidium bromide (0.5 µg/mL) staining prior to UV photography. 
 
Fluorescent labeling of pDNA and PAH. 
 
PAH labelling with Rhodamine IsoThioCyanate (RITC) occurred in a similar way. Twelve 
milligrams of RITC and 300 mg of PAH were separately dissolved in 60 mL of borate buffer (0.1 M, pH 
8.5) and subsequently mixed under vigorous stirring. After overnight incubation, the reaction 
mixtures were dialyzed (MW cutoff of the membrane was 25 kDa) against pure water for several 
days. Finally, the dialyzed RITC-PAH was freeze dried, and the resulting fluffy solid was stored at 4 °C. 
The intercalating dye YOYO-1 was used to label the pDNA. Therefore, 111 µg of pDNA was mixed 
with 57 µL of a 1/100 diluted YOYO-1 (Molecular Probes, Eugene, OR) and diluted in TE buffer (10 
mM tris-HCl; 1 mM EDTA; pH 7.4) until a final pDNA concentration of 1 mg/mL was obtained. The 
dye/base pair ratio was 1:30.  
 
Confocal Laser Scanning Microscopy 
 
The microbubble remainders were put on a glass slide and visualized by a confocal laser 
scanning microscope (CLSM, BioRadMRC1024, Hemel Hempstadt, U.K.) equipped with a krypton-
argon laser and a dichroic mirror that reflects the laser light in a 60x objective. The 488 nm line of 
this laser was used to excite YOYO-1 and the 568 nm line was used to excite RITC. To ensure a proper 
spectral separation, appropriate emission filters were used before the green and red detector. 
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RESULTS & DISCUSSION 
 
Figure 1 gives an overview of the different protocols used in our experimental setup. In 
protocol 1 we pre-incubated the cells for 30 minutes with plasmid DNA. The microbubbles were 
added to the transfection medium after this pre-incubation period, immediately followed by 
ultrasound exposure. We also pre-incubated microbubbles and pDNA (protocol 2 and 3), followed by 
ultrasound exposure of the cells and a further incubation period at 37°C for 90 minutes (protocol 2) 
or 2 hours (protocol 3). Protocol 2’ and 3’ are exactly the same protocols as protocol 2 and 3 
respectively, except that the microbubbles were pre-saturated with SEAP plasmid DNA. In this case, 
all possible pDNA binding places are occupied, preventing any interaction between the microbubbles 
and the pGL-3. 
 
Transfection efficiency in Vascular Smooth Muscle Cells (VSMCs) and melanoma cells 
 
Figure 2 displays the transfection results obtained in primary VSMCs with uncoated and PAH-
coated albumin microbubbles, following the different protocols explained in Figure 1. Lipofectin and 
BR-14 bubbles (Bracco) were used as a positive control. We used protocol 3 to evaluate the 
transfection efficiency of the BR-14 bubbles. We will first focus on the results from the uncoated 
microbubbles. It is clear from figure 2 that pre-incubation of the microbubbles and plasmid DNA 
(protocol 2 and 3) results in a higher transfection efficiency. Although we previously did not observe 
any binding of the plasmid DNA to the uncoated microbubbles6, there should be a (weak) interaction 
resulting in an enhanced transfection. Adherence of the plasmid DNA to the microbubbles assures 
that more pDNA is closely located to the cell membrane poration site, resulting in an increased 
uptake of the pDNA through these pores10,11. Saturation of the microbubbles with the SEAP plasmid 
drastically reduced gene transfer (protocol 2’ and 3’). There are two different hypotheses to explain 
this drop in transfection efficiency. First, the SEAP DNA will occupy all possible binding places on the 
microbubble shell, hampering any association between the pGL-3 plasmid and the microbubbles. As 
explained above, this will limit the chance that pGL-3 plasmids are taken by the fluid streams, 
reducing their ability to enter cell membrane pores. A second explanation is that the presence of 
such a huge amount of SEAP pDNA gets in competition with the pGL-3 pDNA for cellular uptake. 
Because the concentration of SEAP plasmid is more than 6 times higher than pGL-3 concentration, 
more SEAP molecules will be able to passively diffuse through the cell membrane pores. Moreover, 
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after cellular entry, the SEAP pDNA will also get in competition for nuclear transcription with the 
pGL-3. 
 
 
 
 
 
Figure 1 Schematic overview of the used protocols in the transfection experiments. Protocol 1: Cells were first 
incubated with the pGL-3 and after 30 minutes of incubation the microbubbles were added and the cells were 
radiated. Protocol 2: After incubating the cells for 30 minutes with Optimem only, the microbubbles were 
added together with the pGL-3. Microbubbles and pDNA were first incubated together and subsequently added 
to the Optimem medium, immediately after addition of the microbubbles and pDNA ultrasound was applied. 
Protocol 3: Microbubbles and pDNA were incubated for 5 minutes and diluted in Optimem. The transfection 
medium was added to the cells and ultrasound exposure was performed. Cells were incubated for an additional 
2 hours at 37°C with the transfection medium. Protocol 2’ and 3’ are the same as protocol 2 and 3 respectively, 
except that the microbubbles were first incubated with SEAP pDNA to saturate the possible pDNA binding 
places on the microbubbles. 
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Figure 2 Transfection efficiencies of uncoated and polymer coated albumin microbubbles in primary VSMCs. 
The different protocols shown in figure 1 were used. 
 
 
 
 
Figure 3 Transfection efficiencies of uncoated and polymer-coated albumin microbubbles in melanoma cells. 
The different protocols shown in figure 1 were used. 
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Unfortunately the transfection efficiencies obtained with the polymer-coated microbubbles 
were very low. The highest transfection efficiency was obtained with protocol 3 (premixing of DNA 
and microbubbles and 2 hours incubation time). However, gene transfer was only slightly higher as 
the transfection obtained with naked pDNA. 
We repeated these experiments on melanome cells. Figure 3 shows the transfection results 
obtained in a melanoma cell line. We obtained the same results in this cell line as with the primary 
VSMCs.  
 
 
Stability and ultrasound induced release of pDNA from uncoated albumin microbubbles and 
polymer-coated microbubbles.  
 
 
To explain the poor transfection results from the PAH-coated albumin microbubbles, we 
studied the pDNA release from the microbubbles upon ultrasound radiation. Figure 4A shows a gel 
electrophoresis experiment in which pDNA-loaded polymer coated microbubbles were exposed to 
different ultrasound intensities and subsequently loaded onto an agarose gel. Lane 2 displays the 
migration of the free pDNA in the agarose gel. After addition of the microbubbles there was no free 
pDNA detected anymore (Lane 3). Although the intention of our experiment was to release the pDNA 
from the microbubbles after ultrasound exposure, we did not succeeded in releasing any pDNA with 
the different ultrasound parameters used (Lane 4-12). We visually observed that > 90% of the 
microbubbles imploded under the highest ultrasound intensities used (2W/cm2). The fact that there 
was no pDNA detected inside the agarose gel means that the pDNA is still complexed to the 
fragments of the cationic microbubble shell, preventing any diffusion of the pDNA into the gel. To 
verify this hypothesis we performed a confocal laser scanning microscopy experiment in which we 
exposed pDNA loaded, fluorescently labelled polymer coated microbubbles to ultrasound. The 
polymer was labelled in red, and subsequently incubated with green labelled pDNA. After ultrasound 
exposure we saw the appearance of very large (µm in size) and heterogeneous complexes consisting 
of microbubble shell fragments (red) and plasmid DNA (green) (figure 5). Due to their huge size, it is 
very unlikely that these complexes are taken up by the target cells, as cell membrane pores are 
reported to be between 100 and 1µm in size12-15.  
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Figure 4 Gel electrophoresis of naked pDNA (lane 2) and pDNA present in a PAH-coated microbubble (A) or 
uncoated (B) microbubble dispersion (Lane 3). The effect of different ultrasound parameters on the release and 
stability of pDNA was evaluated ( lane 4-12). 
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Figure 5 Confocal laser scanning microscopy image and corresponding transmission image of aggregates 
obtained after ultrasound induced implosion of PAH-coated microbubbles loaded with pDNA. Microbubble 
shell fragments are visible in red and pDNA is visible in green. 
 
 
We also performed the same electrophoresis experiment with uncoated albumin 
microbubbles (Figure 3B). In contrast to the polymer-coated microbubbles, we did not see any 
retardation of the pDNA after incubation with the albumin microbubbles (Lane 3). This implies that 
only a very small fraction of the pDNA is indeed bound to the albumin shell, or that the interaction 
between the microbubbles and the pDNA is too low to prevent pDNA migration under the influence 
of the electric field. Exposure of pDNA to higher ultrasound intensities (2W/cm2) in the presence of 
albumin microbubbles resulted in a partial degradation of the pDNA (lane 9-12). Because the pDNA is 
not complexed, it is more sensitive to the very high mechanical forces occurring during microbubble 
cavitation and implosion. This can result in a mechanical break-down of the pDNA16. This implies that 
the pDNA should be encapsulated or complexed to prevent mechanical degradation17. For this 
reason, pDNA should be bound to the microbubble shell or condensed into electrostatic complexes. 
Two possible solutions exist for preparing a pDNA loaded microbubble, capable of releasing 
pDNA or small pDNA complexes. A first solution can be found in coating the albumin microbubbles 
with another cationic polymer, possessing less cationic charges. This would reduce the interactions 
between microbubble and pDNA. Electrostatic interaction might be lowered to such an extent that 
the pDNA is released during microbubble implosion.  However, this increases the chance that the 
pDNA will become released in the blood circulation after interaction of the microbubbles with 
charged serum components. A second solution can be the attachment of well-defined pre-formed 
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pDNA complexes to the microbubble shell. In this case, the pDNA is protected inside the complexes 
during extracellular circulation. When the microbubbles enter the ultrasonic field, these small 
complexes can then be released and are available for uptake through the created cell membrane 
pores. Several papers have shown that at least part of these complexes are able to dissociate 
intracellularly, after which the pDNA can be transported to the nucleus for transcription18,19. In 
chapter 4 we will focus on the creation of a novel particle loaded microbubble.  
 
CONCLUSION 
 
In conclusion, we showed that the pre-incubation of uncoated albumin microbubbles and 
pDNA drastically increases ultrasound mediated gene transfer. Although the PAH-coated albumin 
microbubbles enable high pDNA loading efficiencies and a good pDNA protection, they are not 
capable of transfecting primary endothelial cells or melanoma cells. Our confocal microscopy 
experiments revealed that this is due to the formation of large aggregates, arising upon microbubble 
implosion. These aggregates might be too large to reach cellular cytoplasm through cell membrane 
pores. Gel electrophoresis experiments confirmed that the pDNA is still associated with the 
microbubble shell fragments, which can also hamper intracellular dissociation. Exposure of pDNA in 
the presence of albumin microbubbles to ultrasound intensities of 2W/cm2 resulted in a partial 
degradation of the plasmid DNA, indicating that the pDNA should be complexed or encapsulated to 
prevent this degradation. In the next chapter we will focus on the attachment of small, pre-formed 
pDNA complexes to the microbubble shell and evaluate whether this will solve the different 
problems encountered in this study.  
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ABSTRACT 
 
Cationic poly(ethylene glycol)ylated (PEGylated) liposomes are one of the most important 
gene transfer reagents in non-viral gene therapy. However, the low transfection efficiencies of highly 
PEGylated lipoplexes currently hamper their clinical use. Recently, ultrasound has been used in 
combination with microbubbles to enhance the uptake of genes in different cell types. However, the 
gene transfer efficiency still remains low in these experiments. To overcome the limitations of both 
techniques, we present the attachment of PEGylated lipoplexes to microbubbles via biotin–avidin–
biotin linkages. Exposure of these lipoplex-loaded microbubbles to ultrasound results in the release 
of unaltered lipoplexes. Furthermore, these lipoplex-loaded microbubbles exhibit much higher 
transfection efficiencies than “free” PEGylated lipoplexes or naked plasmid DNA (pDNA) when 
combined with microbubbles and ultrasound. Interestingly, the lipoplex-loaded microbubbles only 
transfect cells when exposed to ultrasound, which is promising for space- and time-controlled gene 
transfer. Finally, this novel Trojan-horse-like concept can also be exploited to achieve the ultrasound-
triggered release of nanoparticles containing other therapeutic agents such as anticancer drugs. 
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Chapter 4 
Lipoplex loaded microbubbles for 
ultrasound targeted gene delivery 
 
INTRODUCTION 
 
The use of nucleic acids to replace defective genes or silence aberrant ones is an attractive 
strategy for the treatment of genetic disorders. However, the development of efficient and safe 
materials that can deliver therapeutic nucleic acids to the target cells of a patient is an enormous 
challenge. Both viral and non-viral nucleic acid delivery systems, such as cationic liposomes and 
cationic polymers, which electrostatically bind to negatively charged nucleic acids, are currently 
being investigated1. Unfortunately, the former system is plagued by safety issues2, whereas the latter 
systems are vulnerable to non-specific interactions with blood compounds due to their positive 
surface charge, resulting in the formation of life-threatening aggregates and suffering from rapid 
clearance by the mononuclear phagocyte system3,4. These unwanted interactions have been 
prevented by coating the non-viral gene delivery systems with non-fouling polymers like 
poly(ethylene glycol) (PEG)5. However, ‘PEGylation’ drastically reduces the transfection efficacy of 
non-viral gene delivery systems, which has been attributed to reduced cellular uptake and/or limited 
endosomal escape6,7. To overcome these limitations, the use of ultrasound energy in combination 
with gas-filled microbubbles has recently been proposed8-14. Ultrasound may mediate the 
intracellular delivery of nucleic acids by the formation of transient pores in cell membranes. These 
cell perforations are caused by shockwaves and microjets that are generated by the ultrasound-
induced implosion of microbubbles in the vicinity of the cell membranes. The lifetimes of the cell 
membrane perforations have been reported to be very short, in the millisecond to seconds range15-17. 
Therefore, we believe that the binding of nanoparticles to microbubbles will allow the particles to be 
present at the site of cell membrane perforation, which may enhance the number of nanoparticles 
that can enter the cell. In this study, we have attempted to load PEGylated lipoplexes onto 
microbubbles to overcome their low transfection efficiency. Furthermore, the coupling of liposomes 
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to microbubbles could be an interesting approach for the ultrasound-induced release of different 
types of therapeutic molecules. 
 
MATERIALS & METHODS 
 
Preparation and characterization of lipid microbubbles containing DSPE–PEG–Biotin  
 
 Liposomes containing DPPC/DSPE–PEG–biotin in a 95:5 molar ratio were prepared as 
previously described18. Briefly, the lipids dissolved in chloroform were placed in a round-bottomed 
flask and the solvent was removed by evaporation followed by flushing with nitrogen. The obtained 
lipid film was subsequently hydrated in a 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) 
buffer solution (20 mM HEPES, pH7.4) at a final lipid concentration of 5 mg/mL; the film was 
incubated overnight in this solution at 4 °C to allow the formation of liposomes. The resulting 
liposomes were first extruded through a polycarbonate membrane (pore size of 0.2 µm) using a mini-
extruder (Avanti Polar Lipids, Alabaster, AL, USA). Subsequently, the extruded liposomes were 
sonicated with a 20 kHz probe (Branson 250 sonicator, Branson Ultrasonics, Danbury, CT, USA) in the 
presence of perfluorobutane gas (C4F10, molecular weight (MW) 238 g/mol, F2 Chemicals, Preston, 
Lancashire, UK). After sonication, the microbubbles were washed (to remove excess lipids) with 3 mL 
fresh HEPES buffer, and finally resuspended in 5 mL of a fresh HEPES buffer solution. To allow the 
attachment of biotinylated lipoplexes, the biotinylated microbubbles were incubated with 500 µL 
avidin (10 mg/mL) for 10 min at room temperature. Subsequently, the microbubbles were 
centrifuged and washed again with 3 mL fresh HEPES buffer. Finally, the microbubbles were 
resuspended in a 5 mL HEPES buffer solution. The concentration of the avidinylated microbubbles in 
the dispersions was determined with the aid of a Burker chamber and a light microscope, and was 
found to be 4×108 microbubbles/mL. The size distribution of the microbubbles was determined 
within 10 min of preparation by laser diffraction (Mastersizer S, Malvern, Worcestershire, UK). To 
measure the size distribution of the lipoplex-loaded microbubbles, 130 µL of the 15 mol% DSPE–
PEG–biotin-containing lipoplexes was incubated for 5 min with 1 mL of the microbubble suspension 
and the measurement was performed again. The results are expressed as number percentages 
normalized to the most abundant fraction of microbubbles. All these experiments were performed 
using microbubbles dispersed in HEPES buffer. For the visualization of avidin on the surface of the 
biotinylated microbubbles, we incubated the microbubbles with 50 µL of Cy5-labeled streptavidin (1 
mg/mL).  
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Preparation and characterization of PEGylated cationic liposomes and lipoplexes 
 
The phospholipids, N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride 
(DOTAP), dioleoyl phosphatidyl ethanolamine (DOPE), DSPE–PEG, DSPE–PEG–biotin, and cholesteryl 
4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoate (cholesteryl Bodipy FLC12) 
were purchased from Avanti Polar Lipids. Cationic liposomes containing DOTAP/DOPE in a 1:1 molar 
ratio with 0.1 mol% cholesteryl Bodipy FLC12 and 0 to 15 mol% DSPE–PEG or DSPE–PEG–biotin were 
prepared as described above. For the preparation of lipoplexes, we used pDNA (pGL3, Promega, 
Leiden, The Netherlands) containing the luciferase gene from Photinus pyralis as the reporter. The 
pDNA was amplified in Escherichia coli and purified as described elsewhere18. The pDNA 
concentration was set at 1.0 mg/mL in HEPES buffer taking into account that the absorption of a 50 
µg/mL DNA solution at 260 nm equals 1. The pDNA was of high purity as evidenced by the ratios of 
the optical absorptions at 260 and 280 nm varying from 1.8 to 2.0. Lipoplexes (with different 
percentages of DSPE–PEG or DSPE–PEG–biotin) were prepared with a charge ratio of 4. The charge 
ratio is defined as the ratio of the number of the positive charges (originating from DOTAP) to the 
number of the negative charges (originating from the pDNA). pDNA was first diluted in HEPES buffer 
to a concentration of 0.41 mg/mL. Subsequently, the diluted pDNA was added to an equal volume of 
cationic liposomes (5 mM DOTAP), resulting in a final +/– charge ratio of 4. Immediately after the 
addition of pDNA to the cationic liposomes, HEPES buffer was added until the final concentration of 
pDNA in the system was 0.126 mg/mL. This mixture was then vortexed and incubated at room 
temperature for 30 min. To obtain green labeled lipoplexes, liposomes prepared with 0.5 mol% of 
cholesteryl Bodipy FLC12 were used. The average hydrodynamic diameter of the PEGylated 
lipoplexes was determined by DLS (Autosizer 4700, Malvern). The data were analyzed using the 
automatic data analysis mode, i.e., a monomodal fit was used when the polydispersity (PD) was < 
0.05 and a continuous fit was used when the PD was > 0.05. The zeta potential () was determined 
using electrophoretic mobility measurements (Malvern Zetasizer Nano ZS, Malvern). For these 
experiments, the lipoplexes were dispersed in HEPES buffer. The size and zeta potential of lipoplexes 
released from the lipoplex-loaded microbubbles after exposure to ultrasound (1 MHz, 10% duty 
cycle) for 10 s were determined in a similar way. Gel electrophoresis experiments were performed 
following previously described protocols18 to determine the presence of free pDNA in the lipoplexes 
before binding to the microbubbles and after ultrasound-assisted release from the microbubbles.  
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Attachment of biotinylated PEG-lipoplexes to avidinylated microbubbles 
 
130 µL of a solution of biotinylated PEG-lipoplexes was mixed with a 1 mL solution of 
avidinylated mirobubbles and incubated at room temperature for 5 min. The attachment of 
fluorescent-labeled lipoplexes to the microbubbles was visualized by CLSM using a Nikon EZC1-si 
microscope (Nikon, Brussels, Belgium) equipped with a 40 × objective. The 491 nm line of this 
microscope was used to excite the Bodipy label.  
 
Transfection Experiments 
 
BLM cells (melanoma cells)19 were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
with the growth factor F12 and phenol red containing 2 mM glutamine, 10% heat-deactivated fetal 
bovine serum (FBS), 1% penicillin–streptomycin (Gibco, Merelbeke, Belgium), and HEPES buffer (100 
mM, pH7.4). The cells were grown to 90% confluency in Opticell units (Biocrystal, Westerville, OH, 
USA) inside a humidified incubator at 37 °C under 5% CO2. Subsequently, the cells were washed with 
10 mL of phosphate buffered saline (PBS, Gibco) and the transfection medium was added. The 
transfection media were prepared by first mixing 130 µL PEGylated lipoplexes with 1 mL of the 
microbubble suspension (containing 4 × 108 microbubbles). After incubation for 5 min at room 
temperature, Optimem (Gibco) was added to a final volume of 10 mL. The transfection medium was 
prepared in a similar way for transfection experiments with naked pDNA, except that the 130 µL 
solution of the PEGylated lipoplexes was replaced by an equal volume of HEPES buffer containing 
16.5 µg pDNA, the same amount as present in the lipoplexes. 10 mL of the transfection medium was 
added to the Opticell units (surface area of 50 cm2). Subsequently, the cells were placed in a water 
bath at 37 °C with an absorbing rubber substrate at the bottom and immediately subjected to 
ultrasound radiation. The ultrasound irradiation was performed for 10 s with a Sonitron 2000 
instrument (RichMar, Inola, OK, USA) equipped with a 22 mm probe. In all the ultrasound-assisted 
experiments, the following ultrasound settings were used: 1 MHz, 10% duty cycle, and an ultrasound 
intensity of 2 W/cm2. The areas treated with ultrasound were marked and after radiation the 
Opticells were incubated for an additional 2 h at 37 °C. At the end of this incubation period, the 
transfection medium was removed and the cells were washed two times with PBS, before adding 
fresh culture medium. Each transfection experiment was performed three times. Luciferase 
expression by the cells was analyzed 24 h after transfection. The culture medium was removed and 
the cells were washed with PBS. The areas exposed to ultrasound (20 mm diameter) were cut from 
the Opticell membrane and placed in a 24 well plate. A 80 µL solution of cell culture lysis reagent 
(CCLR, Promega, Leiden, The Netherlands) buffer was added to each well and incubated at room 
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temperature for at least 20 min to allow cell lysis. 20 µL of the cell lysate was transferred to a 96 well 
plate and the luciferase activity was measured using a Glomax 96 Microplate Luminometer 
(Promega), as described previously in the literature20. An aliquot (20 µL) of each cell lysate was also 
analyzed for protein concentration using the bichinconinic acid (BCA) protein assay (Pierce, Rockford, 
IL, USA). The transfection results are expressed as relative light units (RLU) per milligram of protein. 
 
Cellular uptake of green-labeled 15 mol% DSPE–PEG–biotin-containing lipoplexes 
 
Bodipy-labeled lipoplexes containing 15 mol% DSPE–PEG–biotin were prepared and attached 
to the microbubbles as described above. BLM cells present in Opticell units were exposed to the 
lipoplex-loaded microbubbles and ultrasound using the same conditions as in the transfection 
experiments. The areas treated with ultrasound were immediately visualized by CLSM using a Nikon 
EZC1-si microscope equipped with a 60 × objective. The 491 nm line of this microscope was used to 
excite the Bodipy label in the lipoplexes.  
 
Statistical Analysis 
 
All the data in this report are expressed as mean ±standard deviation (SD). For the 
transfection results, the student’s t-test was used to determine whether the data groups differed 
significantly from each other. A p-value lower than 0.05 was considered statistically significant. 
 
RESULTS AND DISCUSSION 
 
 Preparation and characterization of lipoplex-loaded microbubbles 
 
 
As schematically illustrated in Figure 1A, PEGylated lipoplexes, i.e., complexes of DNA with 
cationic PEGylated liposomes (Fig. 1B), have been attached to microbubbles via biotin–avidin–biotin 
bridges. To prepare these lipoplex-loaded microbubbles, we have used lipid-based microbubbles that 
contain 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[biotinyl- PEG-2000] (DSPE–PEG–biotin) 
in their lipid shell. To evaluate whether the biotin molecules are present on the outer surface of the 
microbubbles, we have incubated them with Cy5-labeled streptavidin. After removal of the free Cy5–
streptavidin, confocal laser scanning microscopy (CLSM) clearly reveals the presence of red 
fluorescence around the microbubbles, indicating the formation of a biotin–avidin linkage (Fig. 2). 
This confirms that the DSPE–PEG–biotin molecules in the shell of the microbubbles are oriented with
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Figure 1 A) Schematic depiction of a lipoplex-loaded microbubble. The white disk surrounded by the lipids, 
dipalmitoylphosphatidylcholine (DPPC) and 1,2-distearoylsn- glycero-3-phosphoethanolamine-N-[biotinyl-PEG-
2000] (DSPE–PEG–biotin), represents an avidinylated lipid microbubble with a perfluorobutane (C4F10) gas core. 
Lipoplexes with increasing amounts of DSPE–PEG–biotin are attached to these avidinylated microbubbles via 
biotin–avidin–biotin bridges. B) Detailed illustration of a single biotinylated lipoplex.  
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Figure 2 CLSM (left) and transmission (right) image of biotinylated microbubbles after incubation with Cy5-
labeled streptavidin. 
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Figure 3 Size distribution of DPPC/DSPE–PEG–biotin microbubbles before and after the addition of 15 mol% 
PEGylated lipoplexes, as measured by laser diffraction. The y-axis shows the abundance of a certain class of 
microbubbles normalized to the most abundant fraction of microbubbles (y = 1). The data represent the mean 
of three independent measurements. 
 
their hydrophobic tails pointing to the perfluorobutane gas core and with their hydrophilic head 
groups in the aqueous medium, as previously suggested by Unger et al21. To determine whether the 
biotinylated microbubbles have an optimal size distribution for cavitation, we have studied their size 
distribution by laser diffraction (Figure 3, red circles). As shown in Figure 3, the microbubbles are 
between 0.5 and 10 µm in size, which is indeed optimal for cavitation upon exposure to clinically 
relevant ultrasound irradiation21. To enable the binding of the PEGylated lipoplexes to the biotin-
containing microbubbles, we have first incubated  the microbubbles with an excess of avidin. After 
removing the unbound avidin, PEGylated lipoplexes containing increasing amounts of DSPE–PEG–
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biotin (2, 5, and 15 mol%) are added to the microbubbles. Figure 4 demonstrates the binding of 
fluorescently-labeled PEGylated lipoplexes to the microbubbles. We observe that all the 
microbubbles have attached lipoplexes on their surface independent of the percentage of DSPE–
PEG–biotin in the lipoplexes, indicating that the number of lipoplexes greatly exceeds the number of 
microbubbles. The amount of DSPE–PEG–biotin in the PEGylated lipoplexes clearly effects on the 
number of lipoplexes bound per microbubble. Lipoplexes containing 2 mol% DSPE–PEG–biotin do not 
completely cover the surface of the microbubbles, likely because of the limited degree of 
biotinylation of the lipoplexes. The surfaces of most microbubbles are fully covered with PEGylated 
lipoplexes when 5 mol% DSPE–PEG–biotin is incorporated in the lipoplexes, whereas all the 
microbubbles are completely covered with PEGylated lipoplexes when lipoplexes containing 15 mol% 
DSPE–PEG–biotin are used. The inset to Figure 4B shows a high-magnification image of a single 
lipoplex-loaded microbubble.  
 
 
 
Figure 4 CLSM and corresponding transmission images of avidinylated microbubbles incubated with 
fluorescently labeled (green) PEGylated lipoplexes. The PEGylated lipoplexes contain A) 2 mol %, B) 5 mol %, 
and C) 15 mol% DSPE–PEG–biotin. The inset to (B) shows a microbubble with single lipoplexes on its surface. 
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To determine the effect of lipoplex binding on the size of the microbubbles, we have also 
measured the size distribution of the microbubbles after incubation with the biotinylated lipoplexes 
(Figure 3, solid squares). Compared to the unloaded microbubbles, the lipoplex loaded microbubbles 
are slightly smaller, which is probably due to experimental variations such as localization of the 
sonication probe and removal of the subnatant during successive washing steps. To confirm that the 
lipoplexes are specifically bound to the microbubbles through avidin–biotin interactions, we have 
tested the binding of PEGylated lipoplexes lacking biotin. The lipoplexes used in this control 
experiment contain 5 mol% DSPE–PEG instead of DSPE–PEG–biotin. The moderate binding of these 
non-biotinylated lipoplexes to the microbubbles is observed (data not shown). Since avidin is a 
glycosylated protein, non-specific interactions with different types of molecules and particulate 
matter can be expected. 
 
Ultrasound-induced release of PEGylated lipoplexes from microbubbles 
 
As mentioned in Section 1, the exposure of microbubbles to ultrasound causes the implosion 
and hence destruction of the microbubbles. Consequently, nanoparticles that are attached to the 
lipid-based microbubbles can be released from the microbubbles by ultrasound. Lum et al.22 have 
succeeded in attaching latex beads to lipid microbubbles, and have demonstrated the release of 
these beads under ultrasonic treatment. However, in contrast to inert beads, lipoplexes, which arise 
from the self-assembly of cationic liposomes and DNA, may undergo physicochemical alterations 
(which can possibly reduce their biological performance) during ultrasound-triggered release from 
the microbubbles.  
Therefore, some physicochemical properties of the lipoplexes have been measured before 
attachment to the microbubbles and after ultrasound-triggered release from the microbubbles. The 
size of the free lipoplexes has been measured using dynamic light scattering (DLS). The lipoplexes 
decrease in size (from ca. 325 to 125 nm) with increasing degree of PEGylation. No significant 
difference in size is observed after the ultrasound-induced release of the lipoplexes from the 
microbubbles, except that the lipoplexes prepared with 15 mol% DPPC–PEG–biotin become slightly 
larger (Figure 5). The zeta potential before attachment to the microbubbles is around 25 mV for 
lipoplexes containing 2 mol% DSPE–PEG–biotin, around 22 mV for lipoplexes with 5 mol% DSPE–
PEG–biotin, and ca. 14mV  for lipoplexes containing 15 mol% DSPE–PEG–biotin. The zeta potential of 
the lipoplexes is not significantly altered after release from the microbubbles by ultrasound 
treatment (Figure 6). Apart from the retention of the size and zeta potential of the lipoplexes, it is
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Figure 5 Sizes of PEGylated lipoplexes containing 2, 5, and 15 mol% DSPE–PEG–biotin before attachment to the 
microbubbles (white bars) and after ultrasound-mediated release from the microbubbles (black bars). The data 
represent the mean of three independent measurements and the error bars indicate the standard deviation. 
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Figure 6 Zeta potential of PEGylated lipoplexes containing 2, 5, and 15 mol% DSPE–PEG–biotin before 
attachment to the microbubbles (white bars) and after ultrasound-mediated release from the microbubbles 
(black bars). The data represent the mean of three independent measurements and the error bars indicate the 
standard deviation. 
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also important that they do not dissociate upon exposure to ultrasound. Therefore, gel 
electrophoresis has been used to evaluate whether the ultrasound-assisted release of lipoplexes 
from the microbubbles leads to the release of plasmid DNA (pDNA). Free pDNA is not detected 
before the attachment of the lipoplexes or after the ultrasound-induced release of the lipoplexes 
from the microbubbles (Figure 7). This means that the ultrasound-mediated implosion of the 
microbubbles and the induced microjets do not influence the complexation properties of the cationic 
liposomes. 
 
 
 
Figure 7 Gel electrophoresis of PEGylated lipoplexes containing 2, 5 and 15 mol% DSPE-PEG-biotin before 
attachment to the microbubbles (A) and after ultrasound mediated release from the microbubbles (B). A: Lane 
1: free pDNA; Lane 2-4: PEGylated lipoplexes prepared with increasing amounts of DSPE-PEG-biotin: 2 mol%, 5 
mol% and 15 mol%.  B: Lane 5: free pDNA; Lane 6-8: PEGylated lipoplexes prepared with an increasing amount 
of DSPE-PEG-biotin subsequently 2mol%, 5mol% and 15mol%. 
 
 
Gene transfer efficiency of lipoplex-bearing microbubbles 
 
The gene transfer efficacies of PEGylated lipoplexes, a (physical) mixture of PEGylated 
lipoplexes and microbubbles, and the lipoplex-loaded microbubbles have been evaluated. As shown 
in Figure 8 (white bars, part B), the higher the degree of PEGylation of the lipoplexes, the lower their 
transfection capacity. Lipoplexes with a degree of PEGylation of 5 mol% are only slightly better than 
naked DNA (part A in Figure 8), whereas lipoplexes with a degree of PEGylation of 15 mol% show 
almost no transfection. The failure of highly PEGylated lipoplexes to transfect cells is in agreement 
with results of other research groups, and has been ascribed to both a reduced cellular uptake23 and 
an inhibition of the endosomal release of DNA into the cytoplasm by the PEG lipids in the 
lipoplexes23-28. Figure 8 (grey bars, part B) also shows data for the transfection of cells when they are 
exposed to a (physical) mixture of PEGylated lipoplexes using microbubbles and ultrasound. Since the
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Figure 8 A) The transfection efficiency of naked DNA in the absence and presence of microbubbles and 
ultrasound, and the background luciferase signal in untreated cells. B) The transfection efficiency of free 
PEGylated lipoplexes in the absence and presence of microbubbles and ultrasound, and that of lipoplex-loaded 
microbubbles in the presence of ultrasound. The transfection results, i.e., the extent of luciferase expression, 
are expressed as RLUmg–1 (RLU: relative light units) protein. * p < 0.05, compared to lipoplexes or naked DNA 
without microbubbles and ultrasound. **p < 0.05. 
 
ultrasound energy itself does not alter the physicochemical properties of the PEGylated lipoplexes 
(see discussion above), it is reasonable to expect that the transfection of the cells should at least be 
similar to that observed when only free PEGylated lipoplexes are used (white bars, part B of Fig. 8). 
However, we hypothesize that the strong decrease in gene transfer observed for the 2 mol% 
PEGylated lipoplexes arises from an ultrasound-induced blockage of endocytosis, which is line with 
previous observations by Schlicher et al.16 They have shown that ultrasound treatment in the 
presence of microbubbles removes patches of the plasma membrane; these are subsequently 
resealed by lipid vesicles transported from the inside of the cell to the plasma membrane 
(exocytosis). The endocytosis of the cells, which is the major mechanism for the uptake of the 
lipoplexes, may be significantly altered upon exposure to ultrasound. Such repair mechanisms of the 
cell membrane may prevent the endocytic uptake of the lipoplexes29. Figure 8 (grey bars, part B) 
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shows that the presence of microbubbles and the application of ultrasound does not really reduce 
the transfection properties of 5 and 15 mol% PEGylated lipoplexes. Since the 5 and 15 mol% 
PEGylated lipoplexes are much less endocytozed by the cells, it is reasonable to expect that the 
(negative) influence of ultrasound and microbubbles will be much less pronounced. Importantly, 
Figure 8 (black bars, part B) clearly shows that the attachment of the lipoplexes to the microbubbles 
tremendously increases the transfection efficiency of the 5 mol %, and especially the 15 mol %, 
PEGylated lipoplexes. As noted above, free PEGylated lipoplexes encounter difficulties in entering the 
cells and/ or in escaping from endosomes, especially when they are highly PEGylated23,25-28. We 
hypothesize that most of the PEGylated lipoplexes released from the microbubbles do not enter the 
cells by endocytosis, and consequently do not have to escape from the endosomes. To verify this 
hypothesis, we have studied the cellular uptake of the 15 mol% PEGylated lipoplexes after exposure 
to ultrasound. Figure 9 shows a massive internalization of the fluorescently labeled 15 mol% 
PEGylated lipoplexes immediately after exposure of the melanoma cells to lipoplex-loaded 
microbubbles and ultrasound. As mentioned above, several groups have reported the formation of 
transient cell membrane perforations upon the implosion of microbubbles at or near cell 
membranes15-17,30,31. Consequently, it is reasonable to expect that the PEGylated lipoplexes released 
from the microbubbles enter the cells through these perforations, explaining their rapid 
internalization in Figure 9. Since the lifetime of the cell membrane perforations is very short,15 it is 
important that the lipoplexes are closely located to the cell membrane perforations, which is indeed 
the case when they are attached to the microbubbles. This phenomenon most likely also explains 
why the physical mixing of the PEGylated lipoplexes with the microbubbles does not dramatically 
enhance gene transfer (grey bars, part B), since most of the PEGylated lipoplexes are not located 
close to the microbubbles. As indicated by the arrow in Figure 8, the transfection efficiency of the 
lipoplex-loaded microbubbles increases as a function of the amount of DSPE–PEG–biotin in the 
lipoplexes. This can be explained as follows: firstly, more PEGylated lipoplexes are attached to the 
microbubbles when the lipoplexes contain more DSPE–PEG–biotin, which results in an increased 
concentration of PEGylated lipoplexes at the cell membrane perforations. Secondly, we note that the 
higher the degree of PEGylation, the smaller the size of the lipoplexes released from the 
microbubbles, which increases the chances of more PEGylated lipoplexes passing through the cell 
perforations. Finally, when no ultrasound is applied, the cell transfection by lipoplex-loaded 
microbubbles is negligible, and even lower than the transfection by free PEGylated lipoplexes (data 
not shown). This is again reasonable since without ultrasound the lipoplexes remain attached to the 
micrometer- sized bubbles that are too large to enter the cells. Interestingly, this may enable the 
microbubbles to transfect only those cells that are exposed to ultrasound energy, which may be 
promising for targeted in vivo gene delivery. 
Chapter 4 – Lipoplex loaded microbubbles for ultrasound targeted gene delivery 
 
 
120 
 
 
 
 
 
Figure 9 Cellular uptake of green-labeled 15 mol% PEGylated lipoplexes in BLM cells immediately after 
exposure of the cells with lipoplex-loaded microbubbles and ultrasound. Transmission images (A-D) and CLSM 
images (B-E)of green-labeled lipoplexes; overlays of the transmission and the green fluorescent confocal 
images (C-F). High-magnification images of a single cell (D-F). 
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Conclusions 
 
We have designed a novel lipid microbubble to which PEGylated lipoplexes are attached via 
biotin–avidin–biotin linkages. Upon exposure to ultrasound, unaltered lipoplexes are released from 
these lipoplex-loaded microbubbles. This is in contrast to previously developed layer-by-layer coated 
microbubbles, which lead to the release of undefined DNA-containing clusters that are too large to 
pass through the small cell perforations32. The lipoplex-loaded microbubbles have a much higher 
gene transfer capacity than “free” PEGylated lipoplexes and naked pDNA used in combination with 
microbubbles and ultrasound. Interestingly, the lipoplex-loaded microbubbles only transfect cells 
when exposed to ultrasound, which is promising for space- and time-controlled gene transfer33,34. 
Thus far, the lack of gene transfer has impeded the clinical evaluation of PEGylated lipoplexes. To the 
best of our knowledge, we have demonstrated for the first time that gene transfer by lipoplexes 
containing > 5 mol% PEG–lipid can be strongly improved by attaching them to microbubbles and 
exposing them to ultrasound energy. The microbubbles presented in this study are also expected to 
be suitable for systemic applications. Indeed, microbubbles are already routinely injected in the clinic 
to enhance the ultrasound- mediated visualization of blood vessels, whereas highly PEGylated 
lipoplexes are known not to aggregate in blood and have been shown to be harmless4,5. Moreover, 
this novel Trojan-horse-like concept can be used to achieve the ultrasound- controlled delivery of 
drug-loaded liposomes by simply attaching the drug-loaded liposomes or nanoparticles to the 
microbubbles. In this way, a more targeted delivery of drugloaded nanoparticles can be achieved, 
resulting in an increase of the therapeutic index of the drugs. 
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ABSTRACT 
 
Recently we reported that the transfection of cells by PEGylated lipoplexes becomes 
significantly better by binding the PEGylated lipoplexes to the surface of microbubbles and applying 
ultrasound. To further optimize this gene delivery system it is important to understand the working 
mechanism. This paper elucidates the cellular entry path of these lipoplexes. The results clearly show 
that the PEGylated lipoplexes, released from the microbubbles upon applying ultrasound, are not 
taken up by endocytosis, being the most common route for nanoparticles to enter cells. Our data 
demonstrate that upon implosion of the microbubbles, the PEGylated lipoplexes are released and are 
most probably able to passively diffuse through the cell membrane pores or become ejected in the 
cytoplasm of the target cells. This is attractive as the in vivo use of PEGylated nanoparticles remains 
currently limited due to a decreased cellular uptake and inefficient escape of the PEGylated 
nanoparticles from the endosomes. 
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Chapter 5 
Ultrasound exposure of lipoplex loaded 
microbubbles facilitates direct 
cytoplasmic entry of the lipoplexes 
 
INTRODUCTION 
The development of safe and efficient gene delivery systems is crucial for in vivo gene therapy. 
Viral delivery systems are the most efficient gene delivery systems. However, their in vivo use has 
been limited after the dead of several patients during clinical trials with both adenoviral and 
adenoassociated viral (AAV) vectors1. Furthermore, viral delivery systems are expensive while, 
especially, AAV vector cannot host (very) large transgenes. Also the risk of insertional mutagenesis 
and severe immune responses limit their in vivo use. In contrast, non-viral gene delivery systems 
have several advantages: easy and cheap production and the possibility of incorporating large 
plasmids2. Furthermore they cause a relatively lower immune  response2. To improve the efficiency 
of non-viral delivery systems researchers have upgraded them with different functionalities like 
targeting ligands and fusiogenic peptides to enable their endosomal escape. The latter is important 
as almost all non-viral vectors are taken up via endocytosis. Additionally, to avoid (a) aggregation in 
blood and (b) interaction with blood compounds like albumin, the surface of many types of non-viral 
delivery systems has been covered with polymers like poly-ethylene-glycol (PEG)3-5. However, 
PEGylation drastically lowers the transfection efficiency of non-viral vectors by hampering their 
cellular uptake and endosomal release. Therefore, PEG chains have been attached to lipids and 
polymers via chemical bonds that become cleaved in the acidic environment of the late endosomes. 
However, the synthesis of such so-called ‘bioresponsive’ carriers remains rather difficult6,7.  
Recently, the use of ultrasound and microbubbles has gained more and more attention to 
deliver drugs, especially nucleid acids8. Although microbubbles are currently used as contrast agent 
in ultrasound imaging9, they can also provoke several cellular effects. At low ultrasound intensities, 
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the microbubbles oscillate linearly in the acoustic pressure waves, a phenomenenon called stable 
cavitation. This results in micro-streaming which affects the cellular membrane when the 
microbubbles are located close enough to the cells10. At higher ultrasound intensities, the expansions 
of the microbubbles become larger followed by a violent collapse of the microbubbles that results in 
shock waves that can temporarily perforate cell membranes (this phenomenon is called 
sonoporation). This collapse is due to the inertia of the inrushing fluid and is therefore called inertial 
cavitation11.  Ultrasound assisted drug delivery has many advantages and one of the most attractive 
properties is the potential for time and space controlled delivery of drugs. On top, microbubbles and 
ultrasound energy are considered relative safe as both are applied in medical imaging for several 
years12.  
Ultrasound in combination with microbubbles has been intensively evaluated to enhance the 
delivery of naked DNA (genes and antisense oligonucleotides) and siRNA13-21. However, to obtain a 
significant higher biological effect large amounts of DNA and siRNA are required. This is due to the 
fact that naked DNA and siRNA are sensitive to degradation by nucleases, which are widely 
distributed in the body. Also, as the ultrasound induced pores in the cell membranes are short living, 
large amounts of DNA and siRNA are required near the pores to ensure a sufficient influx inside the 
cells. To overcome the limitations of (a) naked DNA combined with ultrasound and microbubbles, 
and (b) PEGylated lipoplexes (which suffer from an inefficient cellular uptake and endosomal escape), 
we previously coupled PEGylated lipoplexes onto ultrasound responsive  microbubbles (Figure 1)22,23. 
The idea being that the lipoplexes will be released upon ultrasound treatment and that they will be 
more easily transported inside the cell. Applying ultrasound to PEGylated lipoplexes bound to 
microbubbles resulted in much higher transfection when compared to the transfection obtained with 
free PEGylated lipoplexes with or without the use of microbubbles and ultrasound (Figure 2B). To 
further optimize this new delivery system it is necessary to understand the mechanism which 
explains this higher transfection efficiency. Therefore, the aim of this work was to elucidate the 
cellular pathway by which PEGylated lipoplexes, upon release from the microbubbles by ultrasound, 
enter the cells. 
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MATERIALS & METHODS 
Preparation and characterization of lipid microbubbles containing DSPE-PEG-biotin 
 
 Liposomes containing DPPC (dipalmitoylphosphatidylcholine) and DSPE-PEG-biotin (1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-(biotinyl(polyethyleneglycol)2000)) in a 95:5 molar 
ratio were prepared as previously described24. Briefly, the lipids were put in a round-bottomed flask, 
dissolved in chloroform. Subsequently, the solvent was removed via evaporation followed by flushing 
with nitrogen. The obtained lipid film was hydrated in HEPES buffer (20 mM HEPES, pH 7.4) at a final 
lipid concentration of 5 mg/mL and incubated overnight at 4°C to allow the formation of liposomes. 
The resulting liposomes were first extruded through a polycarbonate membrane (pore size of 0.2 
µm) using a mini-extruder (Avanti Polar Lipids, Alabaster, AL, USA). Subsequently, the extruded 
liposomes were sonicated with a 20 kHz probe (Branson 250 sonifier, Branson Ultrasonics Corp., 
Danbury, CT, USA) in the presence of perfluorobutane gas (C4F10, MW 238 g/mol, F2 chemicals, 
Preston, Lancashire, UK). After sonication the microbubbles were washed (to remove the excess of 
lipids) with 3 mL fresh HEPES buffer and finally resuspended in 5 mL. To enable the attachment of 
biotinylated lipoplexes, the biotinylated microbubbles were incubated with 500 µL avidin (10 mg/mL) 
and incubated for 10 min at room temperature. Subsequently, the microbubbbles were centrifuged 
and washed again with 3 mL fresh HEPES buffer. Finally the microbubbles were resuspended in 5 mL 
HEPES buffer. The concentration of the avidinylated microbubbles in the dispersions was determined 
with the aid of a Burker chamber and a light microscope and equalled 4 x 108 microbubbles/mL. 
 
 Preparation and characterization of PEGylated cationic liposomes and lipoplexes 
 
The cationic lipid DOTAP (N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride), 
the phospholipid DOPE (dioleoyl phosphatidyl ethanolamine), DSPE-PEG, DSPE-PEG-biotin and 
cholesteryl Bodipy FLC12 (cholesteryl 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-
3dodecanoate) were purchased from Avanti Polar Lipids. Cationic liposomes containing DOTAP and 
DOPE in a 1:1 molar ratio with 0 to 15 mol% DSPE-PEG or DSPE-PEG-biotin were prepared as 
described above.  
For the preparation of lipoplexes we used plasmid DNA (pDNA; pGL3, Promega, Leiden, The 
Netherlands) containing the luciferase gene from Photinus pyralis as reporter (i.e. firefly luciferase). 
The pDNA was amplified in Escherichia coli and purified as described elsewhere24. The pDNA was 
dissolved in HEPES buffer and the concentration was set at 1.0 mg/mL taking into account that the 
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absorption at 260 nm of a 50 µg/mL DNA solution equals 1. The pDNA showed a high purity as the 
ratio of the absorption at respectively 260 and 280 nm was between 1.8 and 2.0.  
Lipoplexes were prepared at a charge ratio of 4. The charge ratio is defined as the ratio of the 
number of the positive charges (originating from DOTAP) to the number of the negative charges 
(originating from the pDNA). pDNA was first diluted in HEPES buffer to a concentration of 
0.41 mg/ml. Subsequently, the diluted pDNA was added to an equal volume of cationic liposomes 
(5 mM DOTAP) resulting in a final +/- charge ratio of 4. Immediately after the addition of pDNA to the 
cationic liposomes, HEPES buffer was added until the final concentration of pDNA in the system was 
0.126 mg/ml. This mixture was then vortexed and incubated at room temperature for 30 min. To 
fluorescently label the liposomes cholesteryl Bodipy FLC12 (cholesteryl 4,4-difluoro-5,7-dimethyl-4-
bora-3a,4a-diaza-s-indacene-3-dodecanoate) was used (Molecular probes, Eugene Oregon, USA).  
 
Melanoma cells stably expressing renilla luciferase (rLuc) 
 
BLM_rLuc cells stably expressing renilla luciferase were generated by transfecting BLM-cells 
(melanoma cells)25 with the pGL4.76_CMV plasmid. The pGL4.76_CMV plasmid was generated by 
ligating the PCR amplified (forward primer AATAGTCGACTAGTTATTAATAGTAATCAA and reversed 
primer AATAGGATCCGATCTGACGGTTCACTAAAC) and SalI/BamHI double digested CMV promotor 
into the XhoI/BglII double digested pGL4.76 plasmid (Promega, Leiden, The Netherlands). The 
resulting pGL4.76_CMV plasmid was linearized with the BamHI restriction enzyme and complexed 
with linear polyethylenimine (pEI; 22 kDa) to transfect the BLM cells. Transfected cells were 
incubated in fresh medium for 48 h and then selected with 250 µg/mL hygromycin. After two weeks, 
clones were isolated and expanded. Subsequently, the generated clones were analyzed and a renilla 
luciferase positive clone was selected. 
 
Transfection experiments 
 
BLM-cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with the growth 
factor F12 and phenol red containing 2 mM glutamine, 10% heat deactivated foetal bovine serum 
(FBS), 1% penicillin-streptomycin (Gibco, Merelbeke, Belgium) and HEPES buffer (100 mM, pH 7.4). 
Cells were grown to 90% confluency in OptiCell units (Biocrystal, Westerville, OH , USA) in a 
humidified incubator at 37°C and 5% CO2. Subsequently, cells were washed with 10 mL of phosphate 
buffered saline (PBS, Gibco) and the transfection medium was added.  
A first transfection medium was prepared by mixing 130 µl PEGylated lipoplexes with 1 mL of the 
microbubble suspension (containing 4 x 108 microbubbles).  After 5 min of incubation at room 
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temperature, Optimem(Gibco, Merelbeke, Belgium) was added to a final volume of 10 mL. A second 
transfection medium was prepared in a similar way except that the 130 µl PEGylated lipoplexes were 
replaced by an equal volume of HEPES buffer containing 16.5 µg pDNA, the same amount as present 
in the lipoplexes.  
The 10 mL transfection medium was completely added to the OptiCell units (surface 50 cm2). 
Subsequently, the cells were placed in a water bath at 37°C with an absorbing rubber at the bottom 
and immediately subjected to ultrasound radiation. The ultrasound radiation was performed for 10 s 
with a sonitron 2000 (RichMar, Inola, OK, USA) equipped with a 22 mm probe. A schematic 
representation of the experimental setup used is displayed in Figure 2A. In all ultrasound 
experiments the following ultrasound settings were applied: 1 MHz, 10% duty cycle and an 
ultrasound intensity of 2 W/cm2. The areas treated with ultrasound were marked and after radiation, 
the OptiCells were incubated for an additional 2 h at 37°C. At the end of this incubation period, the 
transfection medium was removed and the cells were washed two times with PBS, before adding 
fresh culture medium. Each transfection was performed in threefold. Twenty four hours after 
transfection the firefly luciferase expression by the cells was analysed. Therefore, the culture 
medium was removed and cells were washed with PBS. The areas exposed to ultrasound (20 mm 
diameter) were cut from the opticell membrane and brought into a 24-well plate. 80 µL of CCLR (Cell 
Culture Lyse Reagent, Promega, Leiden, The Netherlands) buffer was added to each well and 
incubated at room temperature for at least 20 min to allow cell lysis. Twenty µL of the cell lysate was 
transferred to a 96-well plate and the luciferase activity was measured using the GlomaxTM 96 
Microplate Luminometer (Promega) as described elsewhere26.  An aliquot (20 µl) of each cell lysate 
was also analysed for protein concentration using the BCA protein Assay (Pierce, Rockford, IL). 
Transfection results are expressed as relative light units (RLU) per mg protein.  
In the transfection experiment with methyl-β-cyclodextrin (MβCD), the BLM cell line stably 
expressing renilla luciferase (BLM_rLuc) was used. The cells were preincubated for two hours with 
MβCD before the addition of the lipoplexes or lipoplex loaded microbubbles. Ultrasound radiation 
was carried out as described above. Both, firefly and renilla luciferase were measured with the the 
Dual-Luciferase Reporter Assay System® (Promega, Leiden, The Netherlands) in the GlomaxTM 96 
Microplate Luminometer (Promega). Results were expressed as firefly RLU/ renilla RLU. 
 
Photochemical Internalization experiments 
 
The photosensitizer (PS) TPPS2a, meso-tetraphenylporphine with two sulfonate groups on 
adjacent phenyl rings, was kindly provided by Dr. Anders Høgset (PCI Biotech AS, Oslo, Norway). The 
PS was light protected and stored at 4°C until use. Cells were exposed to blue light from the 
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LumiSource®, a bank of four light tubes emitting light in the region of 375–450 nm, with 13 mW/cm2 
irradiance (PCI Biotech AS, Oslo, Norway). Cells were incubated overnight with 0.8 µg/mL PS. The day 
after, the PS was removed and cells were incubated with lipoplexes or transfected with lipoplex 
loaded microbubbles and exposed to ultrasound. After 2 h incubation time, the transfection medium 
was removed and cells were incubated at 37°C for an additional 2 h with culture medium. 
Subsequenly the cells were exposed to the Lumisource for 40s and again placed at 37°C. Cells were 
analysed 24 h later.  
 
Confocal Experiments 
 
 BLM-cells were seeded into culture dishes or Opticell plates one day before the confocal 
experiment. The cell membrane was labelled with concanavalin A-Alexa647 (Molecular Probes). The 
concanavalin A stock solution was diluted 10 fold in Optimem and added to the cells immediately 
before visualization. Cells were incubated with the free PEGylated lipoplexes for respectively 30 min 
and 150 min at 37°C and 5% CO2. Ultrasound exposure of BLM-cells was performed immediately after 
addition of the lipoplex loaded microbubbles and cells were incubated then at 37°C for respectively 
30 and 150 min. After the incubation time, cells were visualized using a Nikon EZC1-si confocal laser 
scanning microscope (Nikon, Brussels, Belgium) equipped with a 40x objective. The 491 nm line of 
this microscope was used to excite the Bodipy label. The 639 nm line was used to excite concanavalin 
A-Alexa647. 
 
Propidium Iodide (PI) uptake 
 
PI was added to the cells in a concentration of 25 µg/mL in Optimem. The PI was added either 
before the exposure of the cells to lipoplex loaded microbubbles and ultrasound or afterwards. The 
uptake of PI resulted in the appearance of red fluorescent nuclei, that were visualized with the 639 
nm laser of the Nikon EZC1-si confocal microscope.  
 
Statistical analysis 
 
All the data in this report are expressed as mean ± standard deviation (SD). For the 
transfection results, the Student’s t-test was used to determine whether data groups differed 
significantly from each other. A p-value lower than 0.05 was considered statistically significant. 
  
Ultrasound exposure of lipoplex loaded microbubbles facilitates direct cytoplasmic entry of the lipoplexes  – Chapter 5 
 
133 
RESULTS & DISCUSSION 
Design and transfection efficiency of lipoplex loaded microbubbles 
 
As schematically presented in Figure 1, we earlier succeeded in coupling highly PEGylated 
lipoplexes onto lipid microbubbles with the aid of an avidin-biotin link22. Biotinylated lipid 
microbubbles consisting of DPPC and DSPE-PEG-biotin were prepared next to DOTAP/DOPE based 
lipoplexes with 15 mol% DSPE-PEG-biotin. Subsequently, avidin was bound to the biotinylated 
microbubbles and mixed with the biotinylated lipoplexes. As published previously22, exposure of 
these lipoplex loaded microbubbles to ultrasound caused a massive release of intact lipoplexes and 
drastically increased the transfection efficiency of the PEGylated lipoplexes. Figure 2B shows the 
transfection of cells by respectively free PEGylated lipoplexes (light grey bars), PEGylated lipoplexes 
physically mixed with microbubbles (dark grey bars) and lipoplex loaded microbubbles after exposure 
to ultrasound (black bars). Only the PEGylated lipoplexes that were coupled to the microbubbles 
were able to transfect the cells after ultrasound radiation (black bars). It has been postulated that 
sonication of free lipoplexes could increase their transfection efficiency, but this was not confirmed 
in our experiments27-29 in agreement with the observations by Mehier-Humbert and colleagues18. 
Considering the giant increase in transfection efficiency after coupling the PEGylated lipoplexes to 
the microbubbles, we wanted to elucidate the differences in cellular uptake between respectively 
“free” PEGylated lipoplexes and PEGylated lipoplexes released from the lipoplex loaded 
microbubbles by ultrasound. 
 
 
Figure 1 Schematic presentation of a lipoplex loaded microbubble. 
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Which mechanism do lipoplexes use to enter cells after exposure of lipoplex loaded microbubbles 
to ultrasound? 
 
Influence of the endocytic inhibitor methyl-β-cyclodextrine (MβCD) 
 
The intracellular uptake of lipoplexes has been intensively studied and has been ascribed to 
endocytosis30. It is believed that the main reasons for the low transfection efficiency of highly 
PEGylated lipoplexes are their limited endocytic uptake (as the PEG chains prevent association of the 
lipoplexes with the cellular membrane) and, especially, their difficulties to escape from the 
endosome31-35. As lipoplex loaded microbubbles are able to transfect BLM cells efficiently after 
ultrasound exposure (Figure 2B), we hypothesize that the PEGylated lipoplexes released from 
microbubbles by ultrasound do not enter the cell through an endocytic pathway. To evaluate this 
hypothesis, we first investigated the effect of  inhibitors on the cellular uptake and transfection 
efficiency of  respectively free lipoplexes and lipoplex loaded microbubbles exposed to ultrasound. 
We tested the effect of different endocytosis-interfering drugs (chlorpromazin, filipin, genistein, 
methyl-β-cyclodextrin, nystatin) on the transfection efficiency of free DOTAP/DOPE lipoplexes 
without or with 5 mol% DSPE-PEG. The 15 mol% PEGylated lipoplexes were excluded in this 
experiment, as the transfection efficiency of these lipoplexes (in the absence of microbubbles and 
ultrasound) is too low to observe any influence of an endocytic inhibitor. We found that MβCD, 
which depletes cholesterol from the cell membrane, caused the strongest inhibition of the gene 
expression of these lipoplexes (data not shown). This suggests a cholesterol-dependent uptake 
pathway in the BLM-cells for the free DOTAP/DOPE lipoplexes. This is in agreement with the work of 
Zuhorn et al.36 who showed that cholesterol depletion of cells can extensively decrease the 
internalization of SAINT-2/DOPE lipoplexes. To assure that the decrease in gene expression caused by 
MβCD is really due to reduced endosomal uptake and not due to toxic effects on the cells, we 
evaluated the cytotoxicity of MβCD . As depicted in Figure 3, MβCD was not toxic for the BLM cells up 
to a concentration of 1500µM, i.e. the highest concentration used in our experiments. 
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Figure 2A Schematic representation of the experimental set-up. Cells were grown on one side of an Opticell 
unit. For ultrasound exposure, Opticell plates were turned upside down. In this way, microbubbles were able to 
rise against the cell layer. Figure 2B The transfection efficiency of lipoplex loaded microbubbles in the presence 
of ultrasound (black bars) compared to the transfection efficiency of naked DNA and free 15 mol% PEGylated 
lipoplexes in the absence (light grey bars) and presence of microbubbles and ultrasound (dark grey bars). The 
background luciferase signal in untreated cells is also shown (white bars). The transfection results, i.e., the 
extent of luciferase expression, are expressed as RLU (RLU: relative light units) per mg protein.*p < 0.05  
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Figure 3 Cell viability of the BLM cells after incubation with different MβCD concentrations. Results are 
expressed as a percentage of the viability of untreated cells (blank). Phenol (10mg/mL) was used as a positive 
control. 
 
 
 
Figure 4 Effect of increasing MβCD concentrations on the transfection efficiency of non-PEGylated (black bars), 
5 mol% PEGylated lipoplexes (light grey bars) and lipoplex loaded microbubbles (dark grey bars) exposed to 
ultrasound. Results are expressed as a percentage of the transfection efficiency obtained in cells in the absence 
of MβCD. * p < 0.05 
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Subsequently we studied the effect of MβCD on the transfection efficiency of (a) non-
pegylated lipoplexes, (b) 5 mol% PEGylated lipoplexes and (c) microbubbles loaded with PEGylated 
lipoplexes exposed to ultrasound. As demonstrated in Figure 4, even the lowest MβCD 
concentrations had an influence on the transfection efficiency of the non-PEGylated (black bars) and 
PEGylated lipoplexes (light grey bars). Increasing the concentration of MβCD clearly diminished their 
transfection efficiency further. Via confocal microscopy we confirmed that MβCD reduced the gene 
expression of the lipoplexes by lowering the cellular uptake of the lipoplexes. Figure 5A-B shows the 
uptake of the non-PEGylated lipoplexes by BLM-cells in the absence of MβCD. A major part of the 
lipoplexes can be detected in the intracellular space. Incubation of the cells with 500 µM MβCD 
(Figure 5C-D), and especially 1000µM MβCD (Figure 5E-F), almost completely blocked the cellular 
uptake of non-PEGylated lipoplexes. Similar images  were obtained  with the PEGylated lipoplexes. 
 
 
 
Figure 5 Effect of increasing MβCD concentrations on the uptake of non-PEGylated lipoplexes. Panels A, C and E 
are confocal fluorescence microscopy images and B, D and F are overlays of the confocal images with the 
corresponding transmission images. Fig. 5A and B. Uptake of non-PEGylated lipoplexes in the absence MβCD. 
Fig. 5C and D. Uptake of non-PEGylated lipoplexes in the presence of 500 µM MβCD. Fig. 5E and F. Uptake of 
non-PEGylated lipoplexes in the presence of 1000µM MβCD. Cells were pre-incubated with the inhibitor 2 
hours before addition of the non-PEGylated lipoplexes. 
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Figure 6 Effect of increasing MβCD concentrations on the uptake of PEGylated lipoplexes (originating from 
lipoplex loaded microbubbles exposed to ultrasound). Panels A, C and E are confocal fluorescence microscopy 
images and B, D and F are overlays of the confocal images with the corresponding transmission images. Fig. 6A 
and B: Uptake of PEGylated lipoplexes in the absence MβCD. Fig. 6 A and D. Uptake of PEGylated lipoplexes in 
the presence of 500 µM MβCD. Fig. 6 and F. Uptake of PEGylated lipoplexes in the presence of 1000µM MβCD. 
Cells were pre-incubated with the inhibitor two hours before treatment with lipoplex loaded microbubbles and 
ultrasound. 
 
In contrast to the free lipoplexes, the transfection efficiency of the PEGylated lipoplexes 
loaded on the microbubbles and exposed to ultrasound was by far less sensitive to MβCD treatment, 
as depicted in Figure 4 (dark grey bars). The lowest concentrations (100 to 500 µM) did not affect the 
transfection values at all. However, the transfection efficiency slightly dropped starting from 800 µM 
MβCD onwards. We previously found that the ultrasound conditions used in these experiments had 
only minor effect on the cell viability (results not shown). However, it might be possible that an 
extensive depletion of cholesterol may make cells more vulnerable to ultrasound. This may explain 
the drop in gene expression at higher MβCD concentrations (Figure 4, dark grey bars). Alternatively, 
depletion of cholesterol may change the fluidity of the plasma membrane37. As a result this may 
hamper the capability of ultrasound to cause cell perforations. Indeed, Brayman et al. suggested that 
the cell fluidity may influence the extent of membrane poration37. Finally, we also evaluated the 
effect of MβCD on the cellular uptake of lipoplex loaded microbubbles after exposure to ultrasound 
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(Figure 6): image A-B, C-D and E-F present the uptake of the lipoplexes in the presence of 0, 500 and 
1000 µM MβCD, respectively. In contrast to the free lipoplexes, MβCD was not able to prevent the 
cellular uptake of lipoplexes that were released from the lipoplex loaded microbubbles after 
exposure to ultrasound. These results clearly prove that the PEGylated lipoplexes released from the  
microbubbles, do not enter the cell by endocytosis after ultrasound radiation, this in contrast to the 
free lipoplexes. 
 
Influence of photochemical internalization (PCI) on the transfection efficiency of free 
PEGylated lipoplexes and lipoplex loaded microbubbles exposed to ultrasound 
 
We evaluated the effect of PCI on the transfection efficiency of free 15 mol% PEGylated 
lipoplexes (which are poorly transfecting) and lipoplex loaded microbubbles in the presence of 
ultrasound. PCI was first presented in 1999 as a novel technology for the delivery of a variety of 
therapeutic molecules into the cytosol38. PCI technology employs amphiphilic, photosensitizing 
compounds which accumulate in the membranes of the vesicles. Upon illumination, such 
photosensitizers (PS) become excited, and subsequently induce the formation of reactive oxygen 
species, primarily singlet oxygens. These highly reactive intermediates can damage cellular 
components, but the short life-time and thus the short range of action, confines the damaging effect 
to the production site. This localized effect induces the disruption of the  vesicles, thereby releasing 
the entrapped therapeutic molecules into the cytosol39. 
Figure 7 demonstrates that the transfection efficiency of free 15 mol% PEGylated lipoplexes 
became three times higher when PCI was used. In contrast, the transfection efficiency of the lipoplex 
loaded microbubbles was not enhanced by PCI. Figure 7 proofs that the endosomal release is indeed 
a barrier, though not the only one, in the gene transfection process with highly PEGylated lipoplexes. 
The fact that the gene transfer by the same lipoplexes but loaded onto microbubbles and treated 
with ultrasound was not altered upon PCI implies that the lipoplexes released from the microbubbles 
are not present in the endosomes. These observations suggests that they transfect cells through a 
non-endocytic uptake mechanism that delivers the lipoplexes directly in the cytoplasm of the cells. 
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Figure 7 Effect of photochemical internalization (PCI) on the transfection efficiency of respectively 15 mol% 
PEGylated lipoplexes and lipoplex loaded microbubbles in the presence of ultrasound. 
 
 
What happens at the cellular membrane during exposure of lipoplex loaded microbubbles to 
ultrasound?  
 
First we studied the uptake of green labelled 15 mol% PEGylated lipoplexes into BLM-cells (at 
37 °C) by confocal microscopy (Figure 8). Image 8A presents the cellular uptake of free lipoplexes 30 
minutes after addition to the cells, while 8B and C present the cellular uptake of the same lipoplexes 
150 minutes after addition to  the cells.  Free lipoplexes started to stick on the cell membranes 
shortly after their addition to the cells (Figure 8A). As indicated in image 8A, lipoplexes were not 
internalized 30 minutes after addition to the cells. Only after 150 minutes the lipoplexes were 
internalized by the BLM-cells: a punctuate pattern was observed which indeed suggests an endocytic 
uptake for the free PEGylated lipoplexes (Figure 8B and C). In contrast, we saw a completely different 
pattern 30 minutes after sonication of the cells in the presence of the lipoplex loaded microbubbles 
(Figure 8D). Lipoplexes were present near the cellular membrane and inside the cell. Similar images 
were obtained 150 minutes after treatment of the cells with lipoplex loaded microbubbles and 
ultrasound (Figure 8E and F); these images indicate that the uptake of the lipoplexes released from 
the microbubbles occurs during or immediately after ultrasound treatment. 
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Figure 8A Uptake of free 15 mol% PEGylated lipoplexes in BLM cells a 30 minutes incubation after addition to 
the cells. Figure 8B and C Uptake of free 15 mol% PEGylated lipoplexes in BLM cells after 150 minutes 
incubation time. Figure 8D Uptake of lipoplexes in BLM cells 30 minutes after treatment with lipoplex loaded 
microbubbles and ultrasound. Figure 8E and F Uptake of lipoplexes in BLM cells 30 minutes after treatment 
with lipoplex loaded microbubbles and ultrasound. Lipoplexes were labelled with Bodipy FlC12 cholesteryl. 
Figure 8A, B, C and D are confocal fluorescence microscopy images and figures 8C and F are the overlays of the 
confocal images B and E with the corresponding transmission image. 
 
To get further insight into the effect on the cell membrane we stained the cell membrane and 
took z-stacks of the BLM cells after incubating them with respectively free PEGylated lipoplexes 
(Figure 9A and C) and lipoplex loaded microbubbles exposed  to ultrasound (Figure 9B and D). The 
first important difference between image 9A and 9B is the irregular shape of the BLM cells after 
sonication. This was also observed by several other groups18,37,40-42. Although the shape of the cells 
was different after exposure to ultrasound and microbubbles, our propidium iodide uptake 
experiments proved that the cells were still viable (see Figure 10). In image 9A, a smooth, 
undisturbed cell membrane is visible (red) with PEGylated lipoplexes (green) lying on top of it, while 
a small part of the lipoplexes seems present in endocytic vesicles. Figure 9C displays the intensity  
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Figure 9A displays a confocal fluorescence microscopy image and z-scans (at the position indicated by the 
white dotted line) of a BLM cell that was incubated during 30 minutes with free PEGylated lipoplexes. Figure 9B 
displays a confocal fluorescence microscopy image and z-stacks, at the position indicated by the white dotted 
line, of BLM cells 30 minutes after treatment with lipoplex loaded microbubbles and ultrasound. The cell 
membrane was labelled red with concanavaline A-Alexa637 and PEGylated lipoplexes are visible in green. 
Figure 9C and D present the according intensity profiles of respectively image A and B following the X-axis 
(white dotted line) through the cell.  
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profile of the green and red fluorescence following an X-axis (being the dotted line in Figure 9A) 
through the cell. This intensity profile in Figure 9C confirms that the lipoplexes are attached to the 
cell membrane as the green fluorescence of the lipoplexes colocalizes with the red fluorescence of 
the cell membrane. In image 9B the PEGylated lipoplexes appear as bright green structures pinching 
through the cell membrane. Furthermore the cell membrane seems disturbed and lipids seems to be 
relocated, resulting in lipid enhanced areas and areas lacking cell membrane lipids. Lipoplexes and 
membrane lipids seemed partially colocalized, visible as the yellow parts. Earlier, Schlicher et al. also 
reported on the displacement of large lipid areas from the cell membrane upon ultrasound 
treatment41. Also the intensity profile (Figure  9D) of this cell looks completely different: green 
lipoplexes are visible within the cell. The green spots in 8E and 9B most likely originates from intact 
lipoplexes as we recently showed that intact lipoplexes are released from the microbubbles after 
sonication of the lipoplex loaded microbubbles22. To be effective these lipoplexes must dissociate 
intracellulary, so that the DNA can enter the cell nucleus for transcription. Zuhorn and colleagues 
demonstrated that after endosome rupture by osmotic shock, lipoplexes still showed the same 
transfection efficiency, indicating that intact lipoplexes can dissociate in the cytosol43. This is most 
likely  also  the case for the lipoplexes present in the BLM cells after their release from the lipoplex 
loaded microbubbles, as they have a very high transfection efficiency.  
 
 
Why is the coupling of the lipoplexes to the microbubbles so important? 
 
Figure 2B shows that the transfection efficiency of free PEGylated lipoplexes does not improve 
upon (physically) mixing them with microbubbles and applying ultrasound (dark grey bars). 
Therefore, we wondered whether the cells were perforated under our ultrasound conditions. To 
demonstrate the presence of pores in the cell membrane we determined whether  propidium iodide 
(PI) was able to enter the cells during ultrasound  exposure. Figure 10A presents the uptake of PI 
during incubation of the BLM cells with lipoplexes: as expected none of the BLM cells was able to 
take up PI. Figure 10B is an image of BLM cells to which PI, PEGylated lipoplexes and microbubbles 
were added and which were exposed to ultrasound. Almost all the cells had a bright red fluorescent 
nucleus, due to PI, which indicates that upon sonication pores are indeed created in the cell 
membranes which allow the passage of small molecules like PI.To exclude the possibility that all the 
red coloured cells were dead cells, we added PI 15 minutes after the exposure of the cells to 
ultrasound as only dead cells would then be able to take up PI; living cells are expected to quickly 
reseal their (transient) pores after applying ultrasound. As demonstrated in image 10C, only a small 
Chapter 5 – Ultrasound exposure of lipoplex loaded microbubbles facilitates direct cytoplasmic entry of the lipoplexes 
 
 
144 
fraction of the cells took up PI, which proves that the uptake of PI in Figure 10B can be ascribed to 
short-living pores in the cell membrane caused by ultrasound in the presence of microbubbles.  
 
 
 
 
Figure 10 Cellular uptake of propidium iodide (PI) in BLM cells. Figure 10A PI uptake during incubation of the 
cells with free PEGylated lipoplexes. Figure 10B PI uptake in cells simultaneously exposed to PI, free PEGylated 
lipoplexes, microbubbles and ultrasound. Figure 10C Confocal image of cells that were first treated with free 
PEGylated lipoplexes, microbubbles and ultrasound and subsequently, after 15 minutes, exposed to PI. 
 
Our data show that the attachment of the PEGylated lipoplexes to microbubbles is required to 
obtain a good gene transfer in the presence of ultrasound. We would like to present two hypothesis 
that may explain why the lipoplexes should be attached to the microbubbles. First, as the 
microbubbles rise against the cell surface, it is possible that the massive release of lipoplexes upon 
ultrasound radiation results in a higher lipoplex concentration near the cell perforations, which might 
increase the amount of lipoplexes that is able to passively diffuse through these pores. We estimated 
the concentration of lipoplexes released near the cells after exposure of the lipoplex loaded 
microbubbles to ultrasound. Therefore, we first determined how much of the lipoplexes are bound 
to the microbubbles after mixing the biotinylated lipoplexes and avidinylated microbubbles. Half of 
the lipoplexes is able to bind to the microbubbles. As presented in Figure 1B, the Opticells were 
incubated with the cell monolayer on top, so that microbubbles could rise against the cell surface. 
Let us assume that, after exposure of the lipoplex loaded microbubbles to ultrasound, all the 
lipoplexes are released in a 20 µm thick plane just beneath the cells present on the Opticell unit. The 
volume then equals 100µL (an Opticell unit has a surface of 50cm2). Taking into account that half of 
the lipoplexes are attached to the microbubbles, we can calculate that the local concentration of 
lipoplexes near the cell membrane (i.e. the concentration near the cell perforations) is 50 times 
higher than the lipoplex concentration near the cells when uncoupled lipoplexes are mixed with 
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microbubbles and exposed to ultrasound. Thus, the first hypothesis makes sense if the lipoplexes are 
small enough to pass through the cell perforations. This might be the case as pores of up to 1 µm 
have been reported41,44.  
The second hypothesis is that the microjets that occur when the microbubbles collapse drag 
along the released lipoplexes and inject them in and through the cell membrane. Ohl et al. and 
Dijkink et al. previously described the appearance of a jetting flow after the collapse of microbubbles 
in an ultrasonic field10,45. These flow is directed towards the cell layer and causes shear stress on the 
cells which results in pore formation. During the implosion of the microbubbles, the lipoplexes are 
released and can be taken by this jetting flow towards the cell surface. In this way it might be 
possible that lipoplexes become ejected into the cell layer when the streaming forces are high 
enough. Our data obtained via confocal microscopy support this hypothesis (Figure 9). Additionally, 
Marmottant and Hilgenfeldt46 visualized the behaviour of a lipid vesicle in the presence of a stable 
cavitating microbubble. This vesicle was expelled away from the cavitating microbubbles. It is 
possible that lipoplexes are taken by these fluid streams around the microbubble and in this way 
propelled, so that they are deposited in the adjacent cell layer. Especially as most of our 
microbubbles are cavitating transiently and are able to implode, which will cause even stronger 
streaming forces. The actual lipoplex uptake will most presumably be a combination of the two 
described hypothesis, as an increased local lipoplex concentration will make it more plausible that a 
lipoplex is taken by these fluid streams and  increases the chance that it is deposited near or in the 
cell membrane (pores). 
 As earlier mentioned, the aim of this work was to elucidate how the transfection efficiency of 
PEGylated lipoplexes can be increased by loading them onto lipid microbubbles and expose them to 
ultrasound. Our results clearly show that endocytosis of the lipoplexes is circumvented and that 
lipoplexes are able to reach the cytoplasm of the radiated cells. However, direct microscopic 
observations of the lipoplex loaded microbubbles during ultrasound exposure are required to 
elucidate the exact uptake mechanisms. 
 
CONCLUSION 
 
In this study we elucidate the cellular mechanism responsible for the high gene transfection 
efficiency of lipoplex loaded microbubbles in the presence of ultrasound. Inhibition of the 
endocytotic activity of the cells demonstrated that the cellular uptake of the lipoplexes released from 
the lipoplex loaded microbubbles by ultrasound must be governed by a non-endocytotic pathway. 
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Indeed, blockage of the endocytotic activity or stimulation of the endosomal release via PCI did not 
affect the gene expression of the lipoplex loaded microbubbles after exposure to ultrasound. 
Confocal images demonstrated that shortly after exposure of the BLM cells to lipoplex loaded 
microbubbles and ultrasound, lipoplexes are present in the cell membrane and in the intracellular 
space. In contrast, classic “free” PEGylated lipoplexes mainly adhere on top of the cell membranes. 
We also observed that the cell membranes became disturbed after applying ultrasound and lipoplex 
loaded microbubbles. The addition of propidium iodide during the sonication step proved that there 
were short-living pores formed. As ultrasound could not improve the gene transfer of PEGylated 
lipoplexes that were physically mixed (and thus not chemically bound) to microbubbles, it seems that 
coupling of lipoplexes and microbubbles is necessary to obtain a high transfection value. Loading of 
the lipoplexes onto the microbubbles leads to an increase in local lipoplex concentration near the cell 
membrane. Because we have shown that cell membrane porations are formed during our ultrasound 
exposure, it is possible that more lipoplexes are able to passively diffuse through these pores. 
Moreover, lipoplexes might be propelled by the fluid streams that develop around a cavitating and 
imploding microbubble and propelled inside the adjacent cell layer. However, real time fluorescence 
imaging of the lipoplexes during the ultrasound step will be required to completely understand their 
cellular entrance. In summary, we have proven that the endocytotic uptake of PEGylated particles 
can be avoided by loading these particles onto microbubbles and applying ultrasound. In this manner 
the lipoplexes become directly delivered into the cytoplasm of the cell. So far the lack of gene 
transfer hampered the clinical use of PEGylated lipoplexes. We believe that lipoplex loaded 
microbubble may overcome this. Clearly, besides lipoplexes one can also attach other drugs or drug 
containing nanoparticles to the microbubbles which makes this material of special interest for time 
and space controlled delivery of drugs. 
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ABSTRACT 
 
Short interfering RNA (siRNA) attracts much attention for the treatment of various diseases. 
However, its delivery, especially via systemic routes, remains a challenge. Indeed, naked siRNAs are 
rapidly degraded, while complexed siRNAs massively aggregate in the blood or are captured by 
macrophages. Although this can be circumvented by PEGylation, we found that PEGylation had a 
strong negative effect on the gene silencing efficiency of siRNA-liposome complexes (siPlexes). 
Recently, ultrasound combined with microbubbles has been used to deliver naked siRNA but the 
gene silencing efficiency is rather low and very high amounts of siRNA are required. To overcome the 
negative effects of PEGylation and to enhance the efficiency of ultrasound assisted siRNA delivery, 
we coupled PEGylated siPlexes (PEG-siPlexes) to microbubbles. Ultrasound radiation of these 
microbubbles resulted in massive release of unaltered PEG-siPlexes. Interestingly, PEG-siPlexes 
loaded on microbubbles were able to enter cells after exposure to ultrasound, in contrast to free 
PEG-siPlexes, which were not able to enter cells rapidly. Furthermore, these PEG-siPlex loaded 
microbubbles induced, in the presence of ultrasound, much higher gene silencing than free PEG-
siPlexes. Additionally, the PEG-siPlex loaded microbubbles only silenced the expression of genes in 
the presence of ultrasound, which allows space and time controlled gene silencing.  
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Ultrasound assisted siRNA delivery using 
PEG-siPlex loaded microbubbles 
 
INTRODUCTION 
 
RNA interference (RNAi), a naturally occurring process of sequence-specific post-
transcriptional gene silencing, is an important biological process for modulating gene expression. The 
silencing effect of RNAi is highly potent and requires only that the sequence of the target RNA is 
known. One approach to evoke RNAi in target cells is by the delivery of chemically synthesized 
siRNAs, which results in a sequence-specific, robust silencing of the targeted gene1. The potential of 
siRNA molecules as therapeutic agent in the treatment of e.g. cancer, viral infections, arthritis, 
Huntington’s disease and hypercholesterolemia has been widely studied2. However, cells do not 
readily take up siRNAs. Therefore, clinical applications of siRNA largely depend on the development 
of delivery systems that can bring intact siRNA into the cytoplasm of the target cells of a patient.  
Strategies that have been considered for in vivo delivery of synthetic siRNA in laboratory 
animals are hydrodynamic injection of naked siRNA3 or siRNA conjugates4, electroporation5-8 and the 
use of cationic carriers9-15. However, several aspects limit the applicability of these methods in 
humans. Indeed, hydrodynamic injection, which involves the intravascular injection of large volumes, 
generates high pressure in the vascular system and therefore often results in heart failure. 
Additionally, undesirable gene suppression may be induced in non-target organs. Electroporation 
allows targeting, but requires the insertion of electrodes into the target area, and hence invasive 
procedures that limit its range of application. Cationic siRNA delivery carriers, such as cationic lipids 
and polymers, are often cytotoxic and/or not very efficient. Furthermore, they are often not suited 
for systemic application since their positively charged surface makes them vulnerable to non-specific 
interactions with blood compounds, leading to life-threatening aggregates and a rapid clearance by 
the mononuclear phagocyte system10,16. A common approach for reducing these undesired 
interactions is by masking the cationic surface of the nanoparticles with hydrophilic polymers, such 
as poly(ethylene glycol) (PEG). This prevents the aggregation of these nucleic acid containing 
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nanoparticles in blood and prolongs their circulation time17-20. However, it has been observed by 
many groups that shielding the surface of non-viral gene delivery systems with polymers like PEG 
leads to a drastic reduction in gene transfer, due to a reduced cellular uptake or limited endosomal 
release21,22. 
The use of ultrasound energy has intensively been studied for pDNA delivery23-30. Recently, 
ultrasound in combination with microbubbles has also been used in two reports to deliver naked 
siRNA31,32. However, the gene silencing efficiency in these studies was rather low and very high 
amounts of siRNA were required. Nevertheless, ultrasound assisted drug delivery is considered as 
rather safe as ultrasound, in combination with microbubbles, is routinely used in the clinic for 
diagnostic purposes. It is believed that ultrasound, especially when combined with microbubbles, 
causes small (100 to a few 100 nm large) transient pores in the cell membrane which allows large 
molecules to enter the cell cytoplasm33. These perforations are caused by microjets that are 
generated by the ultrasound induced cavitation, i.e. alternate growing and shrinking of 
microbubbles, and implosion of microbubbles. The lifetime of these pores in the cell membranes is 
very short, i.e. milliseconds to seconds34, making high concentrations of nucleic acids in the 
surrounding of the cells beneficial to ensure that a significant amount of nucleic acids can enter the 
cells through these short-living pores. Consequently, as recently shown by our group for pDNA, 
microbubbles that at the same time perforate cells and release massive amounts of nucleic acids 
containing nanoparticles near these perforations may drastically enhance the cellular uptake and 
hence the biological activity of nucleic acids26. 
Therefore, the aim of this study was to evaluate (a) the loading and release of PEGylated 
siRNA-liposome complexes (PEG-siPlexes) on/off ultrasound responsive microbubble, and (b) the 
cellular distribution and gene silencing efficiency of the PEG-siPlex loaded microbubbles after 
ultrasound radiation. 
 
MATERIALS & METHODS 
 
Cell culture 
 
HuH-7 and HuH-7_eGFPLuc cells were cultured in Dulbecco's modified Eagle's medium 
supplemented with F12 (DMEM:F12) containing 2 mM L-glutamine (L-Gln), 10 % heat-inactivated 
fetal bovine serum (FBS) and 100 U/ml penicilline/streptomycine (P/S) at 37°C in a humidified 
atmosphere containing 5 % CO2. All cell culture products were purchased from Invitrogen 
(Merelbeke, Belgium). 
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HuH-7_eGFPLuc cells stably expressing eGFP-Luciferase were generated by transfecting 
HuH-7 cells with the vector pEGFPLuc (Clontech, Palo Alto, USA). The vector was linearized using the 
restriction enzyme DraIII and transfected using linear poly(ethyleneimine) (PEI) 22 kDa. Transfected 
cells were incubated in fresh medium for 72 hrs and then selected with 60 to 400 µg/ml G418. After 
several days, surviving cells were seeded at low densities into 6-well plates in order to generate 
separate colonies. Single cell clones were then isolated and expanded. The generated clones were 
analyzed for the percentage of GFP-positive (eGFPLuc stably transfected) cells. Clones with the 
highest number of GFP-positive cells were then further selectively grown up under the above 
described selective conditions and this procedure was repeated until all cells were positive for GFP. 
 
SiRNA 
 
Atto488-labeled and non labeled siRNA duplexes against firefly luciferase and control siRNA 
duplexes were purchased from Eurogentec (Seraing, Belgium) and dissolved in RNase free water at a 
final concentration of 20 µM. 
 
Preparation and characterization of lipid microbubbles 
 
1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[biotinyl(polyethylene glycol)2000] (ammonium salt) (DSPE-PEG2000-biotin) 
were purchased from Avanti Polar Lipids (Alabaster, AL). 
Lipid microbubbles were prepared from liposomes composed of DPPC and DSPE-PEG2000-biotin 
with molar ratios of 95:5. Therefore, as described previously 35, appropriate amounts of lipids were 
dissolved in chloroform and mixed. The chloroform was subsequently removed by rotary evaporation 
at 37°C followed by flushing the obtained lipid film with nitrogen during 30 min at room 
temperature. The dried lipids were then hydrated by adding Hepes buffer (20 mM, pH 7.4) till a final 
lipid concentration of 5 mg/ml. After mixing in the presence of glass beads, liposome formation was 
allowed overnight at 4°C. Thereafter, the DPPC:DSPE-PEG2000-biotin liposomes were extruded 
through two stacked 0.200 µm polycarbonate membrane filters (Whatman; Brentfort, UK) at 55°C 
using an Avanti Mini-Extruder (Avanti Polar Lipids). Subsequently, the liposome suspension was 
sonicated with a 20 kHz probe (Branson 250 sonifier, Branson Ultrasonics Corp.; Danbury, CT) in the 
presence of perfluorobutane gas (MW 238 g/mol; F2 chemicals; Preston, Lancashire, UK). After 
sonication, the lipid microbubbles were washed with 3 ml Hepes buffer by 5 min centrifugation at 
470 g. The amount of microbubbels per ml was determined by light microscopy and equalled 4 x 108 
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microbubbles/ml. The size distribution of the microbubbles was determined by laser diffraction 
(Mastersizer S, Malvern; Worcestershire, UK). 
 
Preparation of avidin coated lipid microbubbles 
 
Avidinylated microbubbles were prepared by incubating them at room temperature with 
500 µl avidin (10 mg/ml). After 10 min of incubation, the microbubbbles were washed with 3 ml 
Hepes buffer by 5 min centrifugation at 470 g and finally resuspended in 10 ml. For the preparation 
of red labelled lipid microbubbles, the microbubbles were incubated with the unlabelled avidin 
supplemented with 50 µl Cy5-labelled streptavidin (1 mg/ml) (Zymed Laboratories; San Francisco, 
CA). 
 
Preparation and characterization of liposomes and PEG-siPlexes 
 
The cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt) (DOTAP) and the 
helper lipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) were purchased from Avanti 
Polar Lipids. Cationic liposomes containing DOTAP and DOPE in a 1:1 molar ratio, supplemented with 
0 to 15 mol% DSPE-PEG2000-biotin, were prepared at a final DOTAP concentration of 5 mM. All 
liposomes were prepared as described above for the DPPC:DSPE-PEG2000-biotin liposomes, however 
extrusion occurred through two stacked 0.100 µm polycarbonate membrane filters at room 
temperature. To obtain (PEG-)siPlexes, equal volumes of siRNA solution and extruded liposomes 
were mixed in a N:P ratio of 20:1. Subsequently, the obtained mixture was vortexed for 5 sec and 
incubated at room temperature for 30 min. 
The average particle size and the zeta potential ( ) of the (PEGylated) liposomes and siPlexes 
were measured by photon correlation spectroscopy (PCS) (Malvern zetasizer nano ZS; Malvern) and 
by particle electrophoresis (Malvern zetasizer nano ZS; Malvern), respectively. Therefore, the 
liposome and PEG-siPlex dispersions were diluted 40-fold in 20 mM Hepes buffer. The size of the 
liposomes was independent of the degree of PEGylation and averaged 120 nm. In contrast, the zeta 
potential clearly dropped with increasing degree of PEGylation, varying from ~50 mV for the 0 mol% 
and ~20 mV for the 5 mol% DSPE-PEG2000-biotin containing DOTAP:DOPE liposomes The size and zeta 
potential of the siPlexes are displayed in Fig. 5. 
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Preparation and characterization of siPlexes loaded microbubbles 
 
130 µl siPlex dispersion was mixed with 1 ml microbubbles, vortexed shortly and incubated at 
room temperature for 5 min. Subsequently, the size distribution of the siPlex loaded microbubbles 
was determined as described for the non-loaded microbubbles. The time-dependent stability of the 
(PEG-)siPLex loaded microbubbles was followed for 36 hrs at room temperature via light microscopy 
using a motorized Nikon TE2000-E inverted microscope (Nikon Benelux, Brussels, Belgium). The small 
microbubbles (< 2 µm) were stable for at least 24 hrs and the larger ones for at least 36 hrs. 
 
Gel electrophoresis 
 
(PEG-)siPlexes, before binding to the microbubbles and after ultrasound induced release from 
the microbubbles, were loaded on a native 20 % polyacrylamide gel (PAGE). All samples were 
supplemented with 10 % glycerol and subjected to electrophoresis at 100 V for 2 hrs. Finally, the 
siRNA was stained with 1:10000 diluted SYBR-green II dye (Molecular Probes; Merelbeke, Belgium) 
and visualized by UV transillumination. 
 
Confocal laser scanning microscopy 
 
The Cy5-streptavidin coated microbubbles and Atto488-siRNA containing siPlexes were 
visualized using a Nikon C1si confocal laser scanning module attached to a motorized Nikon TE2000-E 
inverted microscope (Nikon Benelux; Brussels, Belgium). Images were captured with a 60 x objective 
lens using the 488 nm line from an Ar-ion laser for the excitation of Atto488-siRNA and the 639 nm 
laser line from a diode laser for the excitation of Cy5-streptavidin. 
 
Cellular distribution of PEG-siPlexes in HuH-7 cells 
 
Atto488-siRNA containing PEG-siPlexes (with 5 mol% DSPE-PEG2000-biotin) were prepared as 
described above. HuH-7 cells were grown in OptiCells and incubated for 20 min with the free PEG-
siPlexes or with the PEG-siPlexes loaded microbubbles, immediately followed by ultrasound 
treatment. The ultrasound settings were the same as in the transfection experiments (see below). 
After one wash step with phosphate buffered saline (PBS; Invitrogen), cells were treated for 10 min 
with Draq5 (Biostatus Limited; Leicestershire, UK), to stain the nucleus, and TRITC-concanavalin A 
(Molecular Probes), to stain the cellular membrane. Subsequently, the cellular distribution of the 
Atto488-siRNA was visualized using a Nikon EZC1-si confocal laser scanning microscope equipped 
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with a 60 x objective. The 488 nm line of the Ar-ion laser was used to excite the Atto488 label and 
the 639 nm line from a diode laser to excite Draq5 and TRITC-concanavalin A.  
 
Transfection experiments 
 
HuH-7_eGFPLuc cells were seeded in OptiCell units (Biocrystal; Westerville, OH) at 4 x 104 
cells/cm2, and allowed to attach overnight in a humidified incubator at 37°C and 5 % CO2. The culture 
medium was removed from the cells and after a washing step with PBS, the free siPlexes or siPlex 
loaded microbubbles, both dissolved in OptiMEM (Invitrogen) and containing 50 nM siRNA, were 
added to the OptiCell units. Subsequently, the OptiCell units were placed in a water bath at 37°C with 
an absorbing rubber at the bottom as shown in Fig. 1B and immediately subjected to ultrasound 
radiation for 10 sec with a sonitron 2000 (RichMar; Inola, OK) equipped with a 22 mm probe. It has 
been reported that standing waves can influence the ultrasound assisted transfection efficiency 
dramatically36. In our ultrasound set up (Fig. 1B) standing waves are eliminated as much as possible 
by (1) using the ultrasound transparent OptiCell units, (2) placing an absorbing rubber at the bottom 
of the water bath and (3) degassing the water. In all experiments the same ultrasound settings were 
applied: 1 MHz, 10 % duty cycle (DC) and an ultrasound intensity of 2 W/cm2 during 10 sec. After 
2 hrs incubation of the cells (at 37°C) with the free siPlexes or siPlex loaded microbubbles, the 
transfection medium was removed, cells were washed twice with PBS and culture medium was 
added. After 48 hrs incubation, discs (22 mm in diameter) were cut from the OptiCell membrane, 
transferred to a 24-well plate and lysed with 80 µl 1x CCLR buffer (Promega; Leiden, The 
Netherlands) to measure both the luciferase activity and the total protein concentration. 
Luciferase activity was determined with the Promega luciferase assay kit according to the 
manufacturer’s instructions in relative light units (RLU). Briefly, 100 µl substrate was added to 20 µl 
cell lysate and after a 2 sec delay, the luminescence was measured during 10 sec with a GloMaxTM 96 
luminometer. To correct for the amount of cells per well, the protein concentration was determined 
with the BCA kit (Pierce; Rockford, IL). Therefore, 200 µl mastermix, containing 50 parts reagent A to 
1 part B, was mixed with 20 µl cell lysate or BSA (to make the standard curve). After 30 min 
incubation at 37°C, the absorbance at 590 nm was measured with a Wallac Victor2 absorbance plate 
reader (Perkin Elmer; Waltham, MA). 
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RESULTS & DISCUSSION 
 
Preparation and characterization of PEG-siPlex loaded microbubbles 
 
As schematically depicted in Fig. 1A, the first goal of this work was to attach PEGylated siRNA-
liposome complexes (PEG-siPlexes) to gas-filled microbubbles via a biotin-avidin-biotin bridge. 
Therefore, we first prepared perfluorobutane filled lipid microbubbles by sonication of a DPPC:DSPE-
PEG2000-biotin liposome dispersion in the presence of perfluorobutane gas. The lipid coating prevents 
a rapid diffusion of the perfluorobutane gas out of the microbubbles. To assure that biotin molecules 
were present at the outer surface of the microbubbles, we incubated them with Cy5 labelled 
streptavidin. As shown by the confocal images in Fig. 2A and 2B, after removal of the unbound 
streptavidin, a thin fluorescent layer of streptavidin molecules surrounding the gas-filled 
microbubbles could be observed, which indicates the formation of biotin-avidin linkages. This 
suggests that the DSPE- PEG2000-biotin molecules in the lipid shell are oriented with their hydrophobic 
tails to the perfluorobutane gas core while their hydrophilic head groups are exposed to the 
surrounding aqueous medium, as previously suggested by Unger 37. 
 
 
Figure 1A Schematic overview of a PEG-siPlex loaded microbubble. The white disk surrounded by lipids (95 
mol% DPPC and 5 mol% DSPE-PEG2000-biotin) represents an avidinylated lipid microbubble with its 
perfluorobutane (C4F10) gas core. PEG-siPlexes with increasing amounts of DSPE-PEG2000-biotin were attached 
to these avidinylated microbubbles via a biotin-avidin-biotin bridge. Figure 1B Experimental setup used in the 
transfection experiments. An OptiCell unit containing a monolayer of HuH-7 cells on one of their membranes 
was placed in a water tank with a rubber plate, designed to minimize ultrasound reflection or scattering, at the 
bottom. In all experiments the same ultrasound settings were applied: 10 sec, 1 MHz, 10 % duty cycle and an 
ultrasound intensity of 2 W/cm
2
. The ultrasound was delivered vertically to the cells which were present on the 
upper membrane of the OptiCell unit, closest to the ultrasound probe. Different regions of the OptiCell unit 
were sonicated separately by moving the ultrasound device. 
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Figure 2 Transmission image (A) and confocal laser scanning microscopy image (B) of avidinylated microbubbles 
coated with Cy5-streptavidin (red). The inserts display a close-up of three microbubbles. 
 
In a next step, we prepared DOTAP:DOPE based siPlexes containing increasing amounts of 
DSPE-PEG2000-biotin (0, 2, 5 and 15 mol%). In all cases, a N:P ratio of 20:1 was chosen as non-
PEGylated siPlexes showed at this ratio the highest gene silencing effect in HuH-7 cells (data not 
shown). The ability of the siPlexes to bind siRNA was analyzed by PAGE (Figure 3A). In case of the 0, 
2 and 5 mol% DSPE-PEG2000-biotin containing siPlexes, no free siRNA could be detected. This implies 
that all the siRNA is complexed with the liposomes, which are too large to migrate into the gel 
network. In contrast, a smear of siRNA was observed in case of the 15 mol% PEG-siPlexes, indicating 
only a partial siRNA complexation in these siPlexes. 
Subsequently, the ability of the different siPlexes to bind to the surface of the biotinylated 
microbubbles was tested. Therefore, the biotinylated microbubbles were first incubated with avidin. 
An excess of avidin was used to avoid massive clustering of the microbubbles, due to avidin mediated 
bridging. After removal of the unbound avidin, siPlexes, containing Atto488 labelled siRNA, were 
added to the avidinylated microbubbles. The confocal images in Fig. 3B till 3E show that the amount 
of DSPE-PEG2000-biotin in the siPlexes clearly influences to which extent the microbubble surface 
becomes covered with siPlexes. Non-PEGylated siPlexes (Figure 3B), thus not containing DSPE-
PEG2000-biotin, only showed some non-specific binding to the avidinylated microbubbles. In contrast, 
the PEGylated siPlexes, containing DSPE-PEG2000-biotin, clearly bound to the avidinylated surface of 
the microbubbles. The surface of the microbubbles became only partially covered with siPlexes 
containing 2 mol% DSPE-PEG2000-biotin (Figure 3C), probably due to the limited degree of 
biotinylation of the siPlexes. In contrast, the microbubble surface was almost completely coated with 
siPlexes when they contained 5 mol% DSPE-PEG2000-biotin (Figure 3D). The 15 mol% containing PEG-
siPlexes also showed an efficient coating of the surface of the microbubbles. However, as these 
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siPlexes showed incomplete complexation of the siRNA, previously shown by gel electrophoresis 
experiments (Figure 3A, lane 5), these siPlexes were further excluded from the study.  
 
 
Figure 3 (A) Polyacrylamide gel after electrophoresis of siPlexes containing 0 mol% (lane 1), 2 mol% (lane 2), 
5 mol% (lane 3) and 15 mol% DSPE-PEG2000-biotin (lane 4) before attachment to the microbubbles. As a 
reference, free siRNA was loaded in lane 5 and each lane contains 0.3 µg siRNA. (B-E) Confocal laser scanning 
microscopy images and corresponding transmission images (inserts) of avidinylated microbubbles incubated 
with siPlexes containing 0 mol% (B), 2 mol% (C), 5 mol% (D) and 15 mol% DSPE-PEG2000-biotin (E). The siPlexes 
were visualized by using Atto488-siRNA. 
 
Subsequently we studied the size distribution of the siPlex coated microbubbles by laser 
diffraction to assure that the microbubbles had the optimal size distribution for cavitation. Figure 4 
shows the size distribution of microbubbles incubated with non-PEGylated siPlexes and microbubbles 
loaded with PEGylated siPlexes. In both cases, the diameter of the microbubbles varied between 0,5 
and 10 µm, which is an appropriate size to favour cavitation upon exposure to clinically relevant 
ultrasound energy. Figure 4 (arrow) also shows a significant amount of sub-micron particles in case of 
the non-PEGylated siPlexes, indicating the presence of non bound siPlexes. In contrast, this sub-
micron peak was not visible in case of the microbubbles loaded with PEGylated siPlexes (Figure 4, 
grey circles). These results are in agreement with the confocal images shown in Figure 3B and 3D. 
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Similar size distributions were found for microbubbles that were loaded with 2 mol% DSPE-PEG2000-
biotin containing siPlexes (data not shown).  
 
Figure 4 Size distribution measured by laser diffraction of microbubbles after addition of non-PEGylated 
siPlexes (black squares) and attachment of 5 mol% DSPE-PEG2000-biotin containing siPlexes (grey circles). The 
data are the mean of three measurements and error bars represent standard deviations. Arrow indicates a 
peak of sub-micron sized particles. 
 
Ultrasound induced release of PEG-siPlexes from microbubbles 
 
It has been shown that coupling of polystyrene beads to the surface of microbubbles via a 
biotin-avidin bridge, results in local delivery of the beads upon ultrasound radiation38. However, in 
contrast to these inert beads, self-assembled siPlexes may undergo physicochemical alterations 
during the ultrasound triggered release, which may influence their biological performance. 
Therefore, we determined the size, zeta potential and siRNA complexation of the siPlexes before 
attachment to the microbubbles and after ultrasound triggered release from the microbubbles.  
The dark grey bars in Figure 5A show that, before binding to the microbubble surface the size 
of the siPlexes was independent of the PEGylation degree and averaged 130 nm. In contrast, the 
surface charge lowered with increasing degree of PEGylation (dark grey bars in Figure 5B) varying 
from 50 mV for the non-PEGylated to 20 mV for the siPlexes containing 5 mol% DSPE-PEG2000-biotin. 
Fig. 5A also shows that binding and subsequent ultrasound assisted release of the PEG-siPlexes from 
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the microbubbles (light grey bars) had only a limited effect on the size of these PEG-siPlexes with a 
maximal increase of ~20 nm, in contrast to the clear increase in size of the non-PEGylated siPlexes. 
 
 
Figure 5 (A) Size and (B) zeta potential of the siPlexes containing 0 mol%, 2 mol% and 5 mol% DSPE-PEG2000-
biotin before attachment to the microbubbles (dark grey bars) and after ultrasound assisted release from the 
siPlex loaded microbubbles (light grey bars). The data are the means of three independent measurements and 
the error bars represent standard deviations. 
 
As observed for the size, the zeta potential (Figure 5B) of the PEG-siPlexes after being released 
from the microbubbles by ultrasound was not significantly altered, while the zeta potential of the 
non-PEGylated siPlexes was significantly lower. The change in size and zeta potential of the non-
PEGylated siPlexes may be due the binding of negatively charged DSPE-PEG2000-biotin lipids from the 
imploded microbubbles to the non-PEGylated siPlexes. 
Clearly, to keep their biological performance, the siPlexes may not dissociate (i.e. release their 
siRNA) upon exposure to ultrasound, as free siRNA is prone to nuclease degradation. Gel 
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electrophoresis revealed that ultrasound energy did not dissociate the siPlexes (data not shown). In 
conclusion, ultrasound mediated implosion of the PEG-siPlex loaded microbubbles and the induced 
microjets did not drastically influence the size, zeta potential and the complexation properties of the 
released PEG-siPlexes. 
 
Cellular distribution of PEG-siPlexes 
 
Next we studied the cellular distribution of PEG-siPlexes. Figure 6A till 6C show HuH-7 cells 
incubation with 5 mol% PEG-siPlexes. The z-scan in Figure 6A reveals that these PEG-siPlexes, after 
20 min incubation at 37°C, were still located on top of the HuH-7 cells. This was confirmed by the 
images in Figure 6B and 6C. In these images, the green labelled PEG-siPlexes (Figure 6C) show exactly 
the same cellular distribution as the red labelled plasma membrane (Figure 6B). This confirms that 
PEGylation indeed has an effect on the cellular uptake of siPlexes 39, as non-PEGylated siPlexes were 
clearly taken up by the cells after 20 min (data not shown). Ultrasound irradiation did not change the 
cellular distribution of these free PEG-siPlexes (data not shown). Interestingly, PEG-siPlexes released 
from siPlex loaded microbubbles by ultrasound showed a totally different cellular distribution 
(Figure 6D till 6F). In this case, the green labelled PEG-siPlexes were localized inside the cells as 
shown by the z-scan (Figure 6D) and the membrane colouring (Figure 6E and 6F). These results 
suggest that PEG-siPlexes enter the cells via a different mechanism when they are released from the 
PEG-siPLex loaded microbubbles by ultrasound. Although further research is needed, we suppose 
that they enter cells via the transient cell membrane perforations that arise during the exposure to 
ultrasound 40. Indeed, such pores, which have been reported to be a few hundreds of nanometers in 
size 34,41, are large enough to allow the passage of the PEG-siPlexes released from the microbubbels. 
This implies that the negative effects of PEGylation on the cellular uptake as well as on the 
endosomal escape of PEG-siPlexes can be circumvented by attaching them to microbubbles and 
subsequently expose these siPlex loaded microbubbles to ultrasound. 
 
Gene silencing efficiency of PEG-siPlex loaded microbubbles 
 
Finally, we determined whether siRNA delivered by ultrasound mediated implosion of the PEG-
siPLex loaded microbubbles could inhibit constitutive luciferase expression in HuH-7eGFPLuc cells 
(Figure 7). The black bars in Figure 7 show that the silencing capacity of the free siPlexes declines 
dramatically with increasing PEGylation degree. SiPlexes with a PEGylation degree of 2 mol% already 
showed a 3-fold reduced gene silencing capacity compared to the non-PEGylated siPlexes.  
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Figure 6 Cellular uptake and intracellular distribution of PEG-siPlexes (A till C) and ultrasound radiated PEG-
siPlex loaded microbubbles (D till F). All PEG-siPlexes contain 5 mol% DSPE-PEG2000-biotin. Images A and D 
display confocal images and z-scans, at the positions indicated by the red lines, through HuH-7 cells with Draq5 
labelled nuclei (blue) and incubated for 20 minutes with Atto488-labelled siPlexes (green). Confocal image (B) 
and (E) show the localisation of TRITC-concanavalin A (red), a plasma membrane marker. Confocal image (C) 
and (F) show the localisation of Atto488-labelled siPlexes (green) in the cells shown in image (B) and (E), 
respectively. The scale bars represent 10 µm. 
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Increasing the PEGylation degree to 5 mol% even completely blocked the silencing capacity of 
the siPlexes. This negative effect of PEGylation has intensively been studied for pDNA delivery and 
some groups suggest that the loss in transfection efficiency of highly PEGylated lipoplexes is due to a 
reduced cellular binding and uptake41,42, while others believe that the PEG-lipids inhibit the 
endosomal release of the nucleic acids into the cytoplasm39,43-46. The white bars in Figure 7 show that 
the negative effect of PEGylation on the gene silencing efficiency of the siPlexes containing 5 mol% 
DSPE-PEG2000-biotin can be completely counteracted by loading of these PEG-siPlexes on the surface 
of microbubbles followed by exposure of these microbubbles to ultrasound. Attachment of siPlexes 
containing 2 mol% DSPE-PEG2000-biotin to the microbubbles and subsequent exposure to ultrasound 
resulted in a similar silencing as the corresponding free PEG-siPlexes. For these PEG-siPlexes the 
number of PEG-siPlexes bound to the microbubbles is probably not enough to further increase their 
gene silencing efficiency. Indeed, as shown in Figure 3C, the 5 mol% DSPE-PEG2000-biotin containing 
siPlexes bind much more efficiently to the microbubble surface than the 2 mol% DSPE-PEG2000-biotin 
containing siPlexes (Figure 3B). Therefore, these data may indicate that the extent of gene silencing 
is governed by the amount of PEG-siPlexes that are released near the cell perforations. Figure 7 (dark 
grey bars) also shows that applying ultrasound energy, in the absence of microbubbles, could not 
enhance the gene silencing efficiency of the different siPlexes. Furthermore, microbubbles loaded 
with 5 mol% PEG-siPlexen were not able to cause gene silencing in the absence of ultrasound 
(Figure 7; light grey bars). This implies that the PEG-siPlex loaded microbubbles described in this 
work allow ultrasound controlled, i.e. targeted, intracellular delivery of siRNA. 
 
CONCLUSION 
 
In conclusion, we developed a novel delivery system in which PEG-siPlexes are attached to 
ultrasound responsive microbubbles via a biotin-avidin-biotin bridge. Exposure of these PEG-siPlex 
loaded microbubbles to ultrasound resulted in a massive release of unaltered PEG-siPlexes. 
Furthermore, PEG-siPlexes (containing 5 mol% DSPE-PEG2000-biotin) loaded on microbubbles were 
able to enter cells rapidly after exposure to ultrasound, while free PEG-siPlexes did not enter cells. 
Moreover, these PEG-siPlex loaded microbubbles caused, in the presence of ultrasound, a much 
higher gene silencing than free PEG-siPlexes. Interestingly, in the absence of ultrasound these PEG-
siPlex loaded microbubbles did not cause any gene silencing. Therefore, the developed siRNA 
delivery system allows both space and time controlled gene silencing. Furthermore, the PEG-siPlex 
loaded microbubbles are expected to be suitable for systematic applications as ultrasound in 
combination with microbubbles is considered as a safe and already used in the clinic for diagnostic 
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purposes. Additionally, PEG-siPlexes are known not to aggregate in serum which is important to 
avoid blockage of small blood capillaries by aggregates47. The developed siRNA delivery system may 
also allow the treatment of patients with metastasized tumours. Indeed, a recently developed device 
that combines magnetic resonance imaging (MRI) and ultrasound can both track down the 
metastasized tumours and guide the ultrasound energy to these tumours48. So, the siRNA delivery 
system presented in this work may open up new perspectives for ultrasound controlled in vivo 
delivery of siRNA. 
 
 
Figure 7 Silencing efficiency of free siPlexes and PEG-siPlexes in the absence and presence of ultrasound, and 
PEG-siPlex loaded microbubbles in the presence of ultrasound. The PEGylation (DSPE-PEG2000-biotin) degree of 
the siPlexes is represented in the x-axis. The black and the dark grey bars represent the gene silencing 
efficiency of free siPlexes in the absence and presence of ultrasound, respectively. The light grey and white 
bars represent the gene silencing of the siPlexes loaded on the microbubbles in the absence or presence of 
ultrasound. In all cases, the following ultrasound settings were used: 1 MHz, 10 % DC, 2 W/cm
2
, 10 sec. The 
results are expressed as percentage of luciferase expression compared to mock siRNA transfected cells. The 
asterixes (*) represent significant differences with p<0.05. (MB = microbubble; US = ultrasound) 
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ABSTRACT 
 
This paper describes the design and working mechanism of doxorubicin (DOX) loaded 
microbubbles for ultrasound mediated delivery of DOX. Compared to DOX-liposomes, DOX loaded 
microbubbles, prepared by attaching DOX-liposomes to the lipid shell of microbubbles killed 
melanoma cells significantly stronger after exposure to ultrasound. After treatment of the melanoma 
cells with DOX-liposome loaded microbubbles and ultrasound, DOX was mainly present in the nuclei 
of the cancer cells, while it was mainly detected in the cytoplasm of cells treated with DOX-
liposomes. Exposure of cells to DOX-liposome loaded microbubbles and ultrasound caused an almost 
instantaneous cellular entry of the DOX. At least two mechanisms were identified which explain the 
fast uptake of DOX and the superior cell killing of DOX-liposome loaded microbubbles and 
ultrasound. First, exposure of DOX-liposome loaded microbubbles to ultrasound results in the release 
of free DOX which is more cytotoxic than DOX-liposomes. Second, the cellular entry of the released 
DOX is facilitated due to sonoporation of the cell membranes.  
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INTRODUCTION 
 
Doxorubicin (DOX), also called adriamycine, is one of the most frequently used anti-cancer 
drugs. DOX is used for the treatment of different solid and haematopoetic cancers such as breast 
cancer, osteosarcomas, aggressive lymphomas and leukemias. Different mechanisms explain its 
cytotoxic activity1. They include DNA intercalation, lipid peroxidation and inhibition of topoisomerase 
II. The use of free DOX is rather limited because of the severe side-effects.  Indeed, besides damaging 
tumours it also causes cardiotoxicity and nephrotoxicity1. Additionally, the efficacy of free DOX is also 
hampered by multidrug resistance, originating from the P-glycoprotein and topoisomerase II 
resistance1. Because of these problems associated with free DOX treatment, DOX has been 
encapsulated inside liposomes. These liposomes contain PEG (polyethylene glycol) chains at their 
surface to prevent recognition by the reticuloendothelial system (RES) (so-called stealth liposomes). 
This results in the passive accumulation of stealth liposomes in the tumour vasculature due to the 
enhanced permeability and retention effect (EPR)2. In 1995 the liposomal DOX formulations Doxil® 
and Caelix® became FDA approved for the treatment of AIDS related Kaposi’s sarcoma and ovarian 
cancer. Although Doxil® strongly reduced the cardiac toxicity of DOX in clinical trials, other side 
effects occured. Several patients suffered from mucositis and the hand and foot syndrome, due to 
the localization of the liposomes in skin capillaries1. Therefore, many research groups try to enhance 
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the targeting of DOX to the tumours by attaching ligands or antibodies to DOX loaded vehicles or by 
incorporating DOX in stimuli responsive carriers like pH and temperature responsive nanocarriers1,3.  
In the past ultrasound has been used as an external trigger to induce drug release from drug 
loaded carriers. In these experiments low frequency (<1 MHz) ultrasound was used. However, the 
clinical applicability of low frequency ultrasound is limited by its low penetration depth in the body. 
More recently it has been demonstrated that high frequency ultrasound (1-10 MHz), when combined 
with diagnostic microbubbles, can enhance the intracellular delivery and extravasation of drugs4-7. 
These effects have been attributed to inertial cavitation of the microbubbles. Cavitation is the 
alternate growing and shrinking of microbubbles under the influence of an ultrasonic field8. When 
the ultrasound intensity is high enough, microbubbles can implode due to the inertia of the inrushing 
fluid (inertial cavitation). As a result, fluid streams and microjets transiently perforate the 
membranes of nearby cells and hence enhance the intracellular uptake of drugs6,7,9,10. This 
phenomenon is called sonoporation. Additionally, it has been shown that such microjets can also 
transiently perforate blood vessels and thus induce extravasation of large molecules11,12. 
Several papers report on the synergistic effect of doxorubicin and ultrasound13. However, 
these papers mainly focused on ultrasound assisted intracellular delivery of respectively free 
doxorubicin14,15 or DOX encapsulated in micelles or liposomes16-22. The forces associated with the 
inertial cavitation of the microbubbles may (a) massively release the encapsulated drug from the 
nanocarriers and (b) improve the intracellular uptake of DOX due to sonoporation of the cell 
membranes. However, a major drawback of co-injecting DOX liposomes and microbubbles is the 
fact that DOX liposomes extravasate and thus still accumulate in undesired tissues (not exposed 
to ultrasound) which explains that a high amount of DOX liposomes remains necessary to 
achieve a sufficiently high concentration in the ultrasound treated region.  This study aimed to 
further improve ultrasound mediated delivery of DOX-liposomes. Therefore we designed 
“doxorubicin loaded microbubbles” through avidin-biotin binding of doxorubicin containing 
liposomes to the lipid shell of microbubbles (DOX-liposome loaded microbubbles)(Figure 1). DOX 
delivery by such constructs could be attractive as it would take profit of both the sonoporation effect 
and targeting potential of ultrasound. Indeed, micobubbles carrying DOX-liposomes at their surface 
are expected to be too large to extravasate in undisered tissue (i.e. not treated by ultrasound). This 
papers shows the killing of tumour cells by DOX-microbubbles and explains the underlying 
mechanisms. 
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MATERIALS & METHODS 
 
Preparation and characterization of lipid microbubbles containing DSPE -PEG-biotin  
 
Liposomes containing DPPC (dipalmitoylphosphatidylcholine) and DSPE-PEG-biotin (1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-(biotinyl(polyethyleneglycol)2000)) in a 85:15 molar 
ratio were prepared as previously described6. Briefly, the in chloroform dissolved lipids were put in a 
round-bottomed flask and the solvent was removed via evaporation followed by flushing with 
nitrogen. The obtained lipid film was subsequently hydrated in HEPES buffer (20 mM HEPES, pH 7.4) 
at a final lipid concentration of 5 mg/mL and incubated overnight at 4°C to allow the formation of 
liposomes. The resulting liposomes were first extruded through a polycarbonate membrane (pore 
size of 0.2 µm) using a mini-extruder (Avanti Polar Lipids, Alabaster, AL, USA). Subsequently, the 
extruded liposomes were sonicated with a 20 kHz probe (Branson 250 sonifier, Branson Ultrasonics 
Corp., Danbury, CT, USA) in the presence of perfluorobutane gas (C4F10, MW 238 g/mol , F2 
chemicals, Preston, Lancashire, UK). After sonication the microbubbles were washed (to remove the 
excess of lipids) with 3 mL fresh HEPES buffer and finally resuspended in 5 mL fresh HEPES buffer. To 
allow the attachment of biotinylated DOX-liposomes, the biotinylated microbubbles were incubated 
with 500 µL avidin (10 mg/mL) and incubated for 10 min at room temperature. Subsequently, the 
microbubbbles were centrifuged and washed again with 3 mL fresh HEPES buffer. Finally the 
microbubbles were resuspended in 5 mL HEPES buffer. The mean size of these microbubbles was 
around 2 µm and their size distribution ranged between 0.5 and 10 µm. 
 
Preparation and characterization of biotinylated doxorubicin liposomes  
 
Liposomes containing DPPC, cholesterol and DSPE-PEG-biotin in a 60:40:5 molar ratio were 
prepared as described above. Liposomes were loaded with doxorubicin following the method 
previously established by Bolotin et al. 23 After removal of the chloroform, the lipid film was hydrated 
with ammonium sulphate buffer (250mM). The resulting liposomes were extruded through a 
polycarbonate membrane (pore size of 0.1µm) as described above. Subsequently, the liposomes 
were dialysed against pure distilled water overnight in a dialysis bag (MWCO 10.000, Spectra/Por 
Biotech, Spectrum laboratories, CA, USA) to remove the ammonium sulphate between the 
liposomes. Liposomes were loaded with DOX by mixing 1 mL of liposomes with 1 mg of DOX. This 
mixture was incubated for 4 h at 65°C. Afterwards, the free DOX was removed by passing the DOX 
loaded liposomes over a Sephadex column (Sephadex G75). Loading efficiency was determined by 
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measuring the absorbance of DOX in the DOX-liposome fraction and the free DOX at 450nm and was 
around 90%. The average hydrodynamic diameter of the PEGylated DOX-liposomes was determined 
by dynamic light scattering (DLS; Autosizer 4700, Malvern).  
 
Attachment of biotinylated DOX-liposomes to avidinylated microbubbles  
 
50 µL of biotinylated DOX-liposomes was mixed with 1 mL avidinylated microbubbles and 
incubated at room temperature for 5 min. The attachment of DOX-liposomes to the microbubbles 
was visualized using a Nikon EZC1-si confocal laser scanning microscope (Nikon, Brussels, Belgium) 
equipped with a 40x objective. The 491nm line of this microscope was used to excite the doxorubicin 
and the doxorubicin was detected with the 580nm detector. 
 
Cell culture 
 
BLM-cells (melanoma cells)24 were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
with the growth factor F12 and phenol red containing 2mM glutamine, 10% heat deactivated foetal 
bovine serum (FBS), 1% penicillin-streptomycin (Gibco, Merelbeke, Belgium) and HEPES buffer 
(20mM, pH 7.4). 
 
Cytotoxicity measurements 
 
Cells were grown to 90% confluency in Opticell units (Biocrystal, Westerville, OH, USA) in a 
humidified incubator at 37°C and 5% CO2. Subsequently, cells were washed with 10 mL of phosphate 
buffered saline (PBS; Gibco, Merelbeke, Belgium) and respectively DOX-liposome loaded 
microbubbles , DOX-liposomes or free DOX (all in Optimem, Gibco, Merelbeke, Belgium) were added 
to the cells. Therefore  we first mixed an appropriate amount of biotinylated DOX-liposomes 
(containing 10, 30, 50 or 100µg of DOX) with 1 mL of the avidinylated microbubbles.  After 5 min of 
incubation at room temperature, Optimem (Gibco, Merelbeke, Belgium) was added to a final volume 
of 10 mL. The medium was prepared in a similar way for the experiments without microbubbles 
except that the microbubbles were substituted by an equal amount of Optimem. The 10 mL medium 
was completely added to the Opticell units (area 50 cm2). Subsequently the cells were placed in a 
water bath at 37°C with an absorbing rubber at the bottom and immediately subjected to ultrasound 
radiation. The ultrasound radiation was performed by moving in 15s a 22 mm ultrasound probe 
(sonitron 2000 (RichMar, Inola, OK, USA) over the whole surface of the Opticell. In all the 
experiments with ultrasound we used the following settings: 1 MHz, 50% duty cycle and an 
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ultrasound intensity of 2W/cm2. Unless otherwise stated, cells were immediately treated with 
ultrasound after addition of respectively DOX-liposomes, DOX-liposome loaded microbubbles or free 
DOX.  Four hours after the addition of the DOX-liposomes, the DOX-liposome loaded microbubbles or 
free DOX we removed the medium and washed the cells two times with PBS, before adding fresh 
culture medium. 48 hours later the cells were incubated with 0.5 mg/mL MTT labeling reagent (Cell 
Proliferation Kit I, Roche diagnostics, Vilvoorde, Belgium) for 4 h. Afterwards the solubilisation 
solution was added and cells were incubated overnight at 37°C. The next day, the absorbance of each 
plate was measured at respectively  590nm (OD590), to determine the amount of formed formazan, 
and at 690nm as a reference. The cell viability was calculated as follows: 
 
 
 
Experiments were performed at least three times and the results shown here are 
representative of the results obtained in the different cytotoxicity measurements. The error bars in 
the graphs are originating from different samples that were taken from one Opticell plate and 
separately measured at 590nm and 690nm. 
 
Cellular uptake of DOX in the BLM cells  
 
Cells were incubated with respectively DOX-liposomes, DOX-liposome loaded microbubbles 
and free DOX according to the protocols described above. The DOX in cells was visualized with a 
Nikon EZC1-si confocal microscope equipped with a 60x objective. The 491nm line of this microscope 
was used to excite the doxorubicin and the doxorubicin was detected with the 580nm detector. 
 
Statistical analysis 
 
 All the data in this report are expressed as mean ± standard deviation (SD). For the 
transfection results, the Student’s t-test was used to determine whether data groups differed 
significantly from each other. A p-value lower than 0.05 was considered statistically significant. 
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RESULTS & DISCUSSION 
 
Design and characterization of DOX-liposome loaded microbubbles 
 
As schematically presented in Figure 1, we aimed to construct lipid microbubbles loaded with 
doxorubicin-liposomes. Therefore, we first prepared doxorubicin-containing liposomes composed of 
55 mol% DPPC, 40 mol% cholesterol, and 5 mol% DSPE-PEG-biotin. After loading the liposomes with 
doxorubicin and GPC purification, DOX-liposomes with an average diameter of 147 nm were 
obtained. We also prepared lipid microbubbles that contained 15 mol% DSPE-PEG-biotin in their 
shell. The biotinylated microbubbles were subsequently incubated with an excess of avidin, to 
saturate the biotin molecules at their surface. After removal of the excess of avidin the microbubbles 
were incubated with the biotinylated DOX-liposomes to couple the DOX-liposomes on the 
microbubbles via an avidin-biotin bridge (Figure 1). The binding of the DOX-liposomes, which are 
fluorescent due to the presence of doxorubicin, on the microbubbles was confirmed via confocal 
laser scanning microscopy (CLSM): Figure 2 clearly shows that the surface of the microbubbles 
becomes surrounded by doxorubicin-containing liposomes. The amount of DOX-liposomes that was 
bound to the microbubbles was estimated by removing the unbound DOX-liposomes from the 
microbubbles via centrifugation. We calculated that 65% of the DOX-liposomes was attached to the 
microbubbles. Knowing that we mixed about 1 x 109 microbubbles with 50 µg of doxorubicin 
encapsulated in liposomes, each microbubble is expected to contain about 3,25 x 10-8 µg 
doxorubicin. 
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Figure 1 Schematic presentation of a DOX-liposome loaded microbubble. 
 
 
 
 
Figure 2 Confocal laser scanning microscopy image and corresponding transmission image of DOX-liposome 
loaded microbubbles. The DOX-liposomes were visualized using the fluorescence of the encapsulated 
doxorubicin. 
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Efficacy of DOX-liposome loaded microbubbles after ultrasound treatment 
 
In Figure 3 the killing of cancer cells by respectively DOX-liposome loaded microbubbles, in the 
presence of ultrasound, and DOX-liposomes is compared. The cell killing by DOX-liposomes (light grey 
bars) was rather limited; the highest concentrations (50 and 100µg/mL) killed about 50 % of the cells. 
In contrast, DOX-liposomes attached onto the microbubbles (white bars) were by far more toxic to 
the cells after ultrasound application. We also observed a nice correlation between the liposome 
concentration present on the DOX-liposome loaded microbubbles and the cell viability, which was 
less clear in case DOX-liposomes were used.  
 
 
Figure 3 Cell viability of the melanoma cells after treatment with DOX-liposomes without (light grey bars) and 
with ultrasound exposure (USE) (dark grey bars) and DOX-liposome loaded microbubbles after ultrasound 
exposure (white bars) as a function of the DOX concentration. * p< 0,05 
 
 
Some groups described a synergistic effect of ultrasound on the killing of cells by DOX-
liposomes25  and DOX-micelles20,26-28. Though we did not observe an outspoken improvement of the 
cell killing by DOX-liposomes when ultrasound was applied (Figure 3: dark gray bars). Most authors 
use low frequency ultrasound (20-100kHz), which is known to favour cavitation at relatively low 
intensities, even in the absence of microbubbles. In our experiment we exposed the DOX-liposomes 
to 1MHz frequency ultrasound in the absence of microbubbles. Under these ultrasound conditions it 
is well known that cavitation is limited and probably too low to release the doxorubicin from the 
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liposomes or to perforate cell membranes. In contrast, DOX-liposome loaded microbubbles in the 
presence of ultrasound significantly lowered the overall viability of the melanoma cells. We observed 
previously that the ultrasound conditions used in this study may detach a (small) part of the cells 
from the Opticell membrane. Therefore, we also studied the effect of microbubbles (not loaded with 
DOX-liposomes) and ultrasound on the viability of the melanoma cells. As Figure 3 shows, this 
reduced the cell viability with about 10%. Though, even if we take this into account, DOX-liposome 
loaded microbubbles and ultrasound seemed much more efficient in killing cancer cells than free 
DOX-liposomes. 
 
Intracellular localization of DOX 
  
We tried to gain more insight into the intracellular doxorubicin concentrations in the melanoma cells 
(Figure 4). Different concentrations of respectively DOX-liposomes and DOX-liposome loaded 
microbubbles were added to the cells. After 4 hours the cells were washed and DOX uptake was 
visualized by CSLM. At the lowest DOX concentration (30 µg/mL) we could detect more DOX in cells 
exposed to DOX-liposome loaded microbubbles and ultrasound than in cells exposed to DOX-
liposomes. This was less obvious at higher DOX concentrations used. The intracellular distribution of 
doxorubicin seemed to strongly depend on the way the doxorubicin was delivered to the cells. It was 
almost exclusively localized in the nuclei when the cells were treated with the DOX-liposome loaded 
microbubbles and ultrasound, while doxorubicin was found in both the cytoplasm and the nucleus of 
cells treated with DOX-liposomes. Sometimes a punctuated pattern could be seen in the cytoplasm 
of these cells (indicated by white arrows in Figure 4), which suggests that the doxorubicin locates in 
endosomes. Two simultaneously occurring phenomena may explain the different intracellular 
distribution of doxorubicin. First, after exposure of cells to DOX-liposome loaded microbubbles and 
ultrasound, free DOX (released from the liposomes destroyed by the ultrasound) probably enters the 
cells and accumulates in the nucleus because of its high affinity for DNA29, which is abundantly 
present in the nucleus. Second, Schlichler et al30 recently described the existence of exocytosis after 
exposure of cells to ultrasound and microbubbles to reseal the pores in the cell membranes. The 
transport of vesicles from the inside  to the outside of the cell may limit endocytosis and thus reduce 
the amount of free doxorubicin or DOX-liposomes that is taken up by endocytosis.  
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Figure 4 Confocal laser scanning microscopy images and corresponding transmission images of the uptake of 
DOX in melanoma cells treated with DOX-liposomes and DOX-liposome loaded microbubbles after ultrasound 
exposure. Cells were treated and incubated for 4 hours. Subsequently the cells were washed and immediately 
visualized with the confocal microscope. The same laser intensities were used to visualize the uptake of the 
same DOX concentrations in the two different formulations. For the uptake experiments of the 100 µg/mL 
DOX, a lower laser intensity was used as for the lower concentrations. For this reason it looks like there has 
been less DOX internalized at a higher concentration. 
 
 
The higher amount of doxorubicin in the nuclei after exposure of the cells to DOX-liposome 
loaded microbubbles and ultrasound suggests the following delivery mechanism. Applying ultrasound 
destroys the liposomes on the microbubbles releasing free doxorubicin near the cell membranes, 
which can enter cells more easily than DOX-liposomes. Secondly, ultrasound may also increase the 
amount of free doxorubicin and DOX-liposomes that enter the cells via perforations in the 
membranes. In the following paragraphs we further investigated the mechanisms which may explain 
the stronger cell killing by doxorubicin loaded microbubbles and ultrasound. 
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Is the stronger cell killing by DOX-liposome loaded microbubbles due to an ultrasound mediated 
release of free DOX from the liposomes? 
 
Several hypotheses have been proposed to explain the synergistic effect of ultrasound on the 
biological activity of anticancer drugs. The first mechanism postulates that ultrasound treatment of 
DOX-liposomes results in the release of doxorubicin from the liposomes which subsequently enters 
the cells via passive diffusion and pinocytosis31. To verify this hypothesis a direct effect of the 
cavitating microbubbles on the cell membrane should be avoided so that only the cytotoxic effect 
coming from doxorubicin can be taken into account. Therefore we performed an experiment in 
which the DOX-liposome loaded microbubbles were first exposed to ultrasound (using the same 
settings as in Figure 3) in an ‘empty’ Opticell (i.e. without melanoma cells). Subsequently, this 
‘medium’ (i.e. the debris of radiated DOX-liposome loaded microbubbles) was transferred to an 
Opticell in which melanoma cells were growing. In this experiment sonoporation of the melanoma 
cells (by cavitating and imploding microbubbles cavitating) was thus avoided. After 4 hours of 
incubation, the ‘medium’ was removed and the cell viability was measured 48 hours later. Figure 5 
shows that the debris of radiated DOX-liposome loaded microbubbles (white bars) showed a stronger 
tumour cell killing than DOX-liposomes (light grey bars). These data indicate that exposure of DOX-
liposome loaded microbubbles to ultrasound most likely results in a release of free doxorubicin, 
which is known to cause a stronger cell killing than DOX-liposomes. Figure 5 reveals that the killing of 
melanoma cells by the debris of radiated DOX-liposome loaded microbubbles was significantly lower 
than that of DOX-liposome loaded microbubbles and ultrasound (especially at higher doxorubicin 
concentrations). It suggests that that the cell killing by DOX-liposome loaded microbubbles and 
ultrasound is explained by both the release of free doxorubicin and the cavitation of the 
microbubbles which perforates the cell membranes.  
We recently loaded PEGylated pDNA containing liposomes (lipoplexes) onto the same type of 
microbubbles as reported in this study6. We could show by dynamic light scattering that exposure of 
the lipoplex loaded microbubbles resulted in the release of intact lipoplexes. However, after 
exposure of the DOX-liposome loaded microbubbles to ultrasound we were no longer able to detect 
DOX-liposomes. This further suggests that indeed a substantial part of the DOX-liposomes becomes 
destroyed upon applying ultrasound to the DOX-liposome loaded microbubbles. Probably this results 
in the release of free doxorubicin that can enter the cells either via passive diffusion or through the 
perforations in the cell membranes, as discussed in the next paragraph.  
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Figure 5 Cell viability of melanoma cells after treatment with DOX liposomes (light grey bars) and DOX-
liposome loaded microbubbles with ultrasound exposure (dark grey bars). Cells were also treated with DOX 
liposome loaded microbubbles that were radiated with ultrasound before addition to the cells (white bars). 
*p<0,05. 
 
 
Is the stronger cell killing by DOX-liposome loaded microbubbles due to an improved cellular 
uptake of DOX? 
 
Several groups have studied the perforation of cell membranes by ultrasound9,30,32,33. SEM 
images and uptake of fluorescent molecules after sonoporation have proven that cavitating 
microbubbles can indeed transiently disrupt cell membranes which allows compounds to enter cells. 
In our study pore formation might enhance the intracellular uptake of both free doxorubicin and 
doxorubicin liposomes. To further evaluate this hypothesis we studied the cellular uptake of 
doxorubicin shortly (i.e. 15-30 minutes) after exposure of melanoma cells to (1) DOX-liposome 
loaded microbubbles and ultrasound (Figures 6a-d), (2) DOX-liposomes (Figures 6e-h) and (3) free 
doxorubicin (Figsures 6i-l). Almost immediately after exposure of the melanoma cells to DOX-
liposome loaded microbubbles and ultrasound a substantial part of the cells contained very high 
levels of doxorubicin in their nuclei (Figures 6a,c). In sharp contrast, melanoma cells exposed to DOX-
liposomes hardly contained doxorubicin after 15 minutes (Figures  6e,g). Free doxorubicin is known 
to be easily taken up by cells through a combined process of passive diffusion and active transport 
mechanisms31. Therefore, we also studied the uptake of free doxorubicin (Figures 6i-l). After 15 
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minutes cells treated with free doxorubicin contained clearly visible amounts of doxorubicin (Figures 
6i,k) in the cytoplasm with only very little fluorescence in the nucleus of the cells. However, the 
amount of doxorubicin internalized by the cells was still much lower than the doxorubicin content in 
the cells exposed to DOX-liposome loaded microbubbles and ultrasound. Note that in the case of 
DOX-liposome loaded microbubbles a part of the cells had taken up extreme amounts of doxorubicin 
15 minutes after exposure to ultrasound (these were probably the cells which were in contact with 
cavitating and imploding microbubbles), while the others were only weakly fluorescent (Figures 6a). 
In the case of free doxorubicin the fluorescence was rather equal in all cells which suggests that 
doxorubicin uptake occurred to the same extent in all cells. 
 
  
Figure 6 Confocal laser scanning microscopy image (A,C,E,G, I and K) and corresponding transmission image (B, 
D, F, H, J and L) of the uptake of doxorubicin after 15 minutes incubation with DOX-liposome loaded 
microbubbles and ultrasound exposure (A-D), DOX-liposomes (E-H) or free DOX (I-L). Image C,D,G,H,K and L 
present a close-up of a single cell. 
 
Several papers have reported the instant uptake of larger molecules after sonoporation34-36. It 
has been shown that the microstreams developing around a cavitating microbubble, and especially 
the shock waves and microjets associated with microbubble cavitation, can result in the formation of 
transient pores in the cell membrane37,38. Pore sizes between 100nm and a few µm in size have been 
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reported30,33, implying that a rather small molecule like DOX should be able to enter the cell through 
such cell membrane pores. To further evaluate the hypothesis that microbubbles in the presence of 
ultrasound enhance the cellular uptake of doxorubicin we compared the killing of cells that had been 
exposed to respectively free doxorubicine and a mixture of free doxorubicine, microbubbles and 
ultrasound. As presented in Figure 7, microbubbles in combination with ultrasound significantly 
enhanced the cytotoxicity of free doxorubicin (dark gray bars). This supports the hypothesis that 
sonoporation indeed improves the cellular uptake of free doxorubicin. We also performed a second 
experiment in which we first exposed the melanoma cells to free DOX; After the 4 hours incubation 
time, the cells were carefully washed and treated with microbubbles and ultrasound. As can be seen 
in Figure 7 (white bars), this even resulted in a stronger killing which may be due to the fact that a 
certain time after internalization of free DOX melanoma cells become more sensitive to 
sonoporation. Cells treated with microbubbles and ultrasound are often irregularly shaped32. This 
was also observed in our experiments (Figure 6d). Despite their clearly damaged cell membrane, 
most cells are capable of resealing their membrane wounds32,39, which was confirmed in our MTT 
experiment: only 10% of the BLM cells was metabolic inactive after exposure of the cells to 
microbubbles and ultrasound (Figure 3). It might be possible that due to the DOX induced 
cytotoxicity, the cells are less able to generate cell repair mechanisms, necessary to repair the cell 
membrane after sonoporation. 
 
  
Figure 7 Cell viability of melanoma cells after treatment with free DOX (light grey bars) and free DOX with 
microbubbles and ultrasound exposure (dark grey bars). Cells were also incubated with free DOX for 4 hours, 
washed and then treated with microbubbles and ultrasound (white bars). *p<0,05 
Design and evaluation of doxorubicin containing microbubbles for ultrasound triggered doxorubicin delivery - Chapter 7 
 
189 
CONCLUSIONS 
 
We succeeded in coupling doxorubicin containing liposomes onto the lipid shell of gas-filled 
microbubbles. DOX-liposome loaded microbubbles plus ultrasound killed much more tumour cells 
than DOX-liposomes. We showed that this is due to: (1) an ultrasonic triggered release of DOX from 
the DOX-liposomes present on the microbubbles, and (2) an enhanced uptake of the released DOX by 
the cells. The latter most likely results from temporary pores in the cell membranes induced by the 
imploding microbubbles (sonoporation). Based on the results in this manuscript we hypothesize that 
DOX-liposome loaded microbubbles in combination with ultrasound may significantly improve the in 
vivo efficacy of Doxil® being the liposomal doxorubicin formulation which is nowadays used in the 
clinic. Indeed, a local ultrasound triggered release of free doxorubicin in the tumour may enhance 
the cell killing by Doxil® as free DOX is expected to be  more efficient than DOX-liposomes. Also, DOX-
liposome loaded microbubbles may show less side-effects than Doxil® as in tissues not exposed to 
ultrasound the micron sized DOX-liposome loaded bubbles (1) will stay intact and thus will not 
release DOX-liposomes and (2) will not extravasate into these tissues. Moreover, the cavitation and 
implosion of the microbubbles in the tumour microvasculature may perforate endothelial cells and 
enhance the extravasation of the released doxorubicin11,12. As demonstrated in Figure 8, the 
enhanced cellular uptake of doxorubicin in endothelial cells may improve doxorubicin to slow down 
angiogenesis and to break down the nutrient supply of the tumour cells40. The in vivo biological 
response of the DOX-liposome loaded microbubbles may be further enhanced by attaching ligands to 
the microbubbles that specifically bind to the tumour endothelium41,42.  
Although several papers describe the use of ultrasound to improve drug release from 
nanoparticles and to enhance cellular uptake18,26,28,43-45, only few have been published on the 
combined use of ultrasound and drug loaded microbubbles to improve antitumor treatment46,47. 
Tartis et al. already developed a paclitaxel containing ultrasound contrast agent47. In this study, the 
paclitaxel was dissolved in triacetin oil, which makes this type of microbubbles unsuited for 
hydrophilic drugs like DOX. Gao and colleagues were the first to report the design of a DOX loaded 
microbubble that was able to release the DOX upon ultrasound treatment46. The doxorubicin was 
present in the shell of perfluorocarbon nanoparticles that vaporized and formed doxorubicin carrying 
microbubbles upon warming till 37 °C. Although they obtained good results both in vitro and in vivo, 
we believe that clinical application of the DOX-liposome carrying microbubbles described in our study 
may be more straightforward as as both DOX-liposomes (Doxil®) and lipid microbubbles (e.g. the 
contrast agent Definity®) are already used in clinical settings. Another advantage of the DOX-
liposome loaded microbubbles is their high DOX loading efficiency. We estimated the 
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Figure 8 Schematic representation of the working principle of DOX-liposome loaded microbubbles compared to 
free DOX-liposomes in the tumor vasulature. When the microbubbles are exposed to ultrasound, the liposomes 
locally release the encapsulated doxorubicin. The cavitating and imploding microbubbles also increase the cell 
membrane permeability and hence increase the amount of doxorubicin that is taken up by especially the blood 
vessel cells. 
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encapsulated doxorubicin attached to one microbubbles to be 3.25 x 10-8 µg. Doxil® is given as a 
single dose of 20 mg/m2. This corresponds to a dose of 40 mg for an adult of about 80 kg. To reach 
amount of this dose we should administer about 1.23 x 1012 DOX-liposome loaded microbubbles. The 
recommended dose of Definity®, which contains 1.2 x 1010 microbubbles/ml, is 10 µl/kg body weight 
which makes 1010 microbubles for a person of 80 kg. This is about 100 times lower than the number 
of DOX-loaded microbubbles we must inject to administer 40 mg of doxorubicin. However, it has 
been demonstrated that Definity® doses that are 1000 times higher than the recommended dose are 
well tolerated in primates48,49. Also, the locale release of the doxorubicin in the tumour after 
exposure of the DOX-liposome loaded microbubbles to ultrasound will most likely allow us to reduce 
the dose below 40 mg. The calculations above demonstrate that we may expect clinical effects in 
humans at a typically used microbubble dose.  
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SUMMARY 
 
Cancer is a genetic disease, caused by mutations in the genome of normal cells. Chemical and 
physical damage to the cellular genome can induce these mutations resulting in the transformation 
of a healthy cell into a tumor cell. Over the past years, researchers have acquired a basic 
understanding of tumor onset. Several important proto-oncogenes and proteins involved in 
angiogenesis have been identified, leading to the development and clinical use of several new 
anticancer agents.  
In chapter 1 we summarized the different chemotherapeutic drugs that are currently available 
for cancer treatment. Until now, the responsiveness of tumor cells to the current chemotherapeutic 
drugs is hampered by the development of tumor resistance genes and limited drug doses. The non-
specificity of these drugs often results in severe side-effects e.g. neutropenia limiting the acceptable 
drug doses. Cancer gene therapy can be employed to suppress  oncogenes, substitute defect tumor 
suppressor genes, improve the patient’s immune system or selectively promote the transformation 
of non-toxic pro-drugs into highly potent drugs. The different approaches in cancer gene therapy are 
briefly discussed in this chapter together with a short overview of the most common genetic drugs. 
Due to the heterogeneity in tumor vasculature and interstitial transport, current cancer treatments 
are hampered by a non-uniform and insufficient delivery of chemotherapeutic and genetic drugs to 
the tumor. To achieve an efficient cancer therapy several important extracellular and intracellular 
barriers have to be conquered. It was recently suggested that ultrasound and microbubbles can be 
used to efficiently transport drugs into target cells. The microstreams and shock waves that develop 
around a cavitating or imploding microbubble are able to temporally disturb the cell membrane, 
resulting in the formation of transient pores through which drugs can enter the cell. As microbubble 
cavitation and implosion is limited to ultrasound treated areas, drug delivery can be targeted simply 
by applying ultrasound on the desired region. Because in most cases drugs and microbubbles are 
injected separately in the bloodstream there is still a risk that drugs are taken up, although less 
efficient, in unwanted areas.  To reduce unwanted side-effects and lower drug doses it could be even 
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more advantageous to design a drug loaded microbubble. In this way drug release may become 
strictly limited to ultrasound treated areas, improving ultrasound targeting even more. Furthermore, 
associating drug and microbubble can assure that more drug molecules are available at the 
sonoporation site, enhancing drug uptake in the sonoporated cells. In this thesis we tried to develop 
drug-loaded microbubbles which are able to selectively deliver their drugs to cancer cells after 
ultrasound exposure. 
Due to their negatively charged backbone it is interesting to couple genetic drugs like plasmid 
DNA electrostatically to the microbubble shell. For this purpose we developed cationic microbubbles 
in chapter 2. Albumin microbubbles were incubated with the cationic polymer poly-(allylamine 
hydrochloride) (PAH), enabling electrostatic loading of pDNA onto the microbubble shell. Polymer 
coating of the microbubbles was confirmed with zeta potential measurements and confocal laser 
scanning microscopy images using fluorescently labeled PAH. The polymer layer around the 
microbubbe shell slows down gas diffusion and results in a 7-fold longer life-time of the 
microbubbles. pDNA loading onto the microbubble shell was demonstrated using confocal 
microscopy with a pDNA loading capacity of 0,1 pg pDNA per microbubble. As evidenced in our gel 
electrophoresis experiments, the pDNA bound onto the polymer shell was resistant to DNAse I 
degradation. 
In chapter 3 we studied the gene transfection efficiency of the uncoated and polymer-coated 
albumin microbubbles. Despite their high pDNA loading efficiency and capacity to protect the 
adhered pDNA against degradation, the polymer coated microbubbles did not succeed in transfecting 
primary endothelial or melanoma cells. Gel electrophoresis experiments revealed that the pDNA was 
still complexed to microbubble shell fragments after ultrasound induced implosion of the 
microbubbles. Additional confocal microscopy images of the imploded microbubbles, showed the 
existence of very large (several µm) and heterogeneous aggregates consisting of microbubble shell 
fragments and pDNA. The large size and heterogeneity of these fragments make it rather unlikely 
that they will be taken up through cell membrane pores. Moreover, even if part of these fragments 
would be able to enter the cellular cytoplasm, the transfection capacity of the pDNA will be limited 
by a difficult intracellular dissociation from the polymer. 
For gene delivery purposes, the microbubble should be able to locally release its genetic 
material in the ultrasound treated area, whereupon it should become available for cellular uptake 
through the cell membrane pores. As we discovered that an electrostatic loading of microbubbles 
with pDNA hampered the transfection efficiency due to a poor pDNA release, we searched for a 
different approach to develop drug loaded microbubbles. It was previously shown that ultrasound is 
capable of breaking avidin-biotin bonds between microbubbles and nanoscopic polystyrene beads. 
For this reason we prepared lipid microbubbles to which well–defined pDNA or siRNA containing 
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nanoparticles were attached with the aid of an avidin-biotin bond, as reported in chapters 4 and 6. 
The pDNA or siRNA molecules were first complexed with DSPE-PEG-biotin containing cationic 
liposomes, leading to the formation of PEGylated lipoplexes with a biotin molecule attached to the 
end of their PEG-tails. Also, biotinylated lipid microbubbles were prepared containing the same 
biotinylated lipid. After incubation of the microbubbles with an excess of avidin, confocal microscopy 
images showed the coupling of these lipoplexes onto the microbubble shell and proved that lipoplex 
loading could be improved by increasing the biotinylation degree of the lipoplexes. Ultrasound 
exposure of lipoplex loaded microbubbles resulted in the release of intact lipoplexes, with an 
unaltered size and surface charge. Also, pDNA and siRNA complexation properties of the lipoplexes 
were not changed after ultrasound induced release from the microbubbles. The gene transfection 
efficiency (chapter 4) or silencing efficiency (chapter 6) of the lipoplexes was significantly improved 
after microbubble coupling and ultrasound exposure, in contrast to free lipoplexes. Interestingly, in 
the absence of ultrasound the lipoplex loaded microbubbles did not result in gene transfection or 
gene silencing, allowing both a space and time controlled delivery.  
PEGylation of lipoplexes is known to be essential for in vivo use, to avoid a rapid clearance 
from the blood stream and to prevent the development of immune responses. However, it has also 
been demonstrated that the presence of the PEG-chains around lipoplexes reduces their gene 
transfection capacity due to a reduced uptake by cells and unefficient escape from endosomes . As 
the lipoplex loaded microbubbes were able to restore these gene transfer capacity in the presence of 
ultrasound we wondered how the lipoplexes, released from the microbubbles, were taken up by cells 
(chapter 5). We first evaluated whether the lipoplexes entered the cell via an endocytic pahway. Pre-
incubation of the cells with the endocytic inhibitor methyl-β-cyclodextrin only reduced the 
transfection efficiency of free lipoplexes, while the transfection efficiency of the lipoplex loaded 
microbubbles remained unchanged. Methyl-β-cyclodextrin hampered the endocytic uptake of free 
lipoplexes as evidenced with confocal microscopy.  We also studied the effect of a photosensitizer, 
which destroys endosomal membranes, on the transfection efficiencies. Disrupting the endosomes 
only improved the transfection efficiency of free lipoplexes, indicating that the lipoplexes released 
from the microbubbles are taken up by an endocytosis independent pathway. Confocal imaging 
revealed that the free lipoplexes mainly adhered onto the cell membranes and were only visible in 
the endosomes after a longer incubation time. In contrast, the membranes of cells exposed o 
lipoplex loaded microbubbles and ultrasound became immediately disturbed and  lipoplexes were 
detected inside the cell membrane, protruding in the cellular cytoplasm.   
The clinical use of doxorubicin liposomes (Caelix® and Doxil®) is up till now hampered by a 
limited therapeutic efficacy, as the available dose mainly depends on the passive diffusion of free 
doxorubicin (released from the liposomes) into the cancer cells. Several research groups have 
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therefore focused on the development of an active delivery system for doxorubicin, aiming at an 
improved therapeutic efficacy. In chapter 7 of this work we used the same microbubble concept to 
couple doxorubicin containing liposomes (DOX-liposomes) on the shell of lipid microbubbles to 
obtain an ultrasound controlled doxorubicin delivery system. While ultrasound exposure of free DOX-
liposomes did not result in an enhanced cell killing, we saw an important increase in DOX cytotoxicity 
after ultrasound exposure of the DOX-liposome loaded microbubbles. Confocal images showed the 
immediate uptake of DOX in the nucleus of melanoma cells exposed to DOX-liposomes loaded 
microbubbles and ultrasound. In contrast, the DOX coming from the free DOX-liposomes was mainly 
located in vesicles in the cellular cytoplasm, suggesting and endosomal uptake. Our findings also 
suggested that three different phenomenons are responsible for the stronger activity of DOX-
liposomes. First, the ultrasound induced implosion of the microbubbles destroys at least a part of the 
attached liposomes, resulting in the release of free DOX. Second, due to the sonoporation effect, 
more free DOX or DOX-liposomes are able to enter the melanoma cells. Third, there is a combined 
cytotoxic effect of DOX and sonoporation, as exposure of the melanoma cells to DOX makes the cells 
less resistant to microbubble and ultrasound exposure. 
 
GENERAL CONCLUSIONS 
 
In conclusion, we succeeded in preparing microbubbles which are able to carry genetic 
(pDNA, siRNA) and chemotherapeutic (doxorubicin) drugs. We proved that these microbubbles can 
selectively deliver their genetic or chemotherapeutic drugs to melanoma cells upon ultrasound 
exposure. We also showed that the activity of currently available drug carriers (pDNA or siRNA 
lipoplexes and doxorubicin-liposomes) was significantly improved by microbubble coupling and 
ultrasound exposure. This enables us to obtain a space and time controlled drug delivery guided by 
ultrasound. The fact that ultrasound and microbubbles have already been approved for ultrasound 
contrast imaging and are currently used in daily clinic, makes it very plausible that the microbubble 
concept reported in this thesis may find its way as an advanced drug delivery system.  
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SAMENVATTING 
 
Kanker is een genetische aandoening die veroorzaakt wordt door mutaties in het genoom van 
normale cellen. Chemische en fysische schade aan het cellulair genoom kunnen mutaties induceren 
die leiden tot de transformatie van een gezonde cel in een kankercel. De laatste jaren zijn 
wetenschappers erin geslaagd om een aantal oorzaken in het ontstaan van kanker te ontrafelen. 
Verschillende belangrijke proto-oncogenen en angiogenese controlerende proteïnen werden 
geïdentificeerd, wat heeft geleid tot de ontwikkeling van verschillende nieuwe antikanker 
geneesmiddelen.  
In hoofdstuk 1 van dit doctoraat werden in eerste instantie de belangrijkste klassen van 
chemotherapeutica die momenteel voorhanden zijn samengevat. Tot vandaag is de therapeutische 
werking van deze geneesmiddelen nog steeds beperkt omwille van hun weinig specifieke aard. Naast 
de kankercellen worden veel snel delende cellen getroffen, wat onder andere kan leiden tot een 
tekort aan witte bloedcellen. Hierdoor is de maximale dosis beperkt, wat kan resulteren in de 
vorming van geneesmiddelresistente kankercellen, waardoor de therapie niet meer aanslaat of de 
patiënt hervalt. Anderzijds kan gentherapie gebruikt worden om oncogenen te onderdrukken, 
defecte tumor suppressor genen te vervangen, de selectieve omzetting van onschadelijke pro-drugs 
naar chemotoxische geneesmiddelen te stimuleren of om het immuunsysteem van de patiënt te 
verbeteren zodat kankercellen vernietigd kunnen worden. De verschillende gentherapie-strategieën 
ter behandeling van kanker worden kort besproken, samen met een overzicht van de meest courante 
genetische therapeutica. Om een efficiënte kankertherapie te kunnen bereiken is het noodzakelijk 
om verschillende barrières in het lichaam te overwinnen. Recent werd aangetoond dat ultrasound en 
microbubbels kunnen aangewend worden om geneesmiddelen in cellen te brengen. Wanneer 
microbubbels blootgesteld worden aan een ultrasoon veld, beginnen ze te caviteren, waarna ze 
eventueel ook kunnen imploderen. De stromingen en schokgolven die ontstaan tijdens cavitatie en 
zeker tijdens de implosie van de microbubbels kunnen de celmembraan van de cel tijdelijk verstoren, 
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wat resulteert in de vorming van tijdelijke poriën in de celmembranen waardoor geneesmiddelen 
kunnen opgenomen worden. Doordat microbubbel-cavitatie en -implosie enkel kan gebeuren in de 
ultrasound bestraalde zones, kan de geneesmiddeltoediening selectief gestuurd worden door alleen 
de zieke weefsels aan ultrasound bloot te stellen. Omdat geneesmiddel en microbubbels meestal 
afzonderlijk worden geïnjecteerd, bestaat nog steeds het risico dat het geneesmiddel, zij het minder 
efficiënt, ook in ongewenste weefsels wordt opgenomen, wat kan leiden tot neveneffecten. Om de 
geneesmiddeldosis en neveneffecten van geneesmiddelen te beperken, is het nog meer aangewezen 
om microbubbels te ontwerpen die het geneesmiddel bevatten zodat het enkel in de ultrasound 
bestraalde weefsels beschikbaar wordt voor opname. Bovendien kan een geneesmiddel beladen 
microbubbel ervoor zorgen dat de geneesmiddelconcentratie ter hoogte van de celmembraan 
perforaties hoger is, waardoor meer geneesmiddel kan opgenomen worden in de doelcellen. Het 
doel van dit doctoraat was om geneesmiddel beladen microbubbels te ontwerpen die in staat zijn om 
hun geneesmiddel lokaal vrij te stellen na ultrasound bestraling en de selectieve opname van dit 
geneesmiddel in kankercellen te bevorderen.  
Omwille van hun negatieve lading is het zeer interessant om nucleïnezuren zoals plasmide 
DNA (pDNA) elektrostatisch aan de microbubbel wand te koppelen. Voor deze reden werden positief 
geladen microbubbels aangemaakt in hoofdstuk 2. Albumine microbubbels werden bedekt met een 
positief geladen polymeer poly-(allylamine hydrochloride) (PAH), zodat het pDNA elektrostatisch kon 
binden op de microbubbel wand. De aanwezigheid van het PAH-polymeer rond de microbubbel werd 
aangetoond door de oppervlaktelading van de bubbel te meten en via fluorescentie microscopie (na 
het fluorescent merken van het PAH). We toonden aan dat de polymeerlaag rond de microbubbel 
zorgt voor een vertraagde gasdiffusie uit de microbubbel, waardoor de stabiliteit van de microbubbel 
aanzienlijk verlengd kan worden. De koppeling van pDNA aan de microbubbel wand werd 
geverifieerd met confocale microscopie en de maximale beladingsgraad werd geschat op 0,1 pg 
pDNA per microbubbel. Bovendien konden we uit gelelectroforese experimenten afleiden dat het 
gebonden pDNA beschermd was tegen degradatie door DNAse I.  
In hoofstuk 3 bestudeerden we de transfectie efficiëntie van onbedekte en polymeer omhulde 
albumine microbubbels. Ondanks hun hoge pDNA beladingsgraad en bescherming van het pDNA 
tegen degradatie waren de polymeer omhulde microbubbels niet in staat om primaire 
endotheelcellen of melanoma cellen te transfecteren. Gelelectroforese experimenten toonden aan 
dat het pDNA na ultrasound geïnduceerde implosie van de microbubbels nog steeds gebonden zit 
aan microbubbelfragmenten. Via confocale microscopie werd duidelijk dat na implosie van de 
microbubbels, grote,  heterogene aggregaten (enkele micrometers groot) overblijven die bestaan uit 
microbubbel-wand en pDNA. Door hun grootte en heterogeniteit is het zeer onwaarschijnlijk dat 
deze fragmenten in staat zijn om opgenomen te worden door de celmembraan perforaties. Zelfs in 
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het geval dat een deel van deze fragmenten het cytoplasma van de cel kan bereiken, zal de 
transfectie wellicht verhinderd worden door de moeilijke intracellulaire dissociatie, waardoor het 
pDNA de nucleus niet kan bereiken. 
Om een efficiënte genexpressie te bekomen dient de microbubbel zijn pDNA vrij te geven na 
ultrasound bestraling, waarna het beschikbaar komt voor cellulaire opname door de celmembraan 
poriën. Omdat we in hoofdstuk 3 aantoonden dat de elektrostatische binding van nucleïnezuren aan 
de microbubbel wand de transfectie verhinderd door een geringe dissociatie, werd gezocht naar een 
alternatieve strategie. Eerder werd aangetoond dat ultrasound in staat is om polystyreen 
nanopartikels die via een avidine-biotine-binding aan het oppervlak van microbubbels zitten lokaal 
vrij te stellen. Hierop voortbouwend werden nieuwe microbubbels aangemaakt waarbij pDNA 
(hoofdstuk 4) of short interfering RNA-bevattende (siRNA) (hoofdstuk 6) nanopartikels aan het 
oppervlak van een lipide microbubbel gekoppeld werden met behulp van een avidine-biotine 
binding. De pDNA of siRNA moleculen werden eerst gecomplexeerd met DSPE-PEG-biotine 
bevattende liposomen. Dit zorgde voor de vorming van gePEGyleerde pDNA of siRNA bevattende 
lipoplexen met een biotine molecule gekoppeld aan het uiteinde van de PEG-staarten. Daarnaast 
werden ook lipide microbubbels aangemaakt die hetzelfde gebiotinyleerde lipide bevatten. 
Confocale microscopie toonde aan dat de lipoplexen eenvoudig aan het oppervlak van de 
microbubbels gekoppeld konden worden na incubatie met avidine  en dat de beladingsgraad van de 
microbubbels verhoogd kon worden door de biotinylatiegraad van de lipoplexen te verhogen. 
Ultrasound bestraling van deze lipoplex beladen microbubbels resulteerde in een massale vrijstelling 
van intacte lipoplexen, met een onveranderde grootte en oppervlaktelading. Ook de pDNA of siRNA 
complexatie eigenschappen van de lipoplexen bleven onveranderd, wat aangetoond werd met 
gelelectroforese. De transfectie efficiëntie (hoofdstuk 4) of onderdrukkingsefficiëntie (hoofdstuk 6) 
van de lipoplexen steeg enorm na koppeling aan de microbubbels en ultrasound bestraling, dit in 
tegenstelling tot de vrije lipoplexen. Zonder ultrasound bestraling waren de met lipoplex beladen 
microbubbels niet in staat om de cellen te transfecteren, wat toelaat om de genexpressie of 
genonderdrukking volledig te controleren door ultrasound.  
Het is algemeen bekend dat PEGylatie van lipoplexen noodzakelijk is voor in vivo applicaties, 
daar dit een snelle bloedklaring van de lipoplexen en ongewenste immunologische reacties 
verhindert. Daarentegen is het ook aangetoond dat PEGylatie van lipoplexen hun transfectie-
efficiëntie verlaagt doordat het de opname in de cellen en de vrijstelling van partikels uit de 
endosomen bemoeilijkt. Omdat we in hoofdstuk 4 aantoonden dat het gebruik van lipoplex beladen 
microbubbels de transfectie-efficiëntie van de gePEGyleerde lipoplexen kan herstellen na ultrasound 
bestraling, onderzochten we in een volgende stap van dit project hoe de lipoplexen afkomstig van de 
lipoplex beladen microbubbels werden opgenomen door melanoma cellen (hoofdstuk 5). Eerst 
Samenvatting & Algemene Besluiten 
 
  
206 
bestudeerden we of de lipoplexen opgenomen werden via endocytose. Hiervoor gingen we het 
effect na van de endocytotische inhibitor methyl-β-cyclodextrine op de transfectie efficiëntie van 
vrije lipoplexen en lipoplex beladen microbubbels na ultrasoundbestraling. Pre-incubatie van de 
cellen met methyl-β-cyclodextrine verlaagde enkel de transfectie efficiëntie van de vrije lipoplexen, 
wat suggereert dat de lipoplexen afkomstig van de microbubbels worden opgenomen via een 
endocytose onafhankelijke weg. Via confocale microscopie zagen we dat methyl-β-cyclodextrine de 
cellulaire opname van de vrije lipoplexen verhinderde, wat niet het geval was voor de lipoplex 
beladen microbubbels. Wanneer we de membranen van de endosomen tijdens de transfectie 
fotochemisch verstoorden, veroorzaakte dit alleen een verhoging van de gentransfer door de vrije 
lipoplexen. Dit bevestigde dat de lipoplexen afkomstig van de lipoplex beladen microbubbels niet via 
endocytose in de cel worden opgenomen. Confocale fluorescentie microscopie-beelden toonden aan 
dat de vrije lipoplexen voornamelijk aanwezig waren ter hoogte van het celmembraan en enkel na 
een langere incubatietijd zichtbaar werden in de endosomen. In tegenstelling hiermee zorgde 
ultrasound bestraling van de lipoplex beladen microbubbels voor een onmiddellijke verstoring van 
het celmembraan en waren de lipoplexen, kort na bestraling, al zichtbaar in de celmembraan en het 
cytoplasma van de cel.  
De klinische bruikbaarheid van doxorubicine liposomen (DOX-liposomen) (Doxil®, Caelix®) 
wordt tot vandaag gehinderd door de beperkte diffusie van doxorubicine uit de liposomen. Daarom 
zoeken verschillende onderzoeksgroepen naar een actief toedieningssysteem voor doxorubicine. In 
hoofdstuk 7 van dit doctoraat gebruikten we hetzelfde microbubbel concept, zoals hierboven 
beschreven, voor de gerichte afgifte van doxorubicine (DOX). Hiervoor werden gebiotinyleerde DOX-
liposomen gekoppeld aan het microbubbel oppervlak. Hoewel ultrasound bestraling van de vrije DOX 
liposomen niet resulteerde in een verhoogde celdood, zorgde bestraling van de DOX-liposoom 
beladen microbubbels voor een sterke stijging van de doxorubicine toxiciteit. Confocale opnames 
toonden aan dat het DOX afkomstig van de microbubbels bijna onmiddellijk zichtbaar was in de kern 
van de melanomacellen. Daarentegen duurde het veel langer vooraleer vrij DOX of vrije DOX-
liposomen werden opgenomen. Bovendien was het DOX hierbij eerder zichtbaar in het cytoplasma 
van de cel en veel minder in de celkern. Onze resultaten bevestigden ook dat de verhoogde 
cytotoxiciteit van de DOX-liposoom bevattende microbubbels veroorzaakt wordt door drie 
verschillende redenen. Ten eerste wordt een deel van de liposomen beschadigd bij microbubbel 
implosie, wat leidt tot een versnelde vrijstelling van DOX. Ten tweede wordt het doxorubicine sneller 
opgenomen door de cellen door de celmembraan-perforaties die ontstaan tijdens microbubbel 
implosie. Tenslotte is er een gecombineerd cytotoxisch effect van DOX en sonoporatie.  
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Onze resultaten tonen aan dat het mogelijk is om microbubbels aan te maken die 
gePEGyleerde pDNA of siRNA bevattende nanopartikels aan hun oppervlak dragen, alsook liposoom 
bevattende chemotherapeutica (doxorubicin). Na ultrasound bestraling zijn deze microbubbels in 
staat om hun genetisch of chemotherapeutische geneesmiddelen efficiënt toe te dienen aan 
melanomacellen. De therapeutische werkzaamheid van verschillende geneesmiddelen (pDNA, siRNA, 
doxorubicin) kan sterk verhoogd worden door koppeling aan de microbubbels en ultrasound 
bestraling. Bovendien kan dit zorgen voor een tijd– en plaatsgecontroleerde afgifte, volledig 
gecontroleerd door ultrasound. Doordat microbubbels en ultrasound al gebruikt worden voor 
ultrasone beeldvorming in de dagelijkse klinische praktijk, is het microbubbel concept bestudeerd in 
dit proefschrift een veelbelovende strategie voor toekomstige geneesmiddeltoediening in de 
klinische praktijk. 
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